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Abstract
HIV-Associated Neurocognitive Disorders (HAND) continue to afflict approximately half of HIV-infected
patients, despite effective viral suppression through antiretroviral therapy (ART). Synaptodendritic damage
and white matter pathologies persist; suggesting that toxicities from antiretroviral drugs combined with viral
protein effects from CNS reservoirs may be at fault. We hypothesized that ART compounds activate cellular
stress pathways leading to dysfunction of neuroglial cells, and that attenuating this stress could ameliorate the
dysfunction. Previous studies have demonstrated abundant oxidative stress in HAND
patients, and antiretroviral compounds are capable of generating reactive oxygen species (ROS) to invoke this
stress in peripheral cell populations. Here we have established that antiretroviral compounds produce robust
levels of oxidative stress in neurons and oligodendrocytes in vitro. In neurons, increased ROS leads to
mitochondrial depolarization and apoptotic cell death, which was successfully rescued by treatment with
fumaric acid ester monomethyl fumarate (MMF) through activation of the endogenous antioxidant response
(EAR). Oligodendrocytes were also negatively affected by specific antiretroviral agents. While not directly
toxic, protease inhibitors invoked dose-dependent, reversible decreases in the differentiation from
oligodendrocyte precursor to mature oligodendrocytes. ROS were produced, but MMF did not rescue the
maturation deficit. Further investigation concluded that MMF, the active metabolite of the drug Tecfidera,
which is approved for treatment of Multiple Sclerosis, does not activate the EAR in oligodendrocytes. In fact,
the EAR was also not activated by any oxidant compound tested, suggesting that precursor cells which
are known to have low levels of antioxidant/detoxifying enzymes may also be susceptible to oxidative stress
because they cannot appropriately activate this response. In vivo, both synaptodendritic damage and myelin
loss were observed in rodent models of antiretroviral administration. In higher primates, synaptodendritic
damage was evident in SIV-infected pigtail macaques that had received an ART regimen, and myelin basic
protein levels were reduced in human HIV patients with HAND who had been ART-medicated for at least
one year. Together these results strongly implicate antiretroviral compounds as a contributing factor for the
persistence of HAND, and necessitate the development of less toxic antiretroviral therapeutics and adjunctive
therapies which can minimize the CNS side-effects of currently utilized compounds.
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ABSTRACT 
 
ANALYSIS OF THE EFFECTS OF THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF  
HIV INFECTION AND MULTIPLE SCLEROSIS IN NEUROGLIAL CELLS  
 
Brigid Kathleen Jensen 
Kelly L. Jordan-Sciutto 
 Judith B. Grinspan 
 
HIV-Associated Neurocognitive Disorders (HAND) continue to afflict approximately half of HIV-infected 
patients, despite effective viral suppression through antiretroviral therapy (ART). Synaptodendritic damage 
and white matter pathologies persist; suggesting that toxicities from antiretroviral drugs combined with 
viral protein effects from CNS reservoirs may be at fault. We hypothesized that ART compounds activate 
cellular stress pathways leading to dysfunction of neuroglial cells, and that attenuating this stress could 
ameliorate the dysfunction. Previous studies have demonstrated abundant oxidative stress in HAND 
patients, and antiretroviral compounds are capable of generating reactive oxygen species (ROS) to invoke 
this stress in peripheral cell populations. Here we have established that antiretroviral compounds produce 
robust levels of oxidative stress in neurons and oligodendrocytes in vitro. In neurons, increased ROS leads 
to mitochondrial depolarization and apoptotic cell death, which was successfully rescued by treatment with 
fumaric acid ester monomethyl fumarate (MMF) through activation of the endogenous antioxidant response 
(EAR). Oligodendrocytes were also negatively affected by specific antiretroviral agents. While not directly 
toxic, protease inhibitors invoked dose-dependent, reversible decreases in the differentiation from 
oligodendrocyte precursor to mature oligodendrocytes. ROS were produced, but MMF did not rescue the 
maturation deficit. Further investigation concluded that MMF, the active metabolite of the drug Tecfidera, 
which is approved for treatment of Multiple Sclerosis, does not activate the EAR in oligodendrocytes. In 
fact, the EAR was also not activated by any oxidant compound tested, suggesting that precursor cells which 
are known to have low levels of antioxidant/detoxifying enzymes may also be susceptible to oxidative 
stress because they cannot appropriately activate this response. In vivo, both synaptodendritic damage and 
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myelin loss were observed in rodent models of antiretroviral administration. In higher primates, 
synaptodendritic damage was evident in SIV-infected pigtail macaques that had received an ART regimen, 
and myelin basic protein levels were reduced in human HIV patients with HAND who had been ART-
medicated for at least one year. Together these results strongly implicate antiretroviral compounds as a 
contributing factor for the persistence of HAND, and necessitate the development of less toxic 
antiretroviral therapeutics and adjunctive therapies which can minimize the CNS side-effects of currently 
utilized compounds.  
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CHAPTER 1 	  
Introduction 	  
1.1 OVERVIEW 
In addition to effects from HIV infection and viral proteins, the antiretroviral compounds used to treat HIV 
have major implications for cell populations of the central nervous system (CNS) which likely contribute to 
the continued prevalence of HIV-Associated Neurocognitive Disorders (HAND) in roughly half of infected 
individuals. In addition to studying the effects of these compounds in neurons and astrocytes, the work 
presented here is novel in that it also focuses heavily on oligodendrocytes and a potential adjunctive 
therapy that may help to ameliorate antiretroviral-mediated side-effects in the CNS. This introduction will 
therefore provide the background for our studies on the effects of ART on these cell populations.  
 
We will begin with an introduction of HAND, mechanisms of CNS neuropathology, and the persistence of 
neurological dysfunction despite therapeutic intervention (1.2). We will then proceed to review 
antiretroviral therapies: their development, suggested regimens, and side-effects (1.3). From this 
knowledge, we hypothesized that ART compounds activate cellular stress pathways in neuroglial cells 
leading to dysfunction, and that attenuating this stress could ameliorate these effects. One prominent 
cellular stress found in HAND is oxidative stress, which is generated by viral infection, viral proteins, and 
antiretroviral agents. This is presented next, as it is a likely mechanism for much of the neuroglial damage 
observed in patients (1.4). While our preliminary experimental endeavor is in neurons, a majority of the 
investigations and implications presented in this body of work regard oligodendrocytes. As such, the 
specific pathologies observed in HAND and susceptibility of oligodendrocytes to oxidative stress are also 
presented, and are followed by a detailed introduction to oligodendrocyte differentiation and myelin 
maintenance (1.5, 1.6). Due to the potential for oxidative stress operating as a mechanism for dysfunction 
in HAND and oligodendrocyte dysfunction, the cellular stress response pathway of the endogenous 
antioxidant response is summarized, and is followed by the consequences of dysfunction of this pathway in 
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disease (1.7, 1.8). Potential avenues for countering oxidative stress in HAND are then described (1.9). 
Finally, taking all of these areas into consideration our rationale and objectives are outlined (1.10).  
 
1.2 HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND) 
According to the most recent reporting in 2014, approximately 36.9 million people worldwide are infected 
with human immunodeficiency virus-1 (HIV-1) (UNAIDS, 2014). This disease, which is characterized by 
depletion of CD4+ T-cells and progression into acquired immunodeficiency syndrome (AIDS), also 
frequently leads to behavioral, cognitive, and motor disturbances collectively termed HIV-Associated 
Neurocognitive Disorders (HAND) (Kaul, 2005, Ozdener, 2005, UNAIDS/WHO, 2009). Before the advent 
of combined antiretroviral therapy (cART) in the late 1990s, approximately 25% of HIV-infected 
individuals were afflicted by a severe neurocognitive dysfunction termed HIV-Associated Dementia 
(HAD), with rampant neuronal death observed in frontal lobes, hippocampi, and basal ganglia (Navia, 
1986, McArthur, 1987, 1994, Glass, 1995).  
 
Neuroinvasion occurs early in the course of HIV infection, and likely enters the central nervous system 
(CNS) within 1-2 weeks post-infection during the time of peak viremia (Chakrabarti et al., 1991, Williams 
et al., 2001). The mechanism by which this occurs is still under some speculation, as this requires viral 
migration across the blood brain barrier (BBB) and blood cerebral spinal fluid barrier, which are normally 
non-permissive to invading pathogens (Atluri et al., 2015). There is accumulating evidence that the virus 
can cross into the CNS within infected monocytes traversing the barrier, as well as through direct 
transcytosis across the endothelial cell barrier (Roberts et al., 2010, Dohgu et al., 2012, Williams et al., 
2012). The “Trojan Horse” model, originally proposed by Haase and colleagues for the spread of visna 
virus, and which has been supported by many in vitro and in vivo studies for other lentiviruses, proposes 
that neuroinvasion and establishment of CNS viral reservoirs occurs as infected monocytes transmigrate 
across the BBB, and subsequently differentiate into macrophages. This pool of infected macrophages can 
then spread infection to neighboring brain-resident microglia, perivascular macrophages, and astrocytes, 
quickly establishing a viral reservoir in this compartment (Peluso et al., 1985, Haase, 1986, Gendelman et 
al., 1994, Liu et al., 2002, Gonzalez-Scarano, 2005, Kaul, 2005). Importantly, neurons themselves are not 
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able to be infected by HIV, as they lack the CD4 receptor required for viral entry (Kaul, 2005). With this in 
mind, several factors play a role in the neuronal damage occurring in those individuals with HAND. The 
first proposed mechanism holds that direct injury occurs from HIV proteins gp120, Tat, and Vpr, which are 
released from infected macrophages and microglia, and interact with receptors on neurons. The second, 
termed the “bystander effect”, suggests that the damage is instead caused by the immune response mounted 
by infected cells. These macrophages, microglia, and astrocytes release a myriad of cytotoxic molecules, 
including reactive oxygen species, nitric oxide, glutamate, and pro-inflammatory cytokines and chemokines 
which culminate in neuronal damage and dysfunction in addition to activation of neighboring uninfected 
immune cells which further secrete toxic factors (Gonzalez-Scarano, 2005). Classic cellular hallmarks in 
response to a neuroinflammatory environment were readily apparent in HAND patients prior to therapeutic 
interventions, including multinucleated giant cells, microglial nodules, astrogliosis, and myelin pallor 
(McArthur et al., 2003). Elevated levels of inflammation can also lead to an excitotoxic state, where excess 
extracellular glutamate chronically activates N-methyl-D-aspartate (NMDA) receptors on neurons, raising 
intracellular calcium levels and causing the activation of calcium-dependent proteases calpains and 
caspases, ultimately leading to apoptotic death. This mechanism of HIV-mediated neuronal toxicity has 
been well documented and characterized (O'Donnell et al., 2006). Both direct viral protein effects and 
indirect bystander effects of viral infection have been demonstrated, with the observed changes in patients 
likely resulting from a combination of the two mechanisms.  
 
Since the introduction of cART, there has been a dramatic reduction in HAD from 25% to only 2% of 
patients (Heaton, 2010). While this was a promising and hopeful development, unfortunately there is now 
an increased prevalence of a broader spectrum of dysfunction in HAND, which includes categories of 
asymptomatic neurocognitive impairment, and mild neurocognitive disorder. Current estimates based on 
clinical findings suggest that approximately half of infected individuals suffer from some level of HAND 
(Gray, 2003, Brew, 2004, Heaton, 2010, 2011). Additionally, a recent study has reported that HIV-positive 
individuals aged 50 years or older with undetectable viral loads were greater than seven times more likely 
to have mild cognitive impairment than age-matched seronegative controls (Sheppard et al., 2015).  
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Changes in pathology have also been discovered following widespread access to antiretroviral therapy, 
with the subcortical pathology evident in untreated individuals shifting to cortical manifestations in treated 
patients (Gray, 2003, Brew, 2004, Gonzalez-Scarano, 2005, Heaton, 2011). While drastic cellular responses 
to neuroinflammation are no longer commonly discovered in cART-mediated HAND patients, abundant 
clinical and pathological studies have demonstrated that synaptodendritic damage and white matter 
pathologies persist (Masliah et al., 1997, Everall et al., 1999, Zheng et al., 2001, Langford et al., 2003, Ellis 
et al., 2007, Everall et al., 2009, Muller-Oehring et al., 2010, Tate et al., 2010). Additionally, while 
extensive neuronal death is no longer observed, evidence for continued neuronal damage in the form of 
dendritic pruning and reduction in synaptic density remain (Everall et al., 2005). Finally, over the course of 
lifetime infection, HIV severely disrupts the integrity of the BBB through a variety of mechanisms, 
including reducing the expression of structural components required for intercellular junctions, transporters, 
and metabolizing enzymes in endothelial cells (Atluri et al., 2015, Shawahna, 2015). Therefore in addition 
to early CNS viral entry, over the lifetime of infected individuals, continuing effects resulting from the 
escape of drug resistant viral species and direct antiretroviral toxicities also need to be considered.  
 
Finally, another critically important area to highlight is the pediatric HIV-infected population. In infected 
children neurological complications are common, with pathologies including progressive multifocal 
leukoencephalopathy, encephalopathy, and cerebrovascular events (Wilmshurst et al., 2006). Additionally, 
there is increasing documentation of neurocognitive deficits, developmental delays, and emerging motor, 
cognitive, and behavioral deficits in young patients (Crowell et al., 2014, Whitehead et al., 2014, 
Wilmshurst et al., 2014). It is urged by the World Health Organization that all infected children under the 
age of 5 receive antiretroviral therapy (WHO, 2013). Despite this mandate for treatment, very little is 
known about the effects of HIV and antiretrovirals on the developing brain. As these children will have 
lifelong effects of both virus and therapy, it is crucial to understand the cellular ramifications of these 
xenobiotic insults during the critical periods for neurological development and cortical myelination. 
 
Through suppression of plasma viremia and reconstitution of immune system function, cART was 
anticipated to resolve HIV-mediated neurological pathologies. While explicit mechanisms remain unclear, 
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it is thought that the early CNS invasion and establishment of a persistent viral reservoir which perpetuates 
an inflammatory and excitotoxic environment underlies continuing neurocognitive deficits despite effective 
peripheral viral suppression in HIV patients, at least in part (Anthony, 2005, Gonzalez-Scarano, 2005).  
Another area of interest, which is the prominent focus of this work, is the potential for CNS side-effects of 
antiretroviral compounds to also play a significant contributing role to the persistence of neurocognitive 
impairment in the ART-era. As it is undeniable that neurologic deficits remain in treated patients, further 
investigation into mechanisms underlying dysfunction is imperative (Palella, 1998, Antinori, 2007, Broder, 
2010, Heaton, 2010, 2011). 
 
1.3 ANTIRETROVIRAL THERAPY 
Due to the error-prone process of reverse transcription during replication, HIV-1 is highly susceptible to 
mutations. This feature of the virus underlies the emergence of drug resistant mutations in patients over 
time, leading to viral resurgence and the ultimate failure of single drug antiretroviral therapy as introduced 
in the early 1990s to combat progression to AIDS. This led to the revision of antiretroviral therapy to a 
multiple drug treatment approach termed ART, which was implemented to simultaneously target multiple 
stages of replication, employing knowledge of HIV replication and its ability to undergo RNA mutational 
selection (Broder, 2010, NIH, 2011). As of March 2015, of the nearly 37 million individuals globally 
infected with HIV, approximately 15 million were currently accessing antiretroviral therapy translating to 
41% of HIV-positive adults, 32% of HIV-positive children, and 73% of HIV-positive pregnant women 
which serves to prevent vertical transmission to their babies (UNAIDS, 2014). 
 
Currently recommended ART regimens include a cocktail of nucleoside/nucleotide reverse-transcriptase 
inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors (nNRTIs), protease inhibitors (PIs), and 
the more recently developed entry and integrase inhibitors (NIH, 2011, AIDSTAR-One, 2012, AIDSInfo, 
2015). These most recent guidelines recommend treatment of all infected children under the age of 5 years, 
irrespective of CD4+ T-cell count. For adults, it is urged that all individuals with severe or advanced HIV 
disease corresponding to clinical stage 3 (advanced) or stage 4 (severe) and those with a CD4 count ≤350 
cells/mm3 to immediately initiate ART (see Table 1.1 for full HIV clinical staging details). It is also 
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suggested for all individuals with a CD4 count between 350 and 500 cells/mm3, and is strongly 
recommended for those with active tuberculosis, those with HBV co-infection with evidence of chronic 
liver disease, as well as those with serodiscordant partners to reduce transmission to the uninfected 
individual (AIDSInfo, 2015). 
 
Components of suggested ART regimens vary according to age of the patient, previous antiretroviral 
experience, and co-morbidities for which treatment produces drug interactions with certain classes of ART 
compounds. For adults and adolescents 10yrs and older weighing more than 35kg, first-line ART should 
consist of two NRTIs supplemented with a nNRTI to inhibit viral reverse transcriptase, thereby suppressing 
pro-viral DNA generation from viral RNA. When second-line ART is necessary due to acquired drug 
resistance, the primary recommendation is two NRTIs + a Ritonavir-boosted PI, which bind the active site 
of HIV-aspartyl protease and prevent maturation of viral gag-pol precursor proteins (Broder, 2010, NIH, 
2011, WHO, 2013). While the NRTIs that make up this secondary regimen differ based on the makeup of 
the original regimen, Darunavir/ritonavir and Lopinavir/ritonavir are the preferred boosted PI options 
(AIDSInfo, 2015). Currently, all infected children under 3 years of age should receive a Lopinavir/ritonavir 
based regimen for first-line ART (WHO, 2013). 
 
This multi-drug approach has led to long-term viral suppression and restoration of immune system 
function, which underlies the reduction in morbidity and mortality caused by HIV-infection since the 
introduction of ART (Heaton, 2010, McArthur et al., 2010, Sacktor and Robertson, 2014). Unfortunately, 
despite undetectable viral load in the periphery, latent viral reservoirs and persistent inflammation exist in 
the CNS of infected individuals (Chun, 1997, Finzi, 1997, Wong, 1997, Li, 1998, Anthony, 2005, 
Persidsky, 2006).   
 
While the criteria for ART initiation have now been made clear based on patient CD4 counts, AIDS-
defining illnesses, and specific co-morbidities, strategies for eradication of CNS viral reservoirs and for 
decreasing the risk of developing HAND have not yet been well-refined. A likely cause for the persistence 
of CNS viral effects is due to limited penetration of ART compounds into brain tissue through actions of 
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the blood brain barrier (BBB). The major proposed method to eliminate viral reservoirs and reduce 
inflammation is to implement therapies with drugs that would attain therapeutic concentrations in the CNS 
of patients. While HIV can circumvent the BBB, the actions of efficient drug efflux and transport proteins 
in the endothelial cells comprising this structure results in reduced levels of ART concentrations in cerebral 
spinal fluid (CSF) and brain parenchyma as compared with blood plasma (Berger, 2004, Letendre, 2008, 
Varatharajan, 2009). To address this issue, researchers have established the CNS penetrance effectiveness 
(CPE) score, which gives a numerical value following an algorithm which takes into account the chemical 
structures, pharmacokinetic, and pharmacodynamic data of antiretroviral compounds (Letendre, 2008, 
Tozzi et al., 2009, Letendre et al., 2010). Unfortunately results of clinical studies incorporating predicted 
highly CNS penetrant regimens utilizing these CPE scores have not yielded consistent results in terms of 
neurological function. Several studies yielded inconclusive outcomes, others reported a positive correlation 
between higher CPE and better neurocognitive outcome, and the study undertaken by Marra and colleagues 
revealed that regimens containing compounds with higher CPE scores may in contrast be associated with 
worse neurocognitive performance (Letendre, 2008, Cysique and Brew, 2009, Marra, 2009, Tozzi et al., 
2009, Garvey et al., 2011, Lanoy et al., 2011, Smurzynski, 2011, Baker et al., 2015).     
 
While these studies were well designed, investigating the effects of CPE scores on neurological outcomes 
in human patients comes with inherent caveats. Due to technical and ethical limitations, in living patients 
clinical studies cannot directly assess brain parenchymal drug concentrations, and rely instead on drug 
levels found in the CSF, usually after a single-dose administration. CSF and parenchyma have very 
different hydrophobic/hydrophilic compositions, which will greatly impact drug solubility and binding to 
cellular proteins and result in dissimilar concentration readings. In addition, other drug-related factors such 
as poor ART adherence or the impact of additional medications taken by the patient can alter the 
concentrations obtained by clinicians and confound the measured outcomes. Efforts to assess the impact of 
high CPE on neurological outcomes is also hindered by CNS reservoirs established early in infection with 
viral species harboring many iterations of rapidly acquired mutations, as well as later escape of drug-
resistant viral species to the protected CNS environment (Chakrabarti et al., 1991, Gonzalez-Scarano, 
2005). Moreover, comorbidities such as drug and alcohol abuse and infections should be considered when 
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assessing CNS drug availability and establishing and evaluating CPE scores, as all of these factors have 
been demonstrated to alter BBB integrity independent of HIV infection (Shiu et al., 2007, Ramirez et al., 
2009). Another crucial factor to consider given the interest of implementing high CNS-penetrant ART 
regimens long-term in patients is the potential for direct toxicities of antiretroviral drugs in the CNS, as 
side-effects in the rest of the body are pervasive. 
 
Unfortunately, peripheral side-effects of antiretroviral compounds are widespread and include metabolic 
syndrome, lipodystrophy, atherosclerosis and peripheral neuropathy (Carr, 1998a, Dalakas, 2001, Cohen, 
2005, Parker, 2005, Ellis et al., 2008, Vidal et al., 2010). These functional deficits have been linked to 
various cellular effects of ART compounds of multiple drug classes. Through careful study in hepatocytes, 
T-cells, macrophages, adipocytes, lymphocytes, a cell line derived from a human laryngeal cancer, and 
purified human proteasomes, activation of ER stress, the unfolded protein response, and proteasome 
inhibition have been documented following PI exposure (Andre, 1998, Carr, 1998b, Piccinini M, 2002, 
Parker, 2005, Zhou, 2005, 2006, Gupta et al., 2007). Dysfunction through these mechanisms leads to 
pathologies culminating in atherosclerosis, hypercholesterolemia, lipodystrophy, and insulin resistance 
(Carr, 1998a, b, Cohen, 2005, Parker, 2005, Zhou, 2005). While not yet studied in the CNS, side-effects of 
antiretrovirals have been demonstrated in the peripheral nervous system (PNS). A debilitating peripheral 
neuropathy has been described in patients, stemming from NRTI and to a lesser extent PI usage (Dalakas, 
2001, Ellis, 2008). Toxicity caused by compounds of the NRTI class arises by competition with cellular 
thymidine triphosphate for DNA pol-γ, resulting in the termination of mitochondrial DNA synthesis 
(Dalakas, 2001). Ensuing decreases in mitochondria number and oxidative phosphorylation enzymes leads 
to electron transport chain uncoupling and an increase in mitochondrially-derived intracellular reactive 
oxygen species (ROS) resulting in mitochondrial depolarization, and ultimately culminates in activation of 
the apoptotic cascade and neuronal death (Dalakas, 2001). 
 
An interesting development was the finding that ART compounds themselves produce oxidative stress, 
even in the absence of virus (Mondal et al., 2004, Blas-Garcia et al., 2011). It has also recently been 
reported that AZT can modulate gene expression through ROS produced in the mitochondria in 
9	  
cardiomyocytes. This study showed that the ROS diminished DNA methylation, which altered gene 
expression and promoted the pathophysiological changes associated with cardiomyopathy (Koczor et al., 
2015). ART may therefore also be a contributing factor to the persistence of chronic oxidative stress 
observed in patients with well-controlled viral titers, and this stress may cause not only direct cellular 
toxicity but also changes in gene expression resulting in alterations of cellular function.  
 
Toxic effects of ART in the CNS have not been rigorously studied, however as antiretroviral-associated 
toxicities are well documented in the periphery, these observations suggest that it is plausible that these 
compounds may contribute to cellular damage and death leading to continued manifestations of HAND in 
the ART-era. In the past several years the idea of direct ART toxicity has begun to be appreciated, as both 
we and others have demonstrated neurotoxic effects in primary neuronal cultures in response to ART 
compounds (Chapter 3) (Robertson et al., 2012).   
 
1.4 OXIDATIVE STRESS IN HAND 
Chronic oxidative stress is thought to play a significant role in the cellular damage resulting in the 
manifestation of HAND, as has also been suggested for many other neurodegenerative diseases (Mariani, 
2005, Romano, 2010). Even in HIV-positive patients with well-controlled viral infection, evidence for 
persistence of oxidative stress is profound (Blas-Garcia et al., 2011). This topic has been thoroughly 
explored in Chapter 2, which has been excerpted from a book chapter we published reviewing the 
Persistence of HAND in the Era of ART. Key evidence demonstrating persistence of oxidative stress in 
patients, and oxidative stress induced by viral infection, viral proteins and antiretroviral therapy have been 
summarized and included here.  
 
Despite effective viral control, lipid peroxidation remains pervasive in HIV-infected individuals, with 
persistently elevated levels of hydroperoxides, isoprostanes, and malondialdehyde detected in ART-treated 
patients compared with seronegative controls (Jareno et al., 1998, Hulgan et al., 2003, Ngondi et al., 2006, 
Masia et al., 2007, Wanchu et al., 2009). Levels of peroxide species were more highly elevated in patients 
on PI-based regimens compared with those on nNRTI-based regimens, suggesting that the PI class may 
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induce or enhance levels of oxidative stress (Hurwitz et al., 2004, Masia et al., 2007). Additionally, through 
chemical-shift magnetic resonance spectroscopy and careful analysis of lipids, lactate, and creatine levels 
derived from patients, it was determined that the inflammation and oxidative stress initiated by HIV-
infection was not ameliorated by suppressive ART (Roc et al., 2007). Through nuclear and mitochondrial 
staining, the oxidized DNA product 8-hydroxy-2’-deoxyguanosine (8-oxoG) was shown to be significantly 
elevated in autopsy tissue from frontal cortex of HAND patients, suggesting that ongoing infection and/or 
ART promote oxidative modification of DNA (Zhang et al., 2012). Furthermore, clastogenic factors, which 
cause chromosomal breaks and DNA damage and may be released from cells undergoing oxidative stress, 
were present in plasma of all HIV-infected individuals regardless of ART status (Edeas et al., 1997). 
Finally, circulating levels of glutathione are markedly reduced in ART-medicated HIV patients, with the 
ratio of oxidized to reduced glutathione also remaining out of balance (Walmsley et al., 1997, Wanchu et 
al., 2009, Gil et al., 2010). Glutathione is a critically important antioxidant molecule in the cell, which acts 
as a reducing agent through its thiol groups and is able to donate an electron to unstable molecules such as 
reactive oxygen and nitrogen species (Espinosa-Diez et al., 2015). Once oxidized, it reacts with another 
similarly oxidized glutathione molecules to become glutathione disulfide, and then is converted back to its 
reduced state by glutathione reductase (Espinosa-Diez et al., 2015). In cells, this enables glutathione to act 
as an efficient buffer for reactive oxygen species produced by normal cellular activity, with homeostatic 
conditions normally supporting a ratio of 1:9 oxidized to reduced glutathione (Halprin and Ohkawara, 
1967). An increase in this ratio, such as is seen in ART-medicated patients described above, is indicative of 
oxidative stress, with buildup of cellular ROS contributing to activation of signaling molecules responsible 
for triggering the endogenous antioxidant response as will be discussed in Section 1.7 (Halprin and 
Ohkawara, 1967).	  	  
 
Therefore, while patients have effective viral suppression to undetectable levels, evidence for persistently 
robust levels of oxidative stress is abundant. Contributing factors to this chronic stress include 
consequences of viral infection, direct effects of viral proteins from brain-resident reservoirs, and side-
effects of antiretroviral therapies, each of which will be discussed in further detail below. 	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1.4a: OXIDATIVE STRESS BY HIV INFECTION 
In the decades since the discovery of HIV, extensive research has been conducted to determine the effects 
of the virus on infected cells and cytotoxic factors released by these cells. Infected macrophages secrete a 
variety of neurotoxic oxidative stress inducing compounds including glutamate, nitric oxide, and 
superoxide (Lipton, 1994, Bukrinsky et al., 1995, Jiang et al., 2001, Mollace et al., 2002, O'Donnell et al., 
2006). In addition, activation and degranulation of macrophages by viral infection leads to release of 
enzymes that further produce free radicals, such as myeloperoxidase. This protein is released as a cellular 
response to infection as it behaves as a viricidal and inactivates HIV, but it also produces oxidative damage 
to surrounding cells through production of hypocholorous acid and oxidation of tyrosine residues causing 
protein cross-linking (Chase and Klebanoff, 1992, Heinecke et al., 1993, Hong and Banks, 2015). 
Furthermore, HIV infection of macrophages and microglia also results in deficiency of intracellular 
glutathione, and imbalance of the oxidized to reduced glutathione ratio (Lipton, 1994, Zhao et al., 2004, 
Erdmann et al., 2007, Huang et al., 2011). Increased malondialdehyde levels in astrocytes treated with 
supernatants from infected macrophages validated that secreted factors have negative oxidative stress-
mediated consequences on neuroglial cells (Mollace et al., 2002). In addition to the oxidative consequences 
as a result of infection, viral proteins found on the HIV envelope or secreted from infected cells also need 
to be considered independently from their roles in viral entry and replication, as they too produce oxidative 
effects in brain resident cells.  
 
1.4b: OXIDATIVE STRESS BY HIV PROTEINS 
When HIV proteins gp120 and Tat were examined in vivo and in vitro in the absence of whole virus, both 
induced glutathione depletion, lipid peroxidation, and increase in malondialdehyde (Banerjee et al., 2010). 
Additionally, both gp120 and Tat alter lipid metabolism in primary cultured neurons, increasing levels of 
hydroxynoneal, sphingomyelin, and ceramide (Haughey et al., 2004). Independent studies investigating 
gp120 effects on astrocytes revealed an accumulation of ROS and activation of the antioxidant response 
(Viviani et al., 2001, Reddy et al., 2011). Studies investigating the oxidant species produced following 
gp120 application determined that production of both nitric oxide and superoxide ions contribute to 
neuronal toxicity (Dawson et al., 1993, Walsh et al., 2004). Exogenously applied Tat protein also triggers 
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the accumulation of ROS in a variety of cell types including microglia, brain microvascular endothelial 
cells, and neurons (Flores et al., 1993, Kruman et al., 1998, Toborek et al., 2003). Tat protein directly 
injected into rat striatum also significantly increases levels of both oxidative modifications and carbonyl 
additions to proteins (Aksenov et al., 2001). Finally, microglia expressing viral protein R (Vpr) have been 
demonstrated to have activated oxidative stress pathways (Deshmane et al., 2009). Studies investigating 
Vpr have shown that exogenous application to human fetal astrocytes resulted in decreased intracellular 
glutathione and ATP levels, and skewed the balance of the remaining glutathione towards the oxidized 
rather than reduced form (Ferrucci et al., 2012).  
 
It has been well documented through these in vivo and in vitro studies that viral proteins can generate 
oxidative stress in multiple cell populations from the periphery and CNS. These findings highlight the 
importance for effective suppression of viral replication via ART to minimize the oxidative damage caused 
by infection. Emerging evidence also suggests that an additional source of oxidative stress includes the 
antiretroviral compounds themselves, which will be discussed in the next section.  
 
1.4c: OXIDATIVE STRESS BY ART  
Through a combined effort of many laboratories, it has been clearly demonstrated that a variety of drugs 
from the PI and NRTI drug families alone or in combination result in accumulation of ROS, hydrogen 
peroxide, and factors promoting the recruitment of monocytes in a wide range of cell populations. The 
compounds shown to cause these effects in human adipocytes, monocytes, aortic endothelial cells, and 
myeloid cell lines included the PIs: Ritonavir, Saquinavir, Lopinavir, Indinavir, Nelfinavir, and Atazanavir, 
as well as the NRTIs: Zidovudine (AZT), Stavudine (d4T), and Didanosine (Mondal et al., 2004, Ferraresi 
et al., 2006, Lagathu et al., 2007, Chandra et al., 2009, Touzet and Philips, 2010, Manda, 2011, Brandmann 
et al., 2012). Combined antiretroviral treatment also led to increased oxidative stress and mitochondrial 
dysfunction in BBB endothelial cells (Manda, 2011). Thus, in many cell populations antiretroviral drugs of 
varying classes show evidence for generation of oxidative stress. The individual effects of specific drug 
classes will be discussed in more detail below.  
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The NRTI AZT has been extensively studied, as it was the first available antiretroviral drug. Within five 
years of clinical approval, AZT-induced deficits in mitochondrial enzymes and electron transport chain 
(ETC) uncoupling had been reported (Lewis et al., 1992). ETC disruption causes the accumulation of 
intracellular ROS and mitochondrial DNA oxidation, which has been demonstrated following AZT 
exposure in both acute and chronic experimental paradigms (de la Asuncion et al., 1999, Bialkowska et al., 
2000, de la Asuncion et al., 2004, Gao et al., 2011). Subsequently, AZT has also been shown to deplete 
intracellular glutathione, increase mitochondrial lipid peroxidation, and ultimately induce caspase-3 
dependent apoptotic cell death (Yamaguchi et al., 2002, de la Asuncion et al., 2004, Gao et al., 2011). 
Another NRTI, d4T, behaves very similarly to AZT. d4T also causes ROS accumulation, mitochondrial 
stress and oxidized DNA, and altered activity of mitochondrial oxidative phosphorylation enzymes 
(Gerschenson et al., 2001, Velsor et al., 2004). The nNRTI drug class includes the compounds Efavirenz, 
Nevirapine, and Rilpivirine, and has also been implicated in the production of oxidative stress in cells. 
Application of Efavrienz to a human hepatoblastoma cell line resulted in superoxide generation, depletion 
of cellular glutathione, and loss of mitochondrial function and membrane potential (Apostolova et al., 
2010). Efavirenz has been linked to neuropsychological side effects, and has since been removed from 
treatment recommendations (Decloedt and Maartens, 2013). It is widely held that the oxidative stress 
effects described above play a role in the neurotoxicity of this compound (Apostolova et al., 2010, 
Ciccarelli et al., 2011). Within the PI drug class, Ritonavir has been demonstrated to increase nitrotyrosine 
levels, and both Ritonavir and Amprenavir invoke noted increases in superoxide anion production in 
porcine coronary arteries (Chai et al., 2005). In astrocytes and pancreatic beta cells, both Indinavir and 
Nelfinavir induce time- and concentration- dependent depletion of intracellular glutathione (Chandra et al., 
2009, Brandmann et al., 2012). Currently, potential oxidative effects of the entry and integrase inhibitor 
antiretroviral drug classes have not been explored. Similarly the lack of studies investigating the effects of 
antiretroviral compounds on the neuroglial cell populations affected in HAND is surprising, despite the 
abundant evidence which supports a role for antiretroviral compounds in oxidative stress-induced cellular 
dysfunction and damage. 
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As has been summarized here, it is clear that pervasive oxidative damage occurs in HIV patients despite 
effective viral control. Therefore it is of upmost importance to recognize the cellular effects of viral 
enclaves and antiretroviral drugs, and how they may be perpetuating these effects.  
 
1.5 OLIGODENDROCYTES IN HAND 
Prior to the introduction of antiretroviral therapy, alterations in white matter including myelin pallor, 
gliosis, and leukoencephalopathy were prominent in HIV-infected patients (Gray et al., 1996, Everall et al., 
2005). Now even with effective viral suppression in the ART-era, while severe forms of 
leukoencephalopathy have been diminished, the prevalence of white matter pathologies in patients has 
increased, with amount of white matter damage positively correlated with the degree of neurocognitive 
impairment observed (Langford et al., 2003, Everall et al., 2005, Muller-Oehring et al., 2010, Tate et al., 
2010). MRI and diffusion tensor imaging studies have revealed that these effects include dramatic thinning 
of the corpus callosum, reduction in blood flow to white matter, and loss of both structural integrity and 
volume from white matter structures including: the superior longitudinal fasciculus, superior corona 
radiata, and the internal capsule (Pomara et al., 2001, Ragin et al., 2004, Gongvatana et al., 2009, 
Wohlschlaeger et al., 2009, Hoare et al., 2010, Tate et al., 2011, Kelly et al., 2014). A transcriptome 
analysis determined genes which were altered following HIV-infection and which remained dysregulated in 
individuals who attained successful viral suppression through ART but were diagnosed with HAND 
(Borjabad et al., 2011). Among the persistently altered transcripts were myelin transcription factor 1, 
myelin basic protein, and myelin-associated oligodendrocyte basic protein, which are critical for 
oligodendrocyte maturation, myelination, and maintenance (Borjabad et al., 2011). Thus, white matter 
pathologies remain prevalent in HIV-infected patients despite viral suppression through ART, with 
dysregulation of myelin mRNAs and loss of structural integrity of myelin evident by imaging technologies.  
 
Similar to their neuronal counterparts, oligodendrocytes lack the CD4 receptor required for HIV entry, and 
thus, changes in these two cell populations must be caused by indirect effects of viral infection of other cell 
populations, rather than direct consequences of infection of neurons or oligodendrocytes (Sattentau et al., 
1986, Wiley et al., 1986). While molecular mechanisms have not yet been investigated, oligodendrocytes 
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exhibit elevated p53 and BAX levels in postmortem brain samples from frontal cortex of HIV-infected 
individuals who had progressed to AIDS, indicating the activation of apoptotic cell death pathways 
(Jayadev et al., 2007). However, in patients with end stage disease of fully developed AIDS, many of 
whom suffered from HIV-Associated Dementia and HIV-encephalitis, it is difficult to attribute specific 
mechanisms leading to neuronal or oligodendrocyte death.   
 
As was discussed in section 1.4, chronically high burdens of oxidative stress are abundant in HIV patients 
even following suppression of viral replication. Oligodendrocytes are exceptionally susceptible to oxidative 
stress-mediated cell death due to low glutathione and antioxidant levels, coupled with high energy demands 
required to efficiently produce and maintain myelin to insulate surrounding neurons (Back et al., 1998, 
Back et al., 2002, Folkerth et al., 2004, Jana and Pahan, 2007). In rodent models of hypoxia/ischemia, 
oxidative stress generated by the insult led not only to immediate death of oligodendrocyte precursor cells 
(OPCs), but also to a subsequent reduction in number of mature oligodendrocytes and hypomyelination of 
white matter (Levison et al., 2001, Reid et al., 2012). In addition to direct OPC dropout due to oxidative 
stress-mediated toxicity, we found in vitro that at sub-toxic doses, oxidative stress caused by oxidant insult 
halts oligodendrocyte differentiation (French et al., 2009). In vitro studies have also demonstrated a 
maturation-stage specific vulnerability of this cell population, as mature oligodendrocytes are far more 
resilient than OPCs and immature oligodendrocytes due to higher glutathione and antioxidant enzyme 
levels (Halliwell, 1992, Back et al., 1998, Fern and Moller, 2000, Baud et al., 2004). Several demyelinating 
disorders including MS and periventricular leukomalacia involve oxidative stress as a contributing factor to 
pathology (Haynes et al., 2003, Gilgun-Sherki et al., 2004, van Horssen et al., 2008). With this in mind, it is 
likely that the chronically high-levels of oxidative stress still observed in ART-medicated HAND patients 
also contributes to the persistence of white matter pathologies in this population.  
 
Despite these striking pathological findings in HIV-infected individuals, there is a notable lack of 
molecular studies detailing the cellular effects of secreted factors from HIV-infected macrophages or direct 
effects of ART on oligodendrocyte precursors or mature oligodendrocytes. However, the laboratory of 
Pamela Knapp has recently published an article investigating the effects on oligodendrocytes in a rodent 
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model of inducible astrocyte-driven Tat expression. After 3 months of Tat-transgene expression, animals 
displayed disruption of myelin in the caudate-putamen, aberrant oligodendrocyte morphology in corpus 
callosum and anterior commissure, and significantly decreased levels of myelin basic protein and myelin- 
associated glycoprotein in striatum (Zou et al., 2015). Additionally, when cells in vitro were exposed to 
exogenously applied Tat protein, viability of immature oligodendrocytes was significantly decreased and 
surviving cells displayed significant deficits in maturation as evidenced by decreased branching processes 
and myelin membrane extensions (Zou et al., 2015). This pioneering study has provided the groundwork 
that viral proteins can affect oligodendrocyte survival and extent of myelination. It is of crucial importance 
now to further understand the effects of HIV on oligodendrocytes in the context of the entire virus and in 
infection. This is extremely challenging due to imperfect animal systems that do not fully recapitulate 
human cellular attributes. In addition to direct effects of viral proteins, evidence has suggested that factors 
secreted by macrophages and astroglia, both which are infected or non-infected but activated due to the 
presence of viral infection, may also contribute to negative neuroglial effects. Therefore the model of 
human macrophage infection and application of supernatants to cells in culture may be utilized to provide 
insight into additional aspects of neuropathology. Furthermore, effects of antiretroviral compounds on 
oligodendrocytes have not been considered in the context of chronic HIV infection. As this cell population 
is vitally important to ensure proper neuronal signaling and cognition, effects of viral infection, 
inflammation, oxidative stress, and antiretrovirals on this cell population need further consideration. 
Oligodendrocytes are frequently overlooked in the study of diseases; however, because myelin formation 
and maintenance occur both during human development and adulthood, the consequences are profound 
when these processes are disrupted.  
 
1.6 THE IMPORTANCE OF OLIGODENDROCYTE DEVELOPMENT AND MYELIN 
MAINTENANCE   
Myelin, produced by oligodendrocytes in the CNS and Schwann cells in the PNS, provides the basis for the 
propagation of rapid neuronal impulses, which is required for proper functioning of the human nervous 
system. This process, known as salutatory conduction, is facilitated by the ensheathment of axons by 
multiple layers of specialized glial membrane, which insulates the neuronal axonal plasma membrane by 
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reducing the transverse capacitance and increasing the resistance. By effectively restricting action 
potentials to small unmyelinated axon segments known as nodes of Ranvier, velocity of signal conduction 
is accelerated up to 100-fold when compared with an unmyelinated axon of the same diameter (Landahl 
and Podolsky, 1949, Frankenhaeuser, 1952, Nave and Werner, 2014). In addition to their function in 
insulating axons, oligodendrocytes also provide trophic support to the axons their myelin membranes 
surround, which is crucially important for maintaining cellular functioning and signaling at long extended 
distances from the neuronal soma (Lappe-Siefke et al., 2003, Edgar and Garbern, 2004). In contrast, loss of 
myelin integrity can disrupt proper signaling, resulting in neuronal degeneration and neurological 
dysfunctions (Criste et al., 2014, Mighdoll et al., 2015). 
 
Mature oligodendrocytes are generated from oligodendrocyte precursors cells (OPCs) according to a well-
characterized progression, allowing for assessment according to stage-specific antigens (Figure 1.1) 
(Miller, 2002). In rodents, at embryonic day 12.5, OPCs originate in ventricular zones and migrate both 
dorsally and radially, expressing markers such as A2B5, platelet-derived growth factor receptor A (PDGF-
A), and NG2. OPCs transition to immature oligodendrocytes expressing galactocerebroside (GalC) and 
begin to extend actin filaments to elaborate processes and adopt the morphology of mature 
oligodendrocytes. During this period, oligodendrocyte precursor cells (OPCs) decrease levels of Inhibitor 
of DNA binding (ID) transcription factors, allowing the pro-differentiation transcription factors Olig1 and 
Olig2 to promote upregulation of proteins required for maturation into oligodendrocytes, as well as myelin 
component mRNAs (Miller, 2002, Chen et al., 2012). Following contact with neurons, these maturing cells 
continue to extend processes, upregulate expression of myelin proteins, and ultimately ensheath neuronal 
axons with the lipid- and protein-based myelin membrane (Grinspan, 2002, Miller, 2002). A majority of 
myelin proteins are translated in the perinuclear endoplasmic reticulum and trafficked via the secretory 
pathway for ultimate insertion into the forming myelin membrane (Colman et al., 1982). In contrast, 
mRNA for myelin basic protein is trafficked intracellularly via microtubules to sites proximal to membrane 
insertion. Translation into protein then occurs on free-ribosomes and is quickly followed by insertion into 
the nearby developing myelin membrane (Colman et al., 1982, Carson et al., 1997). In vivo, myelin is 
highly enriched in lipids, which constitute approximately 75% of membrane constituents, with the 
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remaining 25% being myelin proteins. Chief among the protein components are proteolipid protein (17%), 
myelin basic protein (8%), cyclic nucleoside phosphodiesterase (CNPase, 4%), myelin oligodendrocyte 
glycoprotein (MOG, 1%), and myelin-associated glycoprotein (MAG, 1%) (Jahn et al., 2009). 
 
Myelin maintenance and replacement is a continually ongoing process over the course of an individual’s 
lifetime, which is essential for optimal neuronal functioning and survival (McLaurin and Yong, 1995). In 
addition to baseline myelin maintenance, remyelination of axons from which damaged myelin has been 
stripped off has been extensively documented, primarily through clinical and molecular studies 
investigating the pathology of Multiple Sclerosis (Hartley et al., 2014, Kutzelnigg and Lassmann, 2014). In 
notable recent studies, while myelination was previously viewed solely as an early life event, it has been 
shown that active synthesis and formation of new myelin is required for motor learning in adulthood (Long 
and Corfas, 2014, McKenzie et al., 2014). 
 
Myelin is damaged or improperly formed in a variety of conditions, which primarily result in motor 
dysfunction. Factors contributing to these diseases include genetic mutations of myelin components termed 
leukodystrophies, demyelinating diseases caused by inflammation such as Multiple Sclerosis, and 
hypomyelination or myelin damage caused by injury such as in perinatal white matter injury in preterm 
infants (Volpe, 2001, Garbern, 2007, Lee et al., 2010, Markowitz, 2013). Myelin deficits have now also 
been implicated in neurodegenerative diseases such as ALS, and neurological diseases with cognitive and 
behavioral consequences such as autism and schizophrenia (Kang et al., 2013, Chavarria-Siles et al., 2015, 
Libero et al., 2015). While OPCs persist in the CNS in most of these diseases, they are unable to 
differentiate and effectively form new myelin.  
 
Two of these disorders highlight the contribution of oxidative stress to myelin dysfunction. In Multiple 
Sclerosis, while the mechanism driving initial autoimmune targeting of myelin is not understood, 
inflammation and oxidative stress are thought to drive much of the continuing pathology (Friese et al., 
2014, Mahad et al., 2015). Symptoms arise from disruption of myelin integrity in white matter tracts within 
the brain, resulting in improper transmission of neuronal impulses (Markowitz, 2013, National Multiple 
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Sclerosis Society, 2015). In addition to destruction of myelin sheaths and death of associated 
oligodendrocytes, cellular pathology also includes axonal damage and subsequent cell death of the 
demyelinated neuron (Criste et al., 2014, Mallucci et al., 2015). As was mentioned previously, impaired 
myelination can hasten neuronal axonal degeneration by altering trophic support provided by the 
ensheathing oligodendrocytes (Lappe-Siefke et al., 2003, Edgar and Garbern, 2004, Criste et al., 2014). 
Oxidative stress negatively impacts oligodendrocytes on multiple levels, as it can perturb myelination in 
mature oligodendrocytes, and concomitantly both depletes the OPC pool and prevents effective 
differentiation of the remaining OPCs for replacement of the damaged mature oligodendrocytes to 
remyelinate affected areas (Levison et al., 2001, French et al., 2009, Reid et al., 2012). A devastating loss 
of myelination also occurs in pre-term infants who suffer from perinatal white matter injury (PWMI), 
which frequently results in considerable neurologic dysfunction and diagnosis of cerebral palsy (Volpe, 
1981, 2001). This brain damage targets white matter specifically, and while it can be triggered by several 
independent events, one of the leading causes is lack of cerebral oxygenation (Back and Rosenberg, 2014). 
This causes the generation of robust levels of oxidative stress, and cell death of the particularly vulnerable 
OPC pool as discussed in section 1.5, ultimately resulting in hypomyelination of the cortex in the 
developing child (Volpe, 2001, Back and Rosenberg, 2014). The evidence of oxidative stress-mediated 
damage to oligodendrocytes in these conditions highlights the necessity for reduction of this stress in order 
to facilitate recovery or attenuate dysfunction in demyelinating disorders. 
 
1.7 THE ENDOGENOUS ANTIOXIDANT RESPONSE (EAR) 
In response to an imbalance of redox homeostasis, cells activate a cellular stress pathway known as the 
endogenous antioxidant response (EAR) in order to reduce levels of oxidative stress. This response is 
mediated by the activity of a ubiquitously expressed transcription factor of the Cap’n’Collar family, NF-E2 
(nuclear factor (erythroid-derived 2))-related factor-2 (Nrf2) (Motohashi, 2004b). Nrf2 has been 
demonstrated to be essential for a transcriptional response to oxidative stress (Chan, 1999, Leung, 2003). 
Under homeostatic conditions, Nrf2 is sequestered in the cytoplasm by a Kelch-like ECH-associated 
protein-1 (Keap1) dimer, in complex with Cul3/Rbx/E3 ligase which facilitates constitutive ubiquitination 
and proteasomal protein degradation (Figure 1.2A) (Itoh, 1999, Zipper, 2002, Zhang DD, 2003, Zhang, 
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2004). Cytoplasmic retention of Keap1/Nrf2 complexes are ensured by dual actions of Keap1 through its 
nuclear export signal and actin binding via its Kelch repeat domain (Kang, 2004, Velichkova, 2005). 
 
Under pathway activating conditions, the interaction between Nrf2 and Keap1 is altered, with release from 
Keap1-mediated repression allowing for Nrf2 nuclear translocation (Li, 2009). Two methods of pathway 
activation occur, through either modification of Keap1 cysteines or Nrf2 phosphorylation (Figure 1.2B). 
Several cysteine residues on Keap1 are critically responsible for effective basal ubiquitination of Nrf2, 
which targets the protein for proteasomal degradation (Dinkova-Kostova, 2002, Zhang DD, 2003). During 
pathway activation, modification of these residues results in a conformational change of the Keap1 homo-
dimer sequestering Nrf2 in the cytoplasm (Wakabayashi, 2004, Eggler, 2005, Tong, 2007). In this way, the 
altered Keap1 dimer retains the Nrf2 molecule bound in complex, but ubiquitin transfer to Nrf2 is 
disrupted, no longer successfully targeting it for degradation. As a result, there is an accumulation of 
unbound de novo translated Nrf2 which can enter the nucleus and activate transcription (Zhang DD, 2003, 
Wakabayashi, 2004, Eggler, 2005, Kobayashi, 2006, Purdom-Dickinson, 2007, Tong, 2007). Pathway 
activation by this method also switches the ubiquitin transfer to the Keap1 molecules, instead targeting 
Keap1 for degradation and further enhancing the available Nrf2 pool (Hong, 2005, Zhang, 2005). 
Alternatively, Nrf2 can be phosphorylated by Protein Kinase C or PKR-like ER kinase, which directly 
disrupts the association of Keap1 and Nrf2 (Huang, 2000, 2002, Bloom, 2003, Cullinan, 2003).  
 
Once nuclear translocation has occurred, Nrf2 dimerizes with small musculoaponeurotic fibrosarcoma 
oncogene (sMaf) proteins, conferring binding specificity to the antioxidant response element (ARE) DNA 
motif (Rushmoore, 1991, Itoh, 1997, Nguyen, 2003, Motohashi, 2004a, Kobayashi, 2005, Li, 2009). 
Following assembly of this heterodimer at the ARE, Nrf2 domains then recruit CREB (cAMP Responsive 
Element Binding protein) Binding Protein (CBP), inducing acetylation of Nrf2 and allowing for initiation 
of transcription and translation of a battery of cytoprotective genes (Rushmore, 1990, Rushmoore, 1991, 
Katoh, 2001, Zhu, 2001, Lee, 2003, Shen, 2004, Kobayashi, 2005, Li, 2009, Kawai, 2010). Antioxidant 
response genes driven by this Nrf2-mediated transcription include the antioxidant proteins: heme 
oxygenase 1 (HO-1), peroxiredoxins, thioredoxins, and superoxide dismutase, phase II detoxifying 
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enzymes: NAD(P)H:quinone oxidoreductase (NQO1), glutathione S-transferase, and the xCT subunit of the 
cystine/glutamate exchange transporter, as well as stress response chaperones, transcriptional regulators, 
proteasome components, and phase III detoxifying enzymes (Itoh, 1997, Alam, 1999, Ishii, 2000, Kwak, 
2001, McMahon, 2001, Lee, 2003, Shih, 2003). Additional regulation occurs through competitive ARE 
binding, through both positive (Nrf1), and negative (c-fos, Fra1, Bach1/2) transcriptional modifiers 
(Venugopal, 1996, Muto, 2002, Dhakshinamoorthy, 2005, Sun, 2009, Kaspar, 2010).  
 
While still incompletely understood, two mechanisms have been proposed for cessation of the antioxidant 
response. In the absence of Nrf2, the Keap1 complex can bind prothymosin-α, driving nuclear import 
(Figure 1.2Ci) (Karapetian, 2005, Padmanabhan, 2008, Niture, 2009). Once nuclear, Keap1 switches 
prothymosin-α for Nrf2 binding (Niture, 2009). This nuclear Keap1-Nrf2 complex can either be directed to 
Crm-1 mediated export to resume normal cytoplasmic repression activity, or alternatively can remain 
nuclear and target Nrf2 for internuclear proteasomal degradation (Nguyen, 2005, Velichkova, 2005, Sun, 
2007, Niture, 2009). The second proposed mechanism involves glycogen synthase kinase 3β (GSK3β) 
(Figure 1.2Cii). Free cytoplasmic Nrf2 can be phosphorylated by active GSK3β, which prevents nuclear 
import and targets for Keap1-independent ubiquitination by the SCF/β-TrCP/Cul1/Rbx/E3 ubiquitin ligase 
complex leading to subsequent proteasomal degradation (Salazar, 2006, Rada, 2011). Activated GSK3β can 
also phosphorylate cytoplasmic Fyn kinase, causing its translocation and phosphorylation of nuclear Nrf2, 
which once modified in this manner becomes fated for nuclear export and degradation (Jain, 2006, 2007). 
 
While this pathway has been well described in many cell populations, investigation into EAR activity has 
been somewhat limited in lineages of the central nervous system (Li, 2009). Through many elegant studies 
the laboratory of Johnson and colleagues has demonstrated Nrf2-mediated EAR activity in astrocytes 
(Kraft, 2004) and reviewed in (Vargas and Johnson, 2009). Similarly, it has been well documented that 
upregulation of Nrf2-mediated antioxidant response proteins can occur in macrophages (Itoh et al., 2003, Li 
et al., 2004). Through these studies, it has been shown that activating the EAR in both astrocytes or 
macrophages can provide protection to neurons (Kraft, 2004, Li et al., 2004). Neurons are particularly 
susceptible to toxicity from oxidative stress, with many findings concretely demonstrating that in an in vivo 
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context other cell populations likely provide a supportive buffer (Bell, 2013). In contrast to other cell 
populations, very little is known about the EAR in oligodendrocytes. Studies using OLN-98 cells and 
primary rat oligodendrocytes showed HO-1 protein upregulation following hydrogen peroxide exposure 
(Goldbaum and Richter-Landsberg, 2001, Stahnke et al., 2007). While this suggested EAR pathway 
activation, this insult also culminated in loss of mitochondrial function and apoptosis, suggesting an 
ineffective or incomplete response which was insufficient to protect the cells (Goldbaum and Richter-
Landsberg, 2001). In summary, little is known about the EAR pathway in neurons and oligodendrocytes, 
two cell populations that have been suspected to primarily draw on macrophages and astrocytes for 
cytoprotective support. In support of this, both macrophages and astrocytes have been demonstrated to 
robustly activate the EAR pathway. 
  
1.8 NRF2 PATHWAY DYSFUNCTION IN DISEASE 
Given the pervasive oxidative stress found in many neurodegenerative diseases, better understanding of the 
EAR pathway in CNS cell populations is of vital importance (Gilgun-Sherki et al., 2004, Mariani, 2005, 
Ramsey, 2007, Romano, 2010). In the absence of Nrf2 activity there is heightened susceptibility not only to 
direct oxidative stress, but also to acetaminophen hepatotoxicity, carcinogens, ischemia, and hyperoxic 
lung injury, as well as a general suppression of immune responses (Chan, 2001, Enomoto, 2001, Ramos-
Gomez, 2001, Cho, 2002, Shih, 2005, Thimmulappa, 2006). Postnatal lethality occurs under conditions of 
Keap1 deletion in knockout mice, resulting from Nrf2 pathway dysregulation (Wakabayashi, 2003). As 
these studies indicate, balance of Nrf2 and Keap1 functions are critical for maintaining cellular redox 
homeostasis, with alterations in either component resulting in drastic cellular consequences. Additionally, 
changes in subcellular localization of these proteins can also impact function, as Nrf2 activity is highly 
dependent on its ability to activate transcription of EAR targets.  
 
In many neurodegenerative pathologies, Nrf2 and other transcription factors undergo aberrant cellular 
localization, precluding appropriate transcriptional regulation in response to activation of their respective 
signaling pathways (Chu, 2007, Patel, 2011). Several lines of evidence suggest that dysregulation of the 
EAR through inappropriate localization of Nrf2 may contribute to disease progression. In Alzheimer 
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Disease (AD), levels of nuclear Nrf2 are significantly reduced in affected patients compared to age-
matched controls, even in neurons displaying abundant oxidative damage, suggesting a defect in nuclear 
Nrf2 translocation (Ramsey, 2007). Nrf2 is highly enriched in the nucleus of affected neuronal cell 
populations in Parkinson Disease (PD), suggesting that the EAR has been activated but the response is not 
capable of overcoming the levels of oxidative stress to provide cellular protection (Ramsey, 2007). 
Recently, high levels of nuclear expression of Nrf2 and downstream target HO-1 were found in 
oligodendrocytes in active demyelinating regions from Multiple Sclerosis (MS) patients (Licht-Mayer et 
al., 2015). However, in a similar finding to cells in PD, the highest enrichment of nuclear Nrf2 was found 
in degenerating oligodendrocytes in the MS lesions (Licht-Mayer et al., 2015). Preliminary evidence from 
our laboratory has suggested that Nrf2 localization may also be affected in individuals with HAND. In 
comparison to ART-treated, HIV-positive neurocognitively normal individuals, ART-treated individuals 
with HAND have elevated cytoplasmic Nrf2 levels. This abnormal elevation does not indicate a productive 
antioxidant response, as nuclear Nrf2 is required for EAR-based gene upregulation. Increased evidence of 
oxidative damage (4-HNE) is also seen in the HAND patients compared to seronegative age-matched 
neurocognitively normal controls, supporting the notion that while oxidative stress is accumulating with 
HIV and ART, an effective protective response is not mounted. However, it is challenging to draw 
conclusions regarding stress response proteins in post-mortem tissue derived from patients with a chronic 
degenerative condition. Cells frozen in time at the point of autopsy which display highly enriched levels of 
a particular response protein could be chronically and effectively combatting a stressor, or conversely could 
be ineffectively attempting to overcome a non-survivable level of stress and are instead fated for cell death.   
 
1.9 COUNTERING OXIDATIVE STRESS IN HAND  
Nrf2 pathway upregulation has been suggested as a potential avenue for therapy in ALS, Alzheimer 
Disease, and Parkinson disease (Calkins, 2009, Tufekci, 2011, Kumar et al., 2012, Petri et al., 2012). In 
MS, where oxidative stress is a key pathological feature of the disease, therapies aimed at reducing this 
stress burden have been approved and are used currently in the clinical setting (FDA, 2013, Friese et al., 
2014, Dubey et al., 2015, English and Aloi, 2015, Mahad et al., 2015). Due to the vast amount of 
experimental evidence demonstrating that both HIV and ART induce oxidative stress, it has also been 
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proposed that boosting the EAR through promoting Nrf2 pathway activity may be an effective adjunctive 
therapeutic option for all individuals living with HIV, not only those already affected by HAND.   
 
Encouragingly, multiple compounds activating the Nrf2 pathway have proven effective in preventing 
oxidative consequences of viral infection, viral proteins, and antiretroviral compounds in vitro. Chief 
among these compounds are dimethyl fumarate, resveratrol, and curcurmin (Chai et al., 2005, Touzet and 
Philips, 2010, Cross et al., 2011, Gao et al., 2011). Other antioxidants also show promise in preventing 
oxidative stress invoked by exposure to antiretroviral drugs in vitro, but their actions have not been 
confirmed to be Nrf2-pathway dependent. These compounds include: acetyl-L-carnitine, dihydroxybenzyl 
alcohol, and glutathione mimetic tricyclodecan-9-yl-xanthogenat (D609) (Ferraresi et al., 2006, Opii et al., 
2007, Weakley et al., 2011). In a slightly different approach, the compound diphenylene iodonium was 
used to specifically inhibit NADPH oxidase in adipocytes. Through the action of this compound, the 
generation of oxidative stress was prevented for the PI drug class, but not for the NRTIs (Lagathu et al., 
2007). This finding suggests that different classes of antiretroviral agents may lead to the generation of 
ROS through different mechanisms, requiring adjunctive therapeutics that target these specific cellular 
pathways. 
 
Of the currently proposed potential adjunctive options, dimethyl fumarate is of particular interest, due to its 
dual functionality of activating the Nrf2-mediated EAR, as well as suppressing levels of HIV-replication in 
macrophages (Cross et al., 2011). This compound could potentially become a vital adjunctive therapy for 
HIV, which would lower viral titers in addition to lowering oxidative stress generated by viral proteins and 
co-administered antiretrovirals. DMF has recently been FDA approved for the treatment of MS under the 
trade name Tecfidera and successfully reduces relapse rates (FDA, 2013, Limmroth, 2013, English and 
Aloi, 2015). Surprisingly, while suspected to act as an antioxidant on the basis of previous reports 
demonstrating activation of the Nrf2-pathway, the mechanism of action by which Tecfidera is effective in 
MS has not yet been elucidated. In the body, DMF is rapidly converted to monomethyl fumarate (MMF), 
so that in blood plasma only MMF is ever detected (Litjens et al., 2004, Fox et al., 2014). While the effects 
of MMF on oligodendrocytes, the primary cell population affected in MS pathology currently remains 
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unexplored, antioxidant effects of MMF have been reported in neurons and macrophages through 
upregulation of Nrf2-mediated EAR target genes, similar to findings using the parent compound DMF 
(Cross et al., 2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et al., 2012).  
 
A second alternative approach to combatting oxidative stress is direct scavenging of reactive oxygen and 
nitrogen species through dietary supplementation of antioxidants such as Vitamin C (ascorbate). This has 
been demonstrated to have beneficial outcomes in patients when supplemented to their ART regimens, and 
has protected against effects of HIV protein gp120, PI Nelfinavir, and NRTI AZT in vitro (de la Asuncion 
et al., 2004, Vincent et al., 2004, Walsh et al., 2004). Supplementation with a variety of other antioxidants 
and micronutrients such as vitamins A and E, selenium, coenzyme Q10, and alpha-lipoic acid have also 
demonstrated partial protection from oxidative stress induced by HIV/SIV and ART in vivo, through 
assessment of restored blood glutathione levels (Delmas-Beauvieux et al., 1996, Batterham et al., 2001, de 
la Asuncion et al., 2004, Jariwalla et al., 2008). While still in early stages of determining their efficacy, 
both the NMDA-receptor blocker memantine and monoamide oxidase type B inhibitor selegiline have been 
proposed as potential adjunctive therapeutics for the treatment of HAND (Lindl et al., 2010, Zhao et al., 
2010). Memantine, which is currently approved for Alzheimer Disease, may benefit patients by reducing 
glutamate-mediated excitoxicity (Kutzing et al., 2012). Selegiline, which is utilized for treatment of 
Parkinson Disease, may aid in reducing the oxidative stress burden in HAND through direct reduction of 
oxygen-based free radicals (Nagatsu and Sawada, 2006). Going forward, it is imperative to identify and 
develop adjunctive therapies that can effectively attenuate the oxidative stress caused by HIV infection and 
antiretroviral therapy. Until antiretroviral compounds with less toxic side effects can be designed and 
successfully targeted to all areas of established viral enclaves, oxidative stress will continue to be a 
persistent burden in this patient population who are now living with their infection long-term, over greatly 
enhanced life expectancies.  
 
1.10 RATIONALE AND OBJECTIVES 
Antiretroviral compounds are quite successful at attenuating HIV-replication, yet despite peripheral viral 
titers below the limit of detection, approximately half of infected individuals suffer from some level of 
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impairment within the spectrum of dysfunction characterized as HIV-Associated Neurocognitive Disorders 
(HAND) (Gray, 2003, Brew, 2004, Heaton, 2010, 2011). Peripheral toxicities of these compounds have 
been well characterized, yet the toxic effects of these compounds on the major cell types of the CNS, which 
have potential implications for the persistence of HAND, have been overlooked (Carr, 1998a, Dalakas, 
2001, Cohen, 2005, Parker, 2005, Ellis et al., 2008, Vidal et al., 2010). We anticipated that antiretroviral 
compounds, which activate several cellular stress pathways in the periphery, are likely to affect cell 
populations within the brain, which may contribute to loss of cognitive function (Parker, 2005, Zhou, 2005, 
2006, Gupta et al., 2007). In chapter 2, we extensively review the evidence for oxidative stress in HIV-
infected individuals both before and after the development and widespread use of therapy, the contributions 
of the virus and of antiretrovirals to this continued stress, and potential adjunctive therapeutic interventions 
to combat these effects. 
 
In chapter 3, we then test the hypothesis that antiretroviral compounds negatively impact neuronal function 
in vivo and in vitro. We found that in both pigtail macaques and rats, in vivo antiretroviral administration 
resulted in synaptodendritic damage. In vitro studies demonstrated that exposure to antiretrovirals led to 
accumulation of ROS and slight activation of the EAR, yet culminated in neuronal damage and death. Use 
of the fumaric acid ester monomethyl fumarate (MMF) to potently upregulate the cellular antioxidant 
response prevented both the accumulation of ROS and subsequent neuronal toxicity. These findings 
suggest that oxidative stress is a major contributor underlying neuronal toxicity following antiretroviral 
treatment, and could inform potential adjunctive therapies to ameliorate cellular damage caused by these 
compounds. 
 
In chapter 4, we explore the white matter loss prevalent in HIV patients on ART by directly testing the 
effect of antiretroviral compounds on the survival, maturation, and maintenance of the myelin-producing 
cells of the CNS, oligodendrocytes. We discovered that compounds in the PI drug class invoked reversible 
dose-dependent decreases in the maturation of oligodendrocyte precursor cells. No deficits were noted 
following NRTI treatment. Unlike the rescue from toxicity found in neuronal cultures, MMF was unable to 
restore maturation to normal levels when co-administered with PIs. In vivo administration of Ritonavir 
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resulted in reduced myelin protein levels in frontal cortex. Similarly, prefrontal cortex from HIV-positive 
individuals with HAND who had received antiretroviral therapy displayed a significant decrease in myelin 
basic protein levels compared to HAND individuals who had not received treatment, as well as HIV-
negative control individuals. These findings demonstrate that antiretrovirals in the PI class have damaging 
effects in oligodendrocytes, and have clinical implications for treatment regimen recommendations both in 
juvenile HIV patients who are in the process of initial cortical myelination, as well as maintenance of 
myelin in adults on longitudinal lifelong therapy.  
 
Intrigued by our finding that MMF failed to rescue oligodendrocyte maturation in the presence of 
antiretrovirals where it had succeeded in rescuing neuronal toxicity, we next pursued a thorough 
investigation into the activity of the EAR in oligodendrocytes following oxidant and antioxidant treatment 
(Chapter 5). In vitro application of oxidant tBHP to mouse oligodendrocyte precursors and mature 
oligodendrocytes resulted in robust accumulation of ROS, yet target genes of the antioxidant response were 
not upregulated. As we noted in previous studies (French et al., 2009, Reid et al., 2012), oxidant treatment 
also resulted in a significant reduction in maturation of precursors into maturing oligodendrocytes. 
Application of MMF successfully reduced ROS accumulation induced by multiple oxidants, but also did 
not activate the EAR or rescue maturation deficits in oligodendrocytes. Quite surprisingly, 
oligodendrocytes did not activate the EAR under conditions of oxidative stress to restore homeostasis, even 
after treatment with MMF. In addition to these implications in HAND, this study also aids in explaining the 
mechanism behind the recently FDA-approved drug Tecfidera (DMF), which has proven to be effective in 
reducing relapse rates in Multiple Sclerosis. Based on our findings, the therapeutic effect of the primary 
metabolite MMF in MS patients is not likely a direct antioxidant effect on oligodendrocytes, but rather an 
indirect effect by promoting this response in other CNS cell types, or through anti-inflammatory actions 
that we have not yet investigated.  
 
Finally, we incorporate our findings into the context of previous studies (Chapter 6). We provide a 
summary of this body of work, an interpretation of the significance of our findings, and considerations for 
both clinical ramifications as well as potential future avenues of investigation.   
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Clinical 
Stage: 
HIV-Associated 
Symptoms 
Clinical Event 
1 Asymptomatic No HIV-related symptoms 
Painless enlarged lymph nodes persisting 3+ months 
2 Mild 
Involuntary loss of body weight (<10%) 
Recurrent upper respiratory tract infections 
Herpes zoster (Shingles) 
Recurrent oral ulceration 
Papular pruritic lesions 
Seborrhoeic dermatitis 
3 Advanced 
Involuntary loss of body weight (>10%) 
Chronic diarrhea persisting 1+ months 
Persistent fever-intermittent or constant for 1+ months 
Persistent oral candidiasis, Oral hairy leukoplakia 
Pulmonary tuberculosis 
Severe bacterial infection (pneumonia, meningitis, etc) 
Acute necrotizing ulcerative gingivitis or necrotizing 
    ulcerative periodontitis 
Unexplained anaemia, neutropaenia 
    or chronic thrombocytopaenia 
4 Severe 
HIV wasting syndrome 
Pneumocystis pneumonia 
Recurrent bacterial pneumonia 
Chronic or disseminated- herpes simplex virus  
    infection, mycobacteria infection, cytomegalovirus,  
    isosporiasis. mycosis, cryptosporidiosis,   
    CNS toxoplasmosis, or atypical leishmaniasis. 
Extrapulmonary cryptococcosis (including meningitis) 
Extrapulmonary tuberculosis 
Recurrent non-typhoid Salmonella bacteraemia 
Lymphoma (cerebral or B-cell non-Hodgkin) 
Invasive cervical carcinoma 
Kaposi sarcoma 
Progressive multifocal leukoencephalopathy 
HIV encephalopathy 
HIV-Associated nephropathy 
HIV-Associated cardiomyopathy 
 
Table 1.1 HIV Clinical Staging 
Adapted From “Criteria for HIV Staging Events”, and  “WHO clinical staging of HIV/AIDS for adults and 
adolescents with confirmed HIV infection” (WHO, 2007). Clinical staging score is determined by level of 
HIV-Associated symptoms according to occurrence of specific clinical events in patients.  
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Figure 1.1 Oligodendrocyte Lineage Progression 
Oligodendrocyte maturation stage can be assessed through expression of stage-specific protein markers.  
The top panel shows immunofluorescent images of typical cells in each of the three identified 
oligodendrocyte lineage stages. These cells, isolated from newborn rat pups, were labeled with antibody to 
the ganglioside marker A2B5 for precursors, galactocerebroside (GalC) for immature oligodendrocytes, 
and proteolipid protein (PLP) for mature oligodendrocytes. In the lower panel are illustrations denoting 
process length and complexity with maturation. Under these drawings are the typical markers found at each 
stage in the lineage progression. In addition to PLP, myelin protein components: 2’,3’-cyclic nucleotide 
phosphodiesterase (CNP), myelin-associated glycoprotein (MAG), myelin basic protein (MBP), and myelin 
oligodendrocyte glycoprotein (MOG) begin to be expressed where indicated.  
 
Adapted from oligodendrocyte differentiation figures (Grinspan, 2002, See, 2009).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oligodendrocyte-Diﬀeren0a0on-In#Vitro##
 Adapted from oligodendrocyte differentiation figures (Grinspan JNEN 2002, See et al. JNEN 2009) 
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Figure 1.2 Complex Nrf2 Regulation Occurs Under Varying Cellular Conditions 
A model of Nrf2 pathway regulation is presented as described in the text. A) Basal conditions, B) Pathway 
activation, C) Pathway attenuation with two proposed mechanisms Ci) Keap1 shuttling and Cii) Fyn 
shuttling and Nrf2 phosphorylation. 
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2.1 OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES 
Oxidative stress is a shared pathological finding in a myriad of neurodegenerative diseases including 
Alzheimer Disease, Parkinson Disease, Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and 
HIV-Associated Neurocognitive Disorder (HAND) (Reynolds et al., 2007, Shukla et al., 2011). While it is 
clear that chronic levels of oxidative stress which will overwhelm the protective capacities of the cellular 
endogenous antioxidant responses may be responsible in part for the neuronal death occurring in these 
conditions, in many neurodegenerative diseases it is difficult to ascertain whether oxidative stress is the 
causative factor for disease pathology and progression or rather a resultant downstream event of other 
cellular dysfunctions (Ramsey, 2007, Reynolds et al., 2007, Melo et al., 2011, Shukla et al., 2011). 
Nonetheless, in HAND several lines of evidence suggest that both HIV and antiretroviral compounds may 
result in oxidative and nitrosative stress in the periphery and in the CNS (Lipton, 1994, Mondal et al., 2004, 
Walsh et al., 2004, Lagathu et al., 2007, Li et al., 2008, Chandra et al., 2009, Blas-Garcia et al., 2011). 
Deficits in total antioxidant levels and increases in the markers for oxidative stress are still observed in 
individuals on stable ART regimens with undetectable viral titers, necessitating the need for adjunctive 
therapies to ameliorate this imbalance (Hulgan et al., 2003, Mandas et al., 2009). As has been suggested in 
a variety of neurodegenerative conditions, antioxidant supplementation or upregulation of the endogenous 
antioxidant response in cells of the CNS may ameliorate the neuronal damage and death contributing to 
HAND (Reynolds et al., 2007, Calkins, 2009, Lindl et al., 2010, Melo et al., 2011).   
 
2.2 OXIDATIVE STRESS IN THE ERA OF ART 
The evidence of disrupted antioxidant balance and oxidative stress represent a continued concern for HIV-
infected individuals even when virus is successfully controlled by ART (Blas-Garcia et al., 2011). To 
understand the magnitude and implications of this problem, it is important to understand the initial 
disruptions to the antioxidant system that were observed in infected individuals, and determine whether 
ART contributed to the resolution or the exacerbation of these problems. 
 
2.2a Oxidative stress prior to ART: As early as 1988, while researchers were just beginning to 
understand the HIV virus, Sönnerborg and colleagues determined that plasma levels of malondialdehyde in 
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adults with HIV infection were elevated up to 30% when compared with controls (Sonnerborg et al., 1988). 
Malondialdehyde is the breakdown product of polyunsaturated lipids by reactive oxygen species, and is a 
mainstay in terms of a biological marker for measuring the relative levels of lipid peroxidation and 
oxidative stress in individuals (Moore and Roberts, 1998). A multitude of studies followed, showing 
significant increases in the levels of free radicals, hydroperoxides, hydroxynoneal, and oxidation of thiols 
in infected individuals, and confirming that malondialdehyde is increased significantly in infected adults, as 
well as children (Favier et al., 1994, Malvy et al., 1994, Repetto et al., 1996, Walmsley et al., 1997, Allard 
et al., 1998, Jareno et al., 1998, McLemore et al., 1998, Turchan, 2003, Haughey et al., 2004, Sacktor, 
2004, Suresh et al., 2009). The metabolic synthesis of lipids is closely tied to the oxidative state of the cell 
and the lipids residing in the cell membrane, as certain enzymes such as sphingomyelinase, are sensitive to 
the oxidative status of the cell and regulate their activity based on cellular need (Haughey et al., 2008). 
Studies looking into the production of sphingolipids illustrated an overproduction of both sphingomyelin 
and ceramides with HIV-infection, suggesting a lipid imbalance caused by the virus (Haughey et al., 2004, 
Sacktor, 2004, Haughey et al., 2008). Additionally, studies showed remarkable deficiencies in antioxidant 
micronutrients including zinc, selenium, Vitamin C, Vitamin D, Vitamin E and beta-carotene (Vitamin A) 
(Dworkin et al., 1986, Droge et al., 1994, Favier et al., 1994, Allard et al., 1998, Ogunro et al., 2006, 
Srinivas and Dias, 2008, Suresh et al., 2009, Bilbis et al., 2010, Oliveira et al., 2011, Sudfeld et al., 2012). 
Conflicting reports exist on perturbation of total antioxidant status prior to ART, with several clinical 
studies reporting decreased total antioxidant capacity (Jareno et al., 1998, McLemore et al., 1998, Suresh et 
al., 2009), while Repetto et al. described an increase in the overall antioxidant capacity as individuals 
progressed to AIDS (Repetto et al., 1996). The discrepancies between these findings are likely based on the 
assays utilized to determine “total antioxidant capacity”, as different enzymatic approaches target different 
portions of the antioxidant system. 
 
Activity levels of superoxide dismutase (SOD), which catalyzes the detoxification of the oxidant 
superoxide into hydrogen peroxide and water, were assessed by a variety of laboratories. Elevated SOD 
activity was observed in all evaluated HIV-infected individuals, with further increases occurring with 
disease progression to AIDS. In addition, increases in SOD mRNA levels were reported in individuals with 
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HAD, as compared to those who were neurocognitively normal (Delmas-Beauvieux et al., 1996, Repetto et 
al., 1996, Boven et al., 1999). These changes in SOD were observed in microglial cells, as well as in HIV-
infected macrophages, suggesting a virus-triggered induction (Boven et al., 1999). An essential antioxidant 
found in the brain which buffers many reactive oxygen species is glutathione. In HIV-infected patients, 
overall glutathione levels were found to be reduced, and the remaining glutathione was greatly skewed to 
the oxidized versus reduced form (Buhl et al., 1989, Aukrust et al., 1995, Delmas-Beauvieux et al., 1996, 
Repetto et al., 1996). The enzyme glutathione peroxidase, which promotes the conversion of hydrogen 
peroxide to water through the use of glutathione, was also decreased, illustrating a severe imbalance in this 
system whose goal is to maintain cellular redox homeostasis (Ogunro et al., 2006). Another deleterious 
consequence of rampant pro-oxidants within cells is oxidative modification of DNA bases. Increased levels 
of 5-hydroxyuracil, 5-hydroxycytosine, 8-hydroxyadenine and 8-hydroxyguanine were found when 
comparing DNA isolated from lymphocytes of HIV-infected individuals versus uninfected controls (Jaruga 
et al., 1999). One other common product of an imbalanced oxidative state which is beginning to gain more 
interest and research focus is peroxynitrite. This compound, which is formed when superoxide reacts with 
nitric oxide, is detectable through its nitrotyrosine moiety, and is found at higher levels and with more 
frequency in the brains of patients with HAD, compared with those who are neurocognitively normal 
(Boven et al., 1999). In addition to the generation of superoxide as a direct result of HIV infection, the virus 
also increases mRNA expression of inducible nitric oxide synthase (iNOS), which enables a precipitous 
accumulation of this deleterious oxidation product (Boven et al., 1999). Further research in the Nath 
laboratory has illustrated that thirteen proteins with nitrotyrosine modifications are present in the CSF of 
individuals with HIV-infection. Individuals with dementia had the highest levels of these nitrites and 
nitrates. Importantly, three of these proteins were significantly elevated in individuals who showed declines 
in neurocognitive assessment over a period of 6 months (Li et al., 2008).  
 
While it appears that there is not an all-or-nothing increase or decrease in antioxidant capacity, the evidence 
is clear that the components of the antioxidant defense system prior to ART were greatly affected by HIV-
infection, and that the capabilities of endogenous antioxidant response were not able to alleviate damaging 
oxidative alterations to proteins and DNA. 
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2.2b Persistence of oxidative stress in the era of ART: In the ART era, oxidative stress is still pervasive 
in individuals living with well-controlled HIV-infection (Blas-Garcia et al., 2011). In 2007, a group at the 
University of Pennsylvania sought to ascertain whether ART had an effect on inflammation and oxidative 
stress in the brains of HIV-infected individuals through utilization of chemical-shift magnetic resonance 
spectroscopy. Through careful analysis of lipid, lactate, and creatine levels, they determined that the 
inflammation and oxidative stress initiated by the HIV infection was not ameliorated in ART-treated 
individuals, compared to seronegative controls (Roc et al., 2007). While these effects were observed in all 
HAND patients, the levels of oxidative stress markers were higher in those with more severe cognitive 
deficits (Roc et al., 2007). 
 
Lipid peroxidation is still rampant despite effective viral control. While a couple of studies report decreased 
levels in markers of lipid peroxidation in ART-medicated patients, as compared with those not receiving 
ART, multiple studies have shown persistent statistically significant increases in hydroperoxides, 
isoprostanes, and malondialdehyde in ART-treated HIV-infected individuals, compared to seronegative 
controls (Jareno et al., 1998, Hulgan et al., 2003, Flourie et al., 2004, Ngondi et al., 2006, Masia et al., 
2007, Wanchu et al., 2009, Gil et al., 2010, Ibeh et al., 2011, Ibeh and Emeka-Nwabunnia, 2012). 
Interestingly, two independent groups have determined in patient blood samples that the levels of peroxide 
species and oxidative stress are higher in patients on protease inhibitor (PI) based regimens, as compared 
with those in individuals on non-nucleoside reverse transcriptase inhibitor (nNRTI) based regimens, 
implicating a role for the protease inhibitor class in induction or exacerbation of oxidative stress (Hurwitz 
et al., 2004, Masia et al., 2007). 
 
Micronutrient deficiencies are still problematic with ART, and while most patients have adequate plasma 
concentrations of vitamins C, D, and E, reported levels are still considered sub-optimal and lower than 
seronegative patients (Stephensen et al., 2006, Sudfeld et al., 2012). While subsequent reports have 
indicated that zinc and selenium deficits are no longer observed in individuals on ART, further definitive 
confirmation of these findings is necessary (Stephensen et al., 2007, Sundaram et al., 2008). Additionally, 
in studies which evaluated the serum of adults and the saliva of children, the total antioxidant status was 
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found to be decreased in ART treated HIV-patients when compared to HIV-negative controls, mirroring 
findings in studies conducted in the pre-ART era (Mandas et al., 2009, Padmanabhan et al., 2010). 
 
While several studies have indicated that introduction of ART has been accompanied by an improvement in 
overall glutathione status, this effect is not totally rectified and imbalances still occur (Aukrust et al., 1995). 
In particular, numerous groups have shown that circulating glutathione levels are still markedly reduced in 
HIV-infected individuals, when compared with age-matched controls, with the ratio of oxidized to reduced 
glutathione remaining out of balance (Walmsley et al., 1997, Flourie et al., 2004, Wanchu et al., 2009, Gil 
et al., 2010, Awodele et al., 2012). Unfortunately, studies investigating nitrosative stress and nitrosylated 
proteins in HIV-infected individuals on ART are still lacking; however, the Nath, Hammond, and Sutliff 
laboratories have been investigating nitrosative stress in HIV, and it is likely that such reports are 
forthcoming. 
 
It has been reported that HIV-positive individuals do not have altered levels of 8-hydroxy-2’-
deoxyguanosine [8-oxoG) in their urine regardless of ART or lipodystrophy status (Paul et al., 2003). 
While these findings appear to be promising, in a recent study, autopsy tissue from frontal cortex was 
stained for both nuclear and mitochondrial 8-oxoG. The levels of this oxidized DNA product were 
significantly increased in cases of HAND, suggesting that ART, or ART in combination with ongoing 
infection may promote DNA oxidative modification, cellular dysfunction damage and death (Zhang et al., 
2012). Additionally, the presence of clastogenic factors, which cause chromosomal breaks and DNA 
damage and which may be released from cells under conditions of oxidative stress, was observed in the 
plasma of all HIV-patients tested by Edeas et al.. This was true of patients that were both asymptomatic and 
symptomatic for AIDS-defining pathologies, and was independent of ART status (Edeas et al., 1997). The 
effects of these clastogenic factors appear to persist in multiple cell populations implicated in HAND 
pathogenesis. For example, in leukocytes obtained from HIV-infected individuals, the percentage of cells 
exhibiting DNA fragmentation was increased in individuals on ART, as compared with those who were 
ART-naïve (Gil et al., 2010). However, the results of this study have not addressed the possible 
contribution of latent or low level of infection to the findings.  
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Due to pervasive oxidative damage and antioxidant imbalance despite effective long-term viral control in 
patients, it is now imperative to recognize the direct effects that viral enclaves and antiretroviral drugs 
themselves may have on perpetuating these effects. Further studies are needed to investigate the 
independent effects of ART and the virus on oxidative damage in the CNS, as well as in the periphery in 
order to better determine therapeutic interventions to resolve these dysfunctions. 
 
2.3: OXIDATIVE STRESS BY HIV 
Exhaustive research has been conducted in order to determine the effects of the HIV on infected cells and 
the cytotoxic factors released from these cells. As addressed earlier, it is now clear that HIV-infected 
macrophages secrete a variety of neurotoxic substances including glutamate, nitric oxide, and superoxide 
(Lipton, 1994). Within actively infected human myeloid-monocytic cell lines or monocyte-derived 
macrophages, HIV induces an increase in superoxide anions, with a concomitant increase in superoxide to 
combat these factors (Kimura et al., 1993, Boven et al., 1999). Mollace and colleagues have demonstrated 
that the supernatants from HIV-infected human primary macrophages induced oxidative stress in 
astrocytes, as indicated by increases in malondialdeyde levels (Mollace et al., 2002). They further showed 
that these supernatants, which contained excess superoxide, induced astrocytic apoptosis, confirming HIV-
mediated toxicity of this secreted product (Mollace et al., 2002). In a similar fashion, in HIV-infected 
monocytes, an induction of nitric oxide synthase and subsequent increase nitric oxide was observed 
(Bukrinsky et al., 1995). It is also interesting to note that elevated oxidative stress in the form of 
intracellular singlet oxygen is capable of reactivating latent HIV through long terminal repeat (LTR) 
transactivation in infected monocytes or lymphocytes, suggesting that the virus may rely on oxidative stress 
signaling cascades for continuation of long-term infection or viral rebound (Piette and Legrand-Poels, 
1994).  
 
The amino acid and neurotransmitter glutamate is normally secreted from neurons into the synaptic cleft, 
and is quickly removed and recycled through the actions of astrocytes. This molecule normally activates 
the N-methyl D-aspartate (NMDA) receptor on neurons, and allows for Ca2+ entry into the cell. However, 
it has been clearly demonstrated that excessive extracellular levels of glutamate resulting from 
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overstimulation of neurons, impaired reuptake by astrocytes, or release from other cell populations within 
the brain can lead to hyperactivation of NMDA channels and subsequent increases in Ca2+ levels in the 
neuronal cytoplasm, resulting in excitotoxic neuronal death (Szydlowska and Tymianski, 2010). In 2001, 
Jiang et al. demonstrated through a series of elegant experiments that the molecule responsible for the 
neurotoxicity observed on neuronal cultures was a molecule of less than 3,000 kilodaltons, was not 
sensitive to trypsin digestion, and that its neurotoxic effect was blocked by a selective NMDA receptor 
antagonist, MK-801. It was through this study, as well as a subsequent study by O’Donnell et al. that the 
increased levels of extracellular glutamate secreted by HIV-infected macrophages may be a major factor in 
HIV-infected macrophage mediated indirect neuronal death (Jiang et al., 2001, O'Donnell et al., 2006). The 
increases in extracellular glutamate appears to be an effect of dysregulation of the glutamate synthesis 
pathway, as inhibition of the mitochondrial glutaminase enzyme blocks the production and the secretion of 
glutamate from HIV-infected macrophages (Zhao et al., 2004, Erdmann et al., 2007, Huang et al., 2011). 
As was distinctly noted in human patient samples, a marked deficiency of glutathione and an imbalance 
between the oxidized and the reduced glutathione was observed. Within cells, glutaminase is the enzyme 
which converts glutamine to glutamate. It is tempting to consider that the oxidative stress resulting from the 
lack of the antioxidant properties of glutamine may be very tightly coupled to a depletion of glutamine 
from cells by hyperactivation of glutaminase enzymes, precipitating an overproduction of glutamate and 
triggering an excitotoxic neuronal death pathway. 
 
Similar to effects of whole virus in vivo, when gp120 and Tat were injected into the brains of rats, both of 
these viral proteins induced lipid peroxidation and glutathione depletion (Banerjee et al., 2010). 
Additionally, both of these proteins significantly reduced intracellular glutathione, and increased 
malondialdehyde in immortalized brain endothelial cells, showing that the oxidative status of these cells 
would also be directly affected by the presence of virus. This is of particular importance as the altered 
oxidative status of these endothelial cells comprising the BBB will have potential impact on not only the 
integrity of the BBB, but also on the monocyte/macrophage transmigration to the CNS, an important factor 
in the persistence of HAND (Price et al., 2005). Further, when applied to neurons in culture, gp120 and Tat 
induce disruptions in the lipid metabolism, leading to increased levels of sphingomyelin, ceramide, and 
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hydroxynoneal, paralleling disruptions in these pathways observed in the neurons of HAND patients 
(Haughey et al., 2004). 
 
Studies that investigated gp120 separately have revealed that it is capable of inducing ROS formation, and 
activating the antioxidant response in astrocytes (Viviani et al., 2001, Reddy et al., 2011). Studies looking 
into the production of oxidant species by gp120 have shown that superoxide ions as well as nitric oxide are 
involved in neuronal toxicity (Dawson et al., 1993, Walsh et al., 2004). Mechanistically, gp120-induced 
nitric oxide formation is dependent on a mannose-specific endocytic lectin in macrophages, while gp120-
induced expression and upregulation of iNOS selectively occurs in astrocytes in human fetal neuroglial 
cultures astrocytes (Pietraforte et al., 1994, Walsh et al., 2004). Multiple studies have shown that in neurons 
undergoing gp120-induced toxicity, a significant increase in intracellular Ca2+, likely released from 
intracellular stores, preceded death, suggesting at a mechanism of activation of calpains or other pro-death 
cellular machinery (Viviani et al., 2001, Agrawal et al., 2010). 
 
Studies investigating Tat-induced neuronal death have revealed that this viral protein triggered the 
accumulation of ROS when exogenously applied to a variety of cell types, including lymphocytes, 
microglia, brain microvascular endothelial cells (BMECs) and neurons, as well as in HeLa cells expressing 
Tat (Flores et al., 1993, Israel and Gougerot-Pocidalo, 1997, Kruman et al., 1998, Toborek et al., 2003). 
When directly injected into striatum of rats, Tat produced dramatic increases in protein oxidative 
modifications and protein carbonyls (Aksenov et al., 2001). Protein carbonyls were also markedly 
increased in HeLa cells expressing Tat, supporting in vivo data (Flores et al., 1993). In addition, decreased 
levels of glutathione were observed in cardiac myocytes and BMECs exposed to recombinant Tat protein, 
Tat-expressing transgenic mice, and in Tat-expressing HeLa cells (Westendorp et al., 1995, Choi et al., 
2000, Raidel et al., 2002, Toborek et al., 2003). Two studies pinpointed the involvement of manganese-
dependent superoxide dismutase (Mn-SOD) as a key player in Tat- induced cellular changes. By expressing 
Tat in HeLa cells, the laboratories of Lehman and McCord convincingly showed that Tat suppressed the 
RNA, protein, and activity levels of Mn-SOD, while inducing no changes in the CuZn SOD enzyme levels 
(Flores et al., 1993, Westendorp et al., 1995). In HIV-infected individuals, plasma levels of SOD were 
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increased in plasma, and these changes were in parallel with disease progression to AIDS. If the results 
from these HeLa cell studies can be expanded to other cell populations, it is tempting to speculate that 
perhaps this overall increase in SOD activity is a compensatory mechanism resulting from the Tat-induced 
alterations in Mn-SOD activity and the subsequent increases in superoxide ions that cannot be eliminated. 
The overexpression of Tat in HeLa cells also led to decreases in overall glutathione levels, with a lower 
ratio of reduced to oxidized glutathione in the remaining supply, mimicking the effect seen in HIV infected 
individuals in vivo and in HIV-infected macrophages in vitro (Flores et al., 1993, Westendorp et al., 1995). 
 
Finally, studies focusing on microglia have shown that the expression of HIV viral protein R (Vpr) can 
induce oxidative stress pathways, and can activate HIV latent gene expression (Deshmane et al., 2009). 
When exogenously applied to human fetal astrocytes, the oxidative stress caused by Vpr causes decreases 
in intracellular ATP and glutathione, and skews remaining glutathione in favor of the oxidized versus 
reduced form (Ferrucci et al., 2012). 
 
In summary, exhaustive in vivo and in vitro studies indicate that HIV viral proteins themselves can induce, 
precipitate, and augment oxidative stress in multiple cell types, of both peripheral and CNS tissue. These 
findings further emphasize the importance of complete inhibition of viral replication in alleviating 
oxidative stress via antiretroviral therapy. However, emerging evidence suggests that antiretroviral drugs 
themselves might inadvertently lead to oxidative stress. 
 
2.4: OXIDATIVE STRESS BY ART 
Due to the requirement for lifelong adherence to antiretroviral regimens to prevent viremia and immune 
system compromise, it is necessary to investigate the effects of these compounds in a cellular context. 
Many of these drugs are associated with negative side-effects, and have been linked to the metabolic 
syndrome, atherosclerosis, lipodystrophy, proteasome inhibition and the unfolded protein response (Zhou, 
2005, 2006, Vidal et al., 2010). Additionally, it has become apparent that these compounds themselves 
produce oxidative stress, even in the absence of virus, and may in fact be contributing to the persistence of 
oxidative stress in patients with well-controlled viral load (Mondal et al., 2004, Blas-Garcia et al., 2011). 
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HIV is highly susceptible to mutations, mostly due to the error-prone reverse transcription step during 
replication, and underlies the emergence of drug resistant mutations over time in patients treated with 
single antiretroviral drugs in the early 1990s. Additionally, the development of more sensitive methods for 
HIV RNA detection revealed the presence of viral reservoirs in multiple tissues, including the CNS. These 
findings led to the revision of antiretroviral therapy, which, until that time included mostly single 
antiretroviral drug regimens. A multiple drug treatment approach, termed ART, was implemented to aim at 
different steps in the HIV replication. Currently recommended ART regimens include a cocktail of 
nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs), non-nucleoside reverse-transcriptase 
inhibitors (nNRTIs), protease inhibitors (PIs), and to a lesser extent, entry inhibitors and integrase 
inhibitors (Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 
Available at http://aidsinfo.nih.gov/). This approach has led to improved immune function, long-term viral 
suppression, and underlies the reductions in HIV-associated morbidity and mortality in the era of ART. The 
recently updated guidelines recommend ART initiation to all HIV-infected, ART-naive individuals 
irrespective of CD4+ counts. The impact of early initiation of ART on HIV-associated neurological 
complications remain to be seen. While a consensus has been reached regarding the time to initiate ART 
based on CD4 cell counts, AIDS-defining illnesses, and certain co-morbidity factors; the panel did not 
clearly outline strategies to best eradicate the viral reservoirs in the CNS, and to decrease the risk of 
developing HAND among infected patients. 
 
In the meantime, one major approach to better control HAND has been to implement therapies that include 
drugs which achieve therapeutic concentrations in the CNS. While HIV can circumvent the BBB barrier, 
complex drug transport and efflux mechanisms at this junction hampers the achievement of effective 
antiretroviral concentrations in the brain parenchyma. Recent efforts to address this hurdle have led to the 
establishment of CNS penetrance effectiveness (CPE) score, an algorithm based on the chemical structure, 
pharmacodynamic and pharmacokinetic data of antiretroviral drugs (Letendre et al., 2008, Tozzi et al., 
2009, Letendre et al., 2010). In summary, an antiretroviral drug with high CPE score is small in size 
(molecular mass below 400-500 kDa), has high lipid solubility and low protein binding, and it is not a 
substrate for drug transport or efflux proteins. Unfortunately, results of several clinical studies which 
57	  
incorporated CPE into the design and the analysis of outcomes are not conclusive (Letendre et al., 2008, 
Cysique et al., 2009, Marra et al., 2009, Tozzi et al., 2009, Garvey et al., 2011, Lanoy et al., 2011, 
Smurzynski et al., 2011). While a positive correlation between CPE scores and neurological outcomes are 
observed in several studies, one study revealed that ART regimens with higher CPE scores might be 
associated with worse neurocognitive performance (Marra, 2009).  
 
These studies investigating the effect of CPE scores on neurological outcomes have inherent caveats. First, 
due to limited methodologies, clinical studies cannot assess the drug concentrations in the brain 
parenchyma, and instead depend on the CSF levels, which are usually based on measurements after a 
single-dose administration of the drug. Several factors, such as poor drug adherence and the impact of co-
prescribed drugs on the pharmacokinetics of antiretroviral drugs can impact CNS concentrations and can 
confound the measured outcomes. Additionally, the escape of drug-resistant viral species into the CNS and 
their establishment in viral reservoirs early during infection can lead to the rise of drug-resistant HIV 
species in the CNS, and can hinder the efforts to assess the impact of CPE scores on neurological 
outcomes.  Further, co-morbidity factors impacting the integrity of the BBB should also be considered in 
assessing drug availability in the CNS. Among these factors are cancer, infections, and drug and alcohol 
abuse, all of which are shown to alter BBB integrity independent of HIV infection, and should be 
considered when CPE scores are established and evaluated (Shiu et al., 2007, Qin et al., 2008, Ramirez et 
al., 2009). One final factor to consider in evaluating the long-term effectiveness of ART is the potential for 
direct toxicities of antiretroviral drugs in the CNS, especially given the interest in implementation of ART 
regimens with better CNS penetrance and possibly developing nanoART as part of treatment plans. 
Antiretroviral drugs have known side-effects in the periphery, including dyslipidemia, and lipohypertrophy. 
Furthermore, antiretroviral drug-associated toxicity is well documented in the peripheral nervous system, 
and potential CNS toxicities secondary to ART exist. Oxidative damage elicited by antiretroviral drugs is 
of particular interest, given ample evidence of ongoing oxidative stress in the HAND brain, as described 
above. 
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In several cavalier studies, researchers eloquently demonstrated in several cell populations (human 
adipocytes, monocytes, myeloid cell lines, and human aortic endothelial cells) that a variety of drugs from 
the PI and NRTI families, alone or in combinations, induced the production of ROS, hydrogen peroxide, 
and factors promoting monocyte recruitment. The compounds reported to induce these changes included 
PIs: Indinavir, Nelfinavir, Lopinavir, Ritonavir, Saquinavir, Atazanavir and NRTIs: Stavudine (d4T), 
Zidovudine (AZT), and Didanosine (Mondal et al., 2004, Ferraresi et al., 2006, Lagathu et al., 2007, 
Chandra et al., 2009, Touzet and Philips, 2010, Manda, 2011, Brandmann et al., 2012). The compounds 
Amprenavir (PI) and Abacavir (NRTI) were consistently reported as lacking these effects, making these 
drugs good candidates for inclusion in regimens to be prescribed to patients with HAND (Lagathu et al., 
2007).   
 
As the first available antiretroviral drug, AZT has been extensively studied. While AZT may not be a 
mainstay drug of choice for customized optimal regimens, as the primary ART compound available in 
resource-limited developing countries, it is still of importance to understand its cellular effects. AZT was 
approved for treatment in 1987, and as early as 1992 the Papoian laboratory reported deficits in 
mitochondrial enzymes and uncoupling of the electron transport chain (ETC) (Lewis et al., 1992). The 
disruption of the ETC is a primary cause of mitochondrial-based intracellular ROS accumulation and 
mitochondrial DNA oxidation, an effect since expounded upon in multiple laboratories after acute AZT 
exposure in isolated heart mitochondria and primary human cardiomyocytes, and after chronic gestational 
AZT exposure in mouse liver and kidney and in the lung and brain of fetal patas monkeys (de la Asuncion 
et al., 1999, Bialkowska et al., 2000, de la Asuncion et al., 2004, Gao et al., 2011). This compound has also 
been shown to increase mitochondrial lipid peroxidation, deplete intracellular glutathione, and lead to 
oxidation of remaining glutathione, ultimately inducing a caspase-3- and caspase-7- dependent apoptotic 
death (Yamaguchi et al., 2002, de la Asuncion et al., 2004, Gao et al., 2011). When another NRTI, d4T was 
investigated, it also was shown to produce ROS, mitochondrial oxidative stress, oxidized mitochondrial 
DNA, and altered activity of mitochondrial oxidative phosphorylation enzymes (Gerschenson et al., 2001, 
Velsor et al., 2004). Similarly, NRTI Zalcitabine (ddC) also induces oxidative stress, as evidenced by the 
accumulation of protein carbonyls and nitrotyrosine modifications. Interestingly, this study also reported 
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that the better-tolerated cytidine analog Lamivudine (3TC) did not produce these effects, suggesting that 
3TC may be considered as an alternative to reduce oxidative stress, and that future compounds generated 
from this structural base may behave similarly (Opii et al., 2007). Interestingly, in contrast to studies in 
human lymphoid cells, Brandmann and colleagues have recently reported that in astrocytes AZT, 
Lamivudine, Efavirenz, and Nevirapine do not appear to reduce intracellular levels of glutathione 
(Brandmann et al., 2012). Whether or not these compounds behave similarly in neurons and other cell 
populations in the CNS remains to be elucidated. 
  
In the non-nucleoside reverse transcriptase inhibitor (nNRTI) drug class, Efavirenz applied to a human 
hepatoblastoma cell line resulted in superoxide generation, depletion of intracellular glutathione, and 
decrease in mitochondrial function and membrane potential that was independent of mitochondrial DNA 
replication (Apostolova et al., 2010). In addition, Efavirenz has also been linked to neuropsychological side 
effects in HIV-infected patients, and it is probable that the specific oxidative stress effects on mitochondria 
and glutathione may play a role in the neurotoxicity of this compound, as neurons are particularly sensitive 
to perturbations in the antioxidant system (Apostolova et al., 2010, Ciccarelli et al., 2011). 
 
Within the protease inhibitor class, both Ritonavir and Amprenavir have been associated with increased 
superoxide anion production, while Ritonavir has been shown to cause increases in nitrotyrosine levels in 
porcine coronary arteries (Chai et al., 2005). On the other hand, both Indinavir and Nelfinavir have been 
shown to induce a time and concentration dependent depletion of intracellular glutathione in astrocytes as 
well as in pancreatic beta cells (Chandra et al., 2009, Brandmann et al., 2012). Nelfinavir is of particular 
interest, as it suppresses cytosolic, rather than mitochondrial superoxide dismutase levels, and induces a 
necrotic rather than apoptotic cell death cascade in an adipocyte cell line (Vincent et al., 2004, Chandra et 
al., 2009). Future studies of this compound will undoubtedly prove interesting and may have important 
implications in patients with regard to their neurocognitive outcomes associated with this compound. 
Finally, it is interesting to note that multiple studies investigating the oxidative effects of the thymidine 
analogs in the NRTI class have reported increased ROS, hydrogen peroxide, and nitric oxide intermediates 
but no superoxide anions (Ferraresi et al., 2006, Amatore et al., 2010).  
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Currently, there is no information on possible oxidative effects of the entry inhibitor, integrase inhibitor, 
and mutation inhibitor drug classes. Similarly, the lack of published studies for the neuroglial cell 
populations in the brains of HAND patients is surprising. In order to design custom drug regimens which 
will not precipitate, or can ameliorate oxidative stress, cellular dysfunction and death, it is critical to have 
an understanding of the cellular effects of each currently approved antiretroviral compound, and to design 
future compounds with minimal oxidative effects. Further, it is possible that the continued dysfunction in 
superoxide production and superoxide dismutase levels in patients may be due to the effects of more than 
one drug in a multi-drug regimen. Thus, designing future combinations which do not precipitate oxidative 
stress is of utmost importance in efforts to resolve the persistence of HAND observed in the ART era.  
 
2.5 POTENTIAL THERAPEUTIC AVENUES FOR OXIDATIVE STRESS IN THE ART ERA 
Since the manifestations of oxidative stress induced by HIV and ART have emerged, it has also become 
evident to scientists that boosting the endogenous antioxidant response may be a valid and encouraging 
adjunctive therapeutic option. Within the cell, the antioxidant response is mediated through the activation 
of transcription factor NF-E2 (nuclear factor (erythroid-derived 2))-related factor-2 (Nrf2) and its myriad of 
effector phase II and III detoxifying enzymes. Relevant to the previously discussed aberrations in oxidant 
detoxification, this pathway upregulates superoxide dismutase, peroxiredoxins, thioredoxins, and multiple 
glutathione biosynthesis enzymes (Shih, 2003, Li, 2009).   
 
In vitro, multiple compounds which act upon the Nrf2 pathway have proven effective in ameliorating the 
oxidative effects of viral infection, viral proteins, or antiretroviral drugs. Among these compounds are 
resveratrol, dimethyl fumarate, N-acetylcysteine, and curcurmin (Chai et al., 2005, Touzet and Philips, 
2010, Cross et al., 2011, Gao et al., 2011, Manda, 2011). Antioxidants which have not yet been shown to 
act through the Nrf2 pathway, but which have similar effects in vitro include dihydroxybenzyl alcohol, 
water soluble vitamin E (trolox), glutathione mimetic tricyclodecan-9-yl-xanthogenat, and acetyl-l-carnitine 
(Ferraresi et al., 2006, Opii et al., 2007, Apostolova et al., 2010, Weakley et al., 2011). An alternative 
approach to specifically inhibit the actions of NADPH oxidase through the compound diphenylene 
iodonium, was able to specifically prevent the effects of PIs, but not NRTIs in human adipocytes (Lagathu 
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et al., 2007). This interesting finding suggests that the different antiretroviral classes may lead to ROS 
production through different mechanisms, and that specific therapeutics targeting individual oxidant-
producing enzymes or pathways may need to be considered for specific ART regimens.   
 
An alternative approach to activating Nrf2 pathway is supplementation with the antioxidant vitamin C 
(ascorbate), which is capable of directly scavenging reactive oxygen and nitrogen species. This method has 
been shown to be effective in counteracting the deleterious effects of gp120, as well as Nelfinavir in vitro, 
and has been shown to have beneficial outcomes in patients, when supplemented to ART regimens (de la 
Asuncion et al., 2004, Vincent et al., 2004, Walsh et al., 2004). Along these same lines, supplementation 
with a variety of other antioxidants and micronutrients including minocycline, glutathione replenishing 
peptide alpha-lipoic acid, selenium, vitamin A, Vitamin E, and a multivitamin regimen including vitamins 
A, C, E selenium and coenzyme Q10 have demonstrated partial protection from the deleterious oxidative 
effects of HIV/SIV and ART in vivo, with particular emphasis on restoration of the total blood glutathione 
levels (Delmas-Beauvieux et al., 1996, Batterham et al., 2001, de la Asuncion et al., 2004, Jariwalla et al., 
2008, Meulendyke et al., 2012). Finally, the NMDA-receptor blocker memantine, and monoamide oxidase 
type B inhibitor selegiline, approved for treatment in Alzheimer and Parkinson Diseases, respectively, have 
also been proposed as potential therapeutics for HAND (Batterham et al., 2001, Lindl et al., 2010). 
Memantine might exert therapeutic effects through reduction of residual virus-mediated glutamate 
excitotoxicity, and selegiline has been reported to be capable of reducing oxygen-based free radicals 
(Nagatsu and Sawada, 2006, Kutzing et al., 2012). The use of these compounds and their efficacy in 
reducing oxidative damage in HAND are still in early stages. Initial studies were confounded by the fact 
that much damage was already present in late stage HAD patients and a protective effect at this stage was 
not evident (Schifitto et al., 2009). Further work with these compounds will require identifying patients 
with ANI or MND to enroll in longitudinal studies to determine whether these compounds will have long-
term benefit.  
 
Going forward, it is imperative that the oxidative stresses imposed by HIV and ART are targeted by 
adjunctive therapies. As research progresses with the quest for eliminating viral reservoirs and designing 
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more effective, less toxic antiretroviral compounds, it is important to keep in mind that oxidative stress is 
and will continue to be a persistent burden, especially in a patient population with a significantly enhanced 
life expectancy. 
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3.1 ABSTRACT 
HIV-associated neurocognitive disorder (HAND), characterized by a wide spectrum of behavioral, 
cognitive, and motor dysfunctions, continues to affect approximately 50% of HIV(+) patients despite the 
success of combination antiretroviral drug therapy (cART) in the periphery. Of note, potential toxicity of 
antiretroviral drugs in the central nervous system (CNS) remains remarkably underexplored, and may 
contribute to the persistence of HAND in the cART era. Previous studies have shown antiretrovirals 
(ARVs) to be neurotoxic in the peripheral nervous system in vivo and in peripheral neurons in vitro. 
Alterations in lipid and protein metabolism, mitochondrial damage, and oxidative stress all play a role in 
peripheral ARV neurotoxicity. We hypothesized that ARVs also induce cellular stresses in the CNS, 
ultimately leading to neuronal damage and contributing to the changing clinical and pathological picture 
seen in HIV-positive patients in the cART era. In this report, we show that ARVs are neurotoxic in the 
CNS in both pigtail macaques and rats in vivo. Further, in vitro, ARVs lead to accumulation of reactive 
oxygen species (ROS), and ultimately induction of neuronal damage and death. While ARVs alone caused 
some activation of the endogenous antioxidant response in vitro, augmentation of this response by a 
fumaric acid ester, monomethyl fumarate (MMF), blocked ARV-induced ROS generation and neuronal 
damage/death. These findings implicate oxidative stress as a contributor to the underlying mechanisms of 
ARV-induced neurotoxicity, and will provide an access point for adjunctive therapies to complement ARV 
therapy and reduce neurotoxicity in this patient population. 
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3.2 INTRODUCTION 
Despite introduction of combination antiretroviral therapy (cART), HIV-associated neurocognitive disorder 
(HAND) continues to affect approximately 50% of HIV(+) patients (Dore et al., 1999, Heaton et al., 2010). 
Further, in the cART era, the underlying neuropathology has shifted from overt subcortical involvement to 
a more insidious cortical damage (Gannon et al., 2011). Various factors, such as poor adherence to drug 
regimen, emergence of resistant virus species, and residual viral DNA in the CNS, may contribute to these 
changes (Gannon et al., 2011). However, another likely contributor to HAND in the cART era is the 
virtually unstudied potential for antiretroviral (ARV)-related toxicity in the CNS. cART has decreased 
HIV-related morbidity and mortality by limiting T-cell loss and controlling opportunistic infections. 
However, cART regimens are associated with potentially serious side-effects, including dyslipidemia, 
lipohypertrophy, and increased risk of atherosclerosis (Vidal et al., 2010). Additionally, cART-associated 
toxicity in the peripheral nervous system is well-documented, and it is likely that cART would trigger 
similar responses in the CNS. Pharmacokinetic studies suggest limited ARV penetrance into the CNS and 
indicate low cerebrospinal fluid (CSF) and parenchymal drug concentrations (Yilmaz et al., 2004, Yilmaz 
et al., 2009). However, direct blood-brain barrier (BBB) compromise by viral proteins and 
neuroinflammation and indirect BBB impairment due to concomitant factors, such as coexisting infections, 
can lead to increased CSF and parenchymal drug concentrations. Thus, the impact of ARVs in the CNS of 
HIV(+) patients is clinically relevant and must be examined. 
 
Initial cART usually includes two nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs) in 
combination with a non-nucleoside reverse-transcriptase inhibitor (nNRTI) or with a protease inhibitor (PI) 
boosted with a low dose of a second PI, Ritonavir. NRTIs and nNRTIs bind to the HIV reverse 
transcriptase enzyme and inhibit pro-viral DNA synthesis; PIs inhibit viral proteases needed for virus 
maturation and assembly. Despite some crossover, certain ARV classes are more highly associated with 
particular side effects and toxicities than are other classes. PIs alter lipid metabolism and induce the 
endoplasmic reticulum stress response in macrophages, linking PIs to increased risk of atherosclerosis 
(Touzet and Philips, 2010). NRTIs inhibit DNA polymerase-γ and lead to decreased mitochondrial DNA, 
loss of mitochondrial membrane potential and oxidative phosphorylation, consequently precipitating 
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oxidative stress (Nolan and Mallal, 2004). Previous studies exploring possible side effects of ARVs in the 
CNS are scarce and mostly involve cell lines (Cui et al., 1997). Due to mutations and aberrations in 
immortalized cell lines, these studies may not reflect the ARV toxicity potentially occurring in biological 
settings. Peripheral dorsal root ganglia neurons are the only primary cell type of neural lineage previously 
studied for ARV toxicity (Werth et al., 1994).  In this report, we examined effects of ARVs in primary CNS 
neurons both in vivo and in vitro. Our findings suggest that cART induces oxidative stress and 
neurotoxicity in the CNS, and that the patients on long-term cART regimens would benefit from adjunctive 
therapies that include antioxidant strategies to overcome deleterious effects of cART in the CNS. 
 
3.3 MATERIALS AND METHODS 
Chemicals and reagents. AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, 
NIH: antiretroviral reagents. Abcam (Cambridge, MA): mouse monoclonal NAD(P)H:quinone 
oxidoreductase-1 (NQO-1) antibody (A180), mouse monoclonal synaptophysin antibody (SY38). BioRad 
(Hercules, CA): Biosafe coomassie stain, Immunblot polyvinylidene fluoride (PVDF) membrane, pre-
stained broad range molecular weight ladder. Cell Signaling Technology (Danvers, MA): rabbit polyclonal 
antibody raised against cleaved caspase-3. Citifluor, Ltd. (London, UK): citifluor AF1. Covance (Princeton, 
NJ): mouse monoclonal microtubule-associated protein 2 (MAP2) antibody (SMI-52). Dako (Carpinteria, 
CA): rabbit polyclonal glial fibrillary acidic protein (GFAP) antibody (Z0334). Enzo Life Sciences 
(Farmingdale, N.Y): rabbit polyclonal antibody to heme-oxygenase-1 (HO-1). Frontier Scientific (Logan, 
UT): Sn(IV) mesophorphyrin IX dichloride (SnMP). Jackson ImmunoResearch Labs (West Grove, PA): 
fluorescein isothiocyanate-conjugated goat anti-mouse IgG and Cy3- conjugated goat anti-rabbit IgG 
secondary antibodies. Invitrogen (Carlsbad, CA): Dulbecco’s Modified Eagle’s Medium (DMEM), 
tetramethyl rhodamine methyl ester (TMRM), goat anti-mouse beta-lactamase TEM-1 conjugate, 
fluorocillin green substrate, dihydroethidium (DHE), 4',6-diamidino-2-phenylindole (DAPI), neurobasal 
media, B27 supplement. New England Biolabs (Ipswich, MA): tyramide amplification system. Peptide 
International (Louisville, KY): poly-L-lysine. Sigma Aldrich (St. Louis, MO):  carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), cytosine arabinoside (Ara-C), fetal bovine serum (FBS), monomethyl 
fumarate (MMF), oligomycin, propidium iodide and protease inhibitor cocktail. ScyTek Labs (Logan, UT): 
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normal antibody diluent. Thermo Scientific (Waltham, MA): goat anti-rabbit horseradish peroxidase (HRP) 
antibody and goat anti-mouse HRP antibody, SuperSignal West Dura extended duration substrate. Tocris 
Bioscience (Ellisville, MO): thapsigargin. The antibody against calpain-cleaved spectrin was a generous 
gift from Dr. Robert Siman (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA).  
 
Primary Cortical Neuroglial Cultures. Primary rat cortical neuroglial, pure neuronal, and pure astrocytic 
cultures were isolated from embryonic day 17 Sprague Dawley rat pups, with modifications of protocols 
previously described (Wilcox et al., 1994). Briefly, the cortical cell suspensions isolated from rat pups 
following standard protocols were plated on poly-L-lysine coated T25 tissue culture flasks (2 x 106 
cells/flask), 96-well tissue culture plates (0.5 x 105 cells/well), or glass coverslips (0.25 x 106 cells/well). 
These cultures were maintained in neurobasal media with B27 supplement at 37°C with 5% CO2 for the 
generation of neuroglial cultures, as described previously (Wang et al., 2010, Akay et al., 2011b, White et 
al., 2011). Half of the media was replaced with fresh media every 7 days and the experiments were 
performed at 21 days in vitro (DIV), at which time the cultures contain approximately 85-90% neurons and 
10-15% astrocytes/glia. For the preparation of pure neuronal cultures, cultures were treated with 10µM 
Ara-C 48 hours after plating and maintained in neurobasal media with B27 supplement at 37°C with 5% 
CO2; at 21 DIV, the age at which the experiments were conducted, no astrocytes are detectable by staining 
for GFAP. Pure astrocytic cultures were prepared by initially plating the cortical cell suspensions in 10% 
fetal bovine serum (FBS) in DMEM and maintaining at 37°C with 5% CO2 for 7-12 days, after which time 
astrocytes constitute more than 90% of the cultures. These pure astrocytic cultures are then re-plated in T25 
flask or poly-L-lysine-coated glass coverslips in DMEM/10% FBS and the experiments are conducted 3-5 
days after re-plating. 
 
SIV/pigtail macaque model of HIV CNS Disease. Juvenile pigtailed macaques (Macaca nemestrina) 
were inoculated with SIV/DeltaB670 and SIV/17E-Fr, as described previously (Zink et al., 1999). 
Beginning 12 days after inoculation, animals were treated daily with a four ARV drug combination (cART) 
until necropsy (range, day 161–175). The treatment consisted of the NRTI Tenofovir (Gilead) at 30 mg/kg 
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subcutaneously every day; the PIs Saquinavir (Roche) and Atazanavir (Bristol- Myers Squibb) at 205 and 
270 mg/kg orally twice a day, respectively; and the integrase inhibitor L-870812 (Merck) (Hazuda et al., 
2004) at a dose of 10 mg/kg orally twice a day (Zink et al., 2010). The Tenofovir dose was determined on 
the basis of previous studies (Tsai et al., 1997), while Atazanavir and Saquinavir doses were determined by 
pharmacokinetic experiments conducted in pigtailed macaques, and reflected those that resulted in the same 
area under the curve as detected in humans treated with Atazanavir and Saquinavir (Zink et al., 2010). The 
dose of the integrase inhibitor was based on a previous study conducted in rhesus macaques (Hazuda et al., 
2004). 
 
Rodent model of antiretroviral-induced neurotoxicity. All surgical procedures were performed with the 
approval of the Institutional Animal Care and Use Committee. Adult male Sprague Dawley rats were 
catheterized via jugular vein, as described previously (Thrivikraman et al., 2002). The drug cocktail 
composed of AZT (100mg/kg/day), Ritonavir (20mg/kg/day), and Saquinavir (25mg/kg/day) was 
administered twice daily for 7 days by continuous intravenous injection. Each drug dose was based on 
previously published studies in rodents (Shibata et al., 2002, Huisman et al., 2003, Manda et al., 2010, 
Pistell et al., 2010, Waring et al., 2010, Yang et al., 2010, du Plooy et al., 2011, Fontes et al., 2011, Lledo-
Garcia et al., 2011, Wagner et al., 2011, Mak et al., 2013, Reyskens and Essop, 2013a, b, Reyskens et al., 
2013). The catheters were flushed with 0.3 ml heparin (50 IU/ml) in PBS until the end of treatments. At 
time of euthanasia, preceding decapitation and tissue harvest, catheter patency was re-verified by response 
to pre-euthanasia sedation (100mg/kg ketamine/ 10mg/kg xylazine). The brains were removed, the frontal 
cortex and the hippocampus were dissected on ice, and the tissue samples were stored at -80 °C until 
immunoblot analysis.  
 
Immunofluorescence Staining of Tissue. Tissue slides of paraffin-embedded tissue sections from 
hippocampus of male and female pig-tailed macaques (Macaca nemestrina) were prepared for 
immunofluorescent staining, as described previously (Akay et al., 2011a). Briefly, glass slides containing 
paraffin-embedded sections (10 mm) were heated to 55°C for at least 30 min, deparaffinized in Histoclear, 
and rehydrated with consecutive 100%, 95%, 90% and 70% ethanol washes. Endogenous peroxidase 
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activity was blocked with 3% H2O2 in methanol and antigen unmasking was achieved with target retrieval 
solution at 95°C for 1 h. Tissue sections were blocked with 10% normal goat serum in phosphate-buffered 
saline solution (PBS). Mouse monoclonal antibodies to synaptophysin, MAP2, and rabbit polyclonal 
antibody to GFAP were used at empirically defined dilutions (synaptophysin at 1:500, MAP2 at 1:100; 
GFAP at 1:80), and DAPI was used to stain nuclei. The tyramide amplification system was used to detect 
synaptophysin. Slides were mounted in Citifluor AF1, and for each specimen, 5-10 randomly selected areas 
within the CA1-CA3 layer of the hippocampus were scanned along the z-axis to create z-stack images at 
high-magnification (600X) by laser confocal microscopy on a Biorad Radiance 2100 equipped with Argon, 
Green He/Ne, Red Diode, and Blue Diode lasers (Biorad, Hercules, CA). Post-acquisition analysis was 
conducted using MetaMorph 6.0 (Universal Imaging, Downingtown, PA). Total intensity for 
synaptophysin, MAP2 and GFAP were determined by the measurement of integrated pixel intensity for 
synaptophysin, MAP2 or GFAP per z-stack image, where the integrated pixel intensity is defined as total 
pixel intensity per image times the area of pixels positive for synaptophysin, MAP2 or GFAP. Averages are 
expressed as mean ± SEM. All data was analyzed by Prism 5.0 (GraphPad Software, San Diego, CA).  
 
MAP2 Cell-Based ELISA. A MAP2 cell-based ELISA was performed to quantify neuronal damage/death 
as previously described (White et al., 2011). Briefly, primary rat cortical neuroglial cultures plated in 96-
well plates were fixed for 30 min with 4% paraformaldehyde in 4% sucrose at the conclusion of treatments. 
After blocking for 1 hour with 5% normal goat serum in PBS, the plates were incubated with monoclonal 
MAP2 antibody overnight at 4°C, followed by washes with PBS with 0.1% Tween-20 (PBS-T). The plates 
were then incubated for 30 min with goat anti-mouse secondary antibody conjugated to beta-lactamase 
TEM-1 at room temperature, washed with PBS-T, and incubated in the dark at room temperature for 1 hour 
in fluorocillin green substrate. Fluorescence intensity was measured using a Fluoroskan Ascent fluorometer 
plate reader (Thermo Electron, Waltham, MA) with excitation at 485 nm and emission at 527 nm.  
 
Hand-Counting of MAP2-Positive Cells. As a complementary method to MAP2 ELISA, neuronal 
survival was verified by hand-counting of MAP2-positive neurons. 15mM propidium iodide was added to 
primary cortical neuroglial cultures grown on coverslips 15 minutes before the end of the treatments. The 
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coverslips were washed once with PBS and fixed for 30 min with 4% paraformaldehyde in 4% sucrose, 
followed by blocking and permeabilization in 0.2% BSA + 0.1% Triton X-100 in PBS for 1 hour at room 
temperature (RT). The coverslips were then washed twice with PBS and incubated with anti-MAP2 
antibody (1:100) in normal antibody diluent for 2 hours at RT. After two washes with PBS-T, the 
coverslips were incubated in a fluorescein isothiocyanate-conjugated goat anti-mouse IgG secondary 
antibody (1:200) for 30 min at RT. The coverslips were mounted on slides and alive/dead neurons were 
hand-counted based on MAP2 and PI-positive staining using a Nikon Eclipse E400 fluorescent microscope 
(Nikon Corp, Tokyo, Japan) equipped with Olympus DP70 digital camera (Olympus Corp, Tokyo, Japan). 
Live cells stain negative for PI, while dead cells retain it in their nuclei. The number of surviving MAP2-
positive neurons will be positive for MAP2 and negative for PI staining. The percentage of MAP2-positive 
cells ± SEM were calculated from blinded counting of six fields at 200X in two adjacent vertical columns 
through the center of each coverslip, proceeding from top to bottom and bottom to top. For each condition, 
three coverslips were counted from two or more independent experiments.  
 
Quantification of Synaptophysin. Cultures grown on coverslips, as described above, were 
immunofluorescently stained for synaptophysin (1:1000), MAP2 (1:100), and DAPI. Tyramide 
amplification was used for the detection of synaptophysin. For each treatment condition, images of 10 
randomly selected areas from 3 coverslips from 3 independent experiments were captured by fluorescence 
microscopy. Post-acquisition analysis was performed using the NIH ImageJ program (V1.36b, Bethesda, 
MD). Briefly, synaptophysin-positive puncta were detected by background subtraction and manual 
thresholding. The number of synaptophysin-positive puncta was determined by dividing the total number of 
puncta within a dendrite segment by the length of the segment.  
 
Measurement of Reactive Oxygen Species. The superoxide indicator dihydroethidium (DHE, Invitrogen) 
was used to detect the presence of reactive oxygen species in vitro. 3mM DHE was added to culture media 
15 min prior to conclusion of treatments. Cells were then washed with PBS, fixed with 4% 
paraformaldehyde in 4% sucrose at RT for 8 min, and stained for DAPI. The coverslips were then mounted 
on slides with CytoSeal and visualized using fluorescent microscopy, as described above. Post-acquisition 
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analysis was performed using MetaMorph to determine the fluorescence intensity of DHE normalized to 
the area of DAPI signal.  
 
Immunoblotting. Whole cell extracts of rat tissue samples were prepared by homogenization in ice-cold 
tissue extraction buffer (50mM Tris pH 7.5, 0.5M NaCl, 1% NP-40, 1% SDS, 2mM EDTA, 2mM EGTA, 
5mM NaF, 0.4mM Na3VO4, 1mM dithiothreitol (DTT) and 1:100 protease inhibitor cocktail), followed by 
centrifugation at 12,000 g at 4oC for 20 min. Whole cell extracts of primary rat cortical cultures were 
prepared with ice-cold cell lysis buffer (50mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 10 mM EDTA, 
0.4 mM Na3VO4, 100 mM DTT and 1:100 protease inhibitor cocktail), followed by centrifugation at 14,000 
g at 4oC for 10 min. The protein concentrations of the collected supernatants were determined using the 
Bradford method and 25-50 µg of protein was loaded into each lane of a 4-12% Bis-Tris gradient gel for 
separation. A broad range molecular weight ladder was run on each gel. Subsequent to separation, proteins 
were transferred onto PVDF membranes, and blocked in tris-buffered saline (TBS) with 0.1% Tween-20 
(TBS-T) and 5% bovine serum albumin (BSA) for 1 hour at room temperature. The membranes were 
incubated with the primary antibodies in TBS-T with 5% BSA at 4oC overnight, washed with TBS-T, 
followed by incubation with corresponding HRP-conjugated secondary antibodies. The membranes were 
developed using SuperSignal West Dura extended duration substrate.  Loading controls were obtained by 
staining the membranes and the gels with the Biosafe Coomassie Stain for 20 min, followed by destaining 
with deionized water for 30 min. For densitometric analysis, autographs were scanned into Adobe 
Photoshop (Adobe Systems, San Jose, CA) and regions of interests (ROI) of equal size were determined for 
each band. The pixel intensities of ROIs were quantified using the NIH ImageJ program (V1.36b, 
Bethesda, MD). Target band intensities were normalized to gel and membrane coomassie stain controls to 
account for protein degradation and loading discrepancies, and the normalized target band intensities were 
used to quantify fold changes over controls.  
 
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR). The expression of HO-1 
and NQO-1 genes in rat neuroglial cells was quantified by qRT-PCR. Custom TaqMan® Gene Expression 
Assays were purchased from Applied Biosystems for the genes: NQO-1 (Rn00566528_m1) and HO-1 
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(Rn01536933_m1). Approximately 5ng cDNA was used per reaction. StepOne™ Software v2.0 was used 
to construct the experimental protocol and the qRT-PCR took place in the StepOne Real-Time PCR System 
(Applied Biosystems, Carlsbad, CA). Data was normalized using both b-actin (Rn00667869_m1) and 18S 
(Hs99999901_s1) and was analyzed according to the ΔΔCT method. All samples were run in triplicate from 
three biological replicates.  
 
Statistical analysis. All data was analyzed by Prism 5.0 software (GraphPad Software, San Diego, CA). 
Values are expressed as mean ± SEM, and values of p < 0.05 were considered significant for all statistical 
analyses performed. 
 
3.4 RESULTS 
Antiretroviral drugs lead to neuronal damage in vivo 
cART-induced peripheral neuropathy is well-documented (Power et al., 2009), and it is likely that cART 
triggers similar damage to neurons in the CNS. To determine the neurotoxic potential of cART in the CNS, 
we assessed the effects of an ARV regimen on the expression of synaptophysin and MAP2, indicators of 
synaptic damage and neuronal loss, respectively, utilizing post-mortem tissue from a well-characterized 
SIV/pigtail macaque model of HIV CNS disease, which was designed to address the efficacy of CNS 
penetrant antiretroviral therapy in reducing viral load in the CNS (Zink et al., 2010). In this study, animals 
infected with SIV either received no cART or received early cART treatment that included Tenofovir 
(NRTI), Atazanavir (PI), Saquinavir (PI), and L-870812a (integrase inhibitor) 12 days after the virus 
inoculation. Without cART, 90% of animals develop neurologic disease within 3 months post-inoculation 
(p.i.). In contrast, animals receiving cART do not develop SIV encephalitis. Rather, they show a rapid 
reduction in their plasma and CSF viral load followed by continued suppression of SIV replication with 
maintenance of CD4+ T cell counts until elective euthanasia around day 160 p.i. Additionally, cART-
treated animals do not exhibit any outward signs of neurological deficits. Further, our quantitative 
immunofluorescent analysis of hippocampal tissue sections revealed reduced astrogliosis in the 
hippocampus of SIV-infected, cART-treated animals (SIV(+)/cART), compared with SIV-infected 
macaques that did not receive cART ((SIV(+)/placebo)) (Figure 3.1B). However, we observed statistically 
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significant decreases in synaptophysin expression in the hippocampi of the SIV(+)/cART group, compared 
with that in either the uninfected or the SIV(+)/placebo group (Figure 3.1A and 3.1D). In addition, 
examination of the expression of a second marker of synaptodendritic integrity, calmodulin kinase II 
(CaMKII), by immunoblotting showed that CaMKII levels were significantly lower in the frontal cortex in 
the SIV(+)/cART macaques than in their SIV(+)/placebo counterparts (Figure 3.1E and 3.1F). CaMKII is 
highly expressed in neurons of macaque hippocampus and frontal cortex, whereas its expression in other 
cell-types, including microglia, infiltrating macrophages, and multinucleated giant cells, is minimal; thus, 
the differences in CaMKII expression in frontal cortex of the animals from our experimental groups are 
neuron-specific (Gupta et al., 2010). Our results demonstrate synaptic injury in the presence of cART 
despite effective control of SIV replication in the periphery and CNS. Interestingly, we did not observe 
changes in MAP2 fluorescence in the hippocampus of infected and/or cART-treated animals compared 
with untreated/uninfected animals (Figure 3.1A and 3.1C). 
 
As studies of uninfected, cART-treated macaques have not been performed to determine the contribution of 
cART to neuronal damage independent of SIV infection, we administered combinations of ARVs 
intravenously to adult rats. In patients, initial cART usually includes two nucleoside/nucleotide reverse-
transcriptase inhibitors (NRTIs) in combination with a non-nucleoside reverse-transcriptase inhibitor 
(nNRTI) or with a protease inhibitor (PI) boosted with a low dose of a second PI, Ritonavir (Rit). Thus, we 
used Zidovudine (AZT), an NRTI, along with two PIs, Saquinavir (Saq) and Rit, at doses based on 
previously published pharmacokinetic studies of these ARVs (Busidan and Dow-Edwards, 1999, 
Kageyama et al., 2005, Pistell et al., 2010). In agreement with previous studies (Waring et al., 2010), the 
animals showed no overt signs of distress during the course of the treatment. However, via 
immunoblotting, we observed decreases in hippocampal synaptophysin expression in cART-treated rats 
compared with vehicle-treated rats (Figure 3.1G), complementing our findings of synaptic damage in 
SIV(+)/cART macaques and further supporting a role for ARV-associated neuronal injury in the CNS. Of 
note, we also detected decreases in MAP2 levels in the cART-treated rat hippocampus (Figure 3.1G), 
which likely reflects the acute drug toxicity in this treatment paradigm, compared to the subtler synaptic 
injury observed in the cART-treated macaque brain.    
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Antiretroviral compounds in therapeutically relevant combinations are neurotoxic in vitro 
The only primary neural cell-type previously studied for ARV toxicity was dorsal root ganglia neurons in 
models of peripheral neuropathy (Werth et al., 1994). Here, to expand our studies on ARV neurotoxicity in 
the CNS, we used primary rat cortical neuroglial cultures aged 21 days in vitro (DIV) (O'Donnell et al., 
2006, Wang et al., 2007, White et al., 2011). We first evaluated the neuronal viability in response to 
increasing concentrations of AZT, Rit, or Saq. We based the range of doses on reported plasma and CSF 
levels of ARVs (Wynn et al., 2002, Anthonypillai et al., 2004). Importantly, animal studies predict brain 
parenchymal levels to be equal to or greater than CSF levels (Anthonypillai et al., 2004, Anderson and 
Rower, 2010). At 48 hours post-treatment with individual ARVs, Rit and Saq both led to dose-dependent 
decreases in MAP2-positive cells, as determined via hand-counting (Figure 3.2A and 3.2B, respectively). 
These results were confirmed with a cell-based MAP2 ELISA, which accurately reflects neuronal numbers, 
as well as neuronal damage (Figure 3.2D and 3.2E) (White et al., 2011). Furthermore, neuronal damage and 
death induced by Rit and Saq was time-dependent, as seen in Figure 2G, where the primary cortical 
cultures were exposed to individual ARVs for up to eight days. Additionally, both Rit and Saq led to dose-
dependent decreases in synaptophysin expression after 16 hours of treatment, well before the loss of 
MAP2-positive cells occurred (Figure 3.2H and 3.2I). However, AZT did not lead to decreases in MAP2-
positive cells, MAP2 fluorescence, or synaptophysin expression (Figure 3.2C, 3.2F, and data not shown, 
respectively). Next, we treated primary cortical cultures with drug combinations that included AZT, Rit, 
and Saq, alone or in combinations, for 48 hours, to assess acute neurotoxicity. As seen in Figure 3.2J and 
3.2K, combination treatments that included Rit induced statistically significant neuronal damage/death, 
which were preceded by loss of synaptophysin detected at 16 hours post-treatment (Figure 3.2L). 
Additionally, we observed similar levels of neuronal damage in cortical cultures treated with a combination 
of d4T, Rit, and Saq (not shown). However, as d4T is no longer prescribed in most developed countries and 
the AZT/Rit/Saq combination reflects the first considered/prescribed combination in initial treatment plans, 
we focused on AZT/Rit/Saq combination treatments for further experiments. Next, we determined that 
treatment with either Rit or Saq, alone or in combination with AZT, lead to the activation of the Ca2+-
activated death protease, calpain, as evidenced by the increase of calpain-cleaved spectrin observed in these 
cultures (Figure 3.3). Interestingly, none of the treatment combinations caused increases in the cleaved, and 
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therefore active, form of caspase-3 (Figure 3.3), suggesting that neuronal death observed in our model may 
be a necrotic cell death rather than an apoptotic cell death. Together the findings presented here suggest 
that combination ARV treatments that include PIs are toxic to cortical neurons in vitro. 
 
Combination antiretroviral drug treatments induce oxidative stress in neurons   
An extensive number of studies have linked ARVs, especially PIs, to oxidative stress (Touzet and Philips, 
2010). To determine whether neurons undergo oxidative stress when exposed to ARVs, we used 
dihydroethidium (DHE) as a marker for the presence of reactive oxygen species (ROS) (Rodriguez-Pallares 
et al., 2009). We included tert-Butyl hydroperoxide (tBHP), an organic pro-oxidant, at 100 mM, as a 
positive control. As seen in Figure 3.4A and quantified in Figure 3.4D, Rit/Saq and AZT/Rit/Saq 
combination drug treatments for 6 hours lead to ROS accumulation in cortical cultures, whereas ROS levels 
in vehicle-treated cultures were comparable to those in untreated cultures.  
 
The cortical cultures generated for our studies contain 85-90% neurons and 10-15% astrocytes (Figure 
3.4B); thus, we also determined the presence of ROS in pure neuronal and pure astrocytic cultures exposed 
to individual ARVs. As seen in Figure 3.4C and quantified in Figure 3.4E, Rit led to an early and sustained 
ROS production in pure neuronal cultures, while Saq-induced ROS accumulation occurred 24 hours after 
treatment. The transient ROS accumulation induced by AZT was resolved at 24 hours post-treatment. On 
the other hand, in pure astrocytic cultures, none of the three ARVs examined induced an appreciable 
sustained ROS generation, and only Rit caused a transitory ROS accumulation (Figure 3.5A and 3.5B). 
These data further suggest that the ARV-induced ROS production observed in primary cortical neuroglial 
cultures are occurring in neuronal cell populations.   
 
Endogenous antioxidant response activation by combination antiretroviral drugs 
Oxidative stress in cells triggers the transcriptional induction of oxidative stress responsive genes through 
the activation of the endogenous antioxidant response element (ARE) in their promoter regions (Chen and 
Kong, 2004). Thus, we determined the effect of ARVs on two such genes, NAD(P)H:quinone 
oxidoreductase-1 (NQO-1) and heme oxygenase-1 (HO-1). By quantitative reverse transcription 
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polymerase chain reaction (qRT-PCR), we observed increased mRNA levels of both NQO-1 and HO-1 in 
cultures treated with any of the tested combinations of ARVs, when compared with the levels in untreated 
cultures (Figure 3.6A and 3.6B, respectively), with the most striking increases observed in Rit/Saq-treated 
cultures. To determine whether the changes in the mRNA levels were reflected in protein levels, we used 
immunoblotting to examine protein levels of NQO-1 and HO-1. While we observed increases in NQO-1 
and HO-1 protein levels at 16h (Figure 3.6C), the changes were more robust in cultures treated for 48 hours 
(Figure 3.6D). Further, in vivo, we detected increased levels of HO-1 protein in hippocampal lysates from 
cART-treated rats (Figure 3.6E and 3.6F). Interestingly, NQO-1 levels were not increased in cART-treated 
rat hippocampus (Figure 3.6E). Of note, we did not observe an antioxidant response in ARV-treated pure 
astrocytic cultures (Figure 3.5C, D and E). These data collectively suggest an activation of HO-1, as part of 
the endogenous antioxidant response, following ARV treatments in neurons.  
 
Monomethyl fumarate (MMF) protects against ROS generation and induces activation of the 
endogenous antioxidant response  
NQO-1 and HO-1 are targets of the fumaric acid ester, dimethyl fumarate (DMF), and of its hydrolyzed and 
active metabolite, monomethyl fumarate (MMF) (Linker et al., 2011). Our recent study (Cross et al., 2011) 
has shown that DMF and MMF reduce neurotoxin release from HIV-infected macrophages through 
induction of HO-1. We reasoned that augmented or earlier induction of NQO-1 and HO-1 in neurons by 
pre-treatment with the active metabolite, MMF, would provide protection in our in vitro model of ARV-
induced neurotoxicity through an antioxidant effect. We first determined that MMF at 30-100 mM was not 
toxic in neuronal cultures, as determined by MAP2 ELISA (data not shown). Next, we pre-incubated 
primary cortical cultures with 100 mM MMF for 30 minutes before adding either Rit/Saq or AZT/Rit/Saq. 
Pre-incubation with MMF blocked ROS generation induced by ARV treatments lasting 6 hours (Figure 
3.7A), 16 hours, and 48 hours (data not shown). Quantification showed ROS levels in cultures pre-
incubated with MMF to be comparable to those detected in untreated and vehicle-treated cultures (Figure 
3.7B). Further, we observed an early increase in HO-1 protein levels at 4 hours in cultures pre-incubated 
with MMF, whether or not pre-treatment was followed by ARV treatment (Figure 3.7C). This trend was 
sustained at 16 hours after combination ARV treatment, as well. Next, we determined whether augmenting 
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the endogenous antioxidant response by MMF blocks MAP2 loss induced by combination ARV treatments. 
As detected by the cell-based MAP2 ELISA, MMF blocked neuronal damage/death in cultures treated with 
Rit/Saq and AZT/Rit/Saq for 72 hours (Figure 3.7D). Finally, pre-treatment of the cultures with an HO-1 
inhibitor, Sn(IV) mesophorphyrin IX dichloride (SnMP) (Zhao et al., 2004), reversed the MMF-induced 
decreases in ROS accumulation (Figure 3.7E), suggesting that MMF protection occurs through its 
augmentation of HO-1 expression.  
 
3.5 DISCUSSION 
Virus-related factors, such as resistant virus species and persistent viral DNA in the CNS, may contribute to 
the persistence of HAND in the post-cART era. One recent focus in HIV neurovirology is the development 
of ARVs with greater CNS penetrance (Letendre et al., 2008, Marra et al., 2009, Tozzi et al., 2009, Edén et 
al., 2010, Heaton et al., 2010, Garvey et al., 2011, Smurzynski et al., 2011). However, potential ARV 
toxicity in the CNS remains largely unexplored. Our study supports a possible contribution of the ARVs 
themselves to neuronal and synaptic damage observed in patients with HAND.  
 
In this study, we show cART-induced synaptophysin loss, indicative of synaptic injury in two animal 
models. In our first model, in an in vivo model of SIV-infected pig-tailed macaques, we report decreased 
synaptophysin and CaMKII levels in the SIV(+)/cART group compared with uninfected or SIV(+)/placebo 
groups, indicating synaptodendritic damage. Interestingly, MAP2 levels did not change significantly across 
groups, which may be due to the relatively short duration of infection in this retrospective study cohort. 
While these data demonstrate potential effects of cART drugs in the presence of viral infection, there are 
three variables to consider in interpretation of these findings: 1) the time to euthanasia from the start of the 
experiments is different between SIV(+)/placebo and SIV(+)/cART groups, 2) persistent viral DNA in the 
CNS of SIV(+)/cART group, and 3) the lack of SIV(-)/cART group. It is not yet known whether brain SIV 
DNA is replication competent. As we utilized post-mortem samples obtained from a cohort of macaques 
enrolled in a previous study addressing the efficacy of CNS penetrant cART in reducing viral loads in the 
CNS, further experiments that include an additional control group receiving cART but not inoculation with 
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SIV will be instrumental to more clearly determine the contribution of viral DNA and cART to synaptic 
damage in this model.  
 
In the second in vivo model presented here, adult rats received a therapeutically relevant combination of 
ARVs (NRTI+PI+Rit boost).  In the small number of studies where pharmacokinetics and effects of ARVs 
in the CNS were examined, pathological read-outs of neuronal damage, such as MAP2 or synaptophysin 
loss, were not determined (Huisman et al., 2003, Anthonypillai et al., 2004, Anthonypillai et al., 2006).  
Synaptic injury is a known indicator of neuronal damage and dysfunction in various neurodegenerative 
diseases, including HAND (Gupta et al., 2010) and synaptodendritic injury persists in HIV-infected 
individuals in the post-cART era (Xu and Ikezu, 2009). We observed decreases in synaptophysin and 
MAP2 protein levels in the hippocampus in response to ARV administration over 7 days. Thus, our model 
demonstrates that ARV-associated neurotoxicity warrants consideration in developing therapeutic regimens 
for HIV-infected patients.  
 
We also show that the PIs, Rit and Saq, alone or in combinations with the NRTI, AZT, induce oxidative 
stress and neuronal damage/death in primary cultures at clinically relevant doses. Previous studies 
examined ARV-induced toxicity in cell lines, and Robertson et al. have provided the first evidence for 
ARV-induced neurotoxicity in primary rat neurons (Robertson et al., 2012). Here, we provide further 
evidence that PI-induced oxidative stress and neuronal death in primary neurons can be blocked by the 
activation of the endogenous antioxidant response. Interestingly, in our experimental paradigm, the NRTI, 
AZT, neither induced neuronal damage/death by itself, nor augmented PI-induced damage/death when used 
in combination. We observed similar effects from a combination using another NRTI, stavudine (d4T) (not 
shown). In agreement with our observations, a previous study presented similar findings, specifically that 
neither AZT nor d4T inhibited cell growth or neurite regeneration in PC-12 cells after long-term drug 
exposure (Cui et al., 1997). It should be noted that NRTIs are unequivocally tied to peripheral neuropathy, 
where the underlying pathology is mitochondrial toxicity and oxidative stress. However, NRTIs affect only 
certain cell populations, as they are formulated as pro-drugs and, to become active, need to be 
phosphorylated by two kinases, thymidine kinase 1 and 2 (TK1, TK2), and the expression of the 
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cytoplasmic TK1 is cell cycle-dependent (Bazzoli et al., 2010). Thus, in our model utilized to study post-
mitotic neurons, AZT is most likely not converted to its active form, and thus does not contribute to 
neuronal damage/death. It is of note that our in vitro model of ARV-induced neurotoxicity utilized primary 
neuroglial cultures rather than cell lines. Primary cells are untransformed, and therefore more accurately 
reflect and predict ARV-associated effects occurring in the brains of patients on cART than would 
immortalized cell lines. The molecular pathways we investigated in this study are highly conserved from 
yeast to human cells; thus, the results obtained here in cells of rodent origin are likely conserved in human 
cells as well.  
 
The drug concentrations used in this study are based on the plasma and cerebrospinal fluid (CSF) levels 
reported by various in vitro and in vivo studies (Huisman et al., 2003). As reported in such studies, AZT 
can be detected in the CSF at concentrations that are similar to those measured in the plasma (Wynn et al., 
2002). Contrarily, as backed by various in vitro and in vivo studies (Wynn et al., 2002), both Rit and Saq 
are predicted to have limited CNS penetrance due to the strong tendency of these drugs to bind plasma 
protein because of their lipophilic nature and pharmacokinetic properties. However, a comprehensive study 
conducted in an in situ guinea pig model suggests that Rit can achieve high concentrations in choroid 
plexus and parenchyma through diffusion via the choroid plexus; in fact, the levels of Rit were comparable 
to levels measured in plasma (Anthonypillai et al., 2004). Further, the study showed that, surprisingly, the 
CSF levels of Rit were lower than the levels measured in the choroid plexus and the parenchymal 
compartments. Thus, the authors concluded that CSF concentrations of Rit may not necessarily reflect the 
parenchymal levels, which are indeed a better indicator of effective drug levels in the CNS. Rit and Saq 
concentrations in our experiments fall well within plasma ranges reported in patients receiving cART.  
 
Evidence of oxidative stress has long been associated with the most severe forms of HAND (Ngondi et al., 
2006, Mielke et al., 2010). Interestingly, despite systemic control of viral replication in cART-treated 
patients, markers of oxidative stress, such as elevated levels of lipid and protein oxidation, are still 
detectable in the brains of these individuals (Ances et al., 2008). Of note, oxidative stress is one of the 
underlying mechanisms involved in NRTI and PI-induced toxicity in the periphery. Our data suggest that 
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the sustained ROS accumulation in neurons due to prolonged exposure to ARVs might induce the oxidative 
stress associated with cART-induced toxicity in the CNS, leading to the observed changes in synaptophysin 
levels and the subsequent neuronal death.  
 
Our data also suggests that astrocytes do not show either ROS accumulation or the endogenous antioxidant 
response in vitro. We also observe that astrogliosis in SIV-infected animals is resolved in cART-treated 
animals. While these findings suggest that astrocytes may not be highly impacted by ARVs in the short 
term, it is possible that prolonged exposure to ARVs might overwhelm astrocytes, which help buffer ROS 
accumulation in neurons under normal conditions, precipitating further neuronal damage.  
 
We further show that the ARV drug-induced effects observed in this study can be blocked by MMF via 
activation of an endogenous antioxidant response. Cells respond to oxidative stress by activating the 
transcription of a subset of genes in an effort to clear excess ROS within the cell. Among these genes are 
NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1) (Chen and Kong, 
2004). Here, we show increased levels of NQO-1 and HO-1 mRNA and protein in ARV-treated neuronal 
cultures. Additionally, pre-treatment of cultures with MMF led to further increases in HO-1 protein levels 
in ARV-treated cultures and provided protection against ARV-induced toxicity. Finally, our finding that the 
protection provided by MMF is reversed with chemical inhibition of HO-1 further provides evidence that 
ARV toxicity is mediated via induction of oxidative stress. The neuronal damage and death that occurs 
despite the cellular initiation of the endogenous antioxidant response following exposure to ARVs suggests 
that this response may be insufficient or too delayed to protect cultures from ARV toxicity. In support of 
this explanation, we observed that MMF-mediated augmentation of antioxidant responses is strongly 
protective against the neurotoxic effects of ARVs. Further studies using this in vitro model are warranted to 
determine whether other clinically relevant ARV drug combinations induce neurotoxicity and, if so, to 
establish whether similar pathways are involved.  
 
DMF, a psoriasis treatment used in Europe since 1994, is currently being tested as a disease-modifying 
agent for Multiple Sclerosis (MS) ((2011), Krieger, 2011, Linker et al., 2011). MMF is the active DMF 
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metabolite in vivo. Our report is the first to show MMF as a neuroprotectant against ARV-induced damage. 
Data from studies in MS patients show that DMF/MMF has good tolerability, can cross the blood-brain 
barrier efficiently, and has relatively few and minor side-effects. Further, we have recently shown that 
DMF suppresses HIV replication, induces the antioxidant response in macrophaghes, and blocks 
neurotoxin release from macrophages (Cross et al., 2011). Overall, our findings make this 
immunomodulatory and antioxidant agent a good potential adjunctive therapeutic for use in HAND.  
 
One of the paradoxical outcomes of cART is the persistence of HAND, despite successful viral control. 
Moreover, there is a shift from overt dementia to more subtle neurocognitive impairments. Based on data 
presented here, we propose that different mechanisms by which HIV infection and cART induce neuronal 
damage underlie the changing neuropathology of HAND. Extensive studies have shown that during 
lentiviral infection, viral proteins and soluble factors secreted by infected cells lead to neuronal and 
synaptic damage via several direct as well as indirect mechanisms involving several cell types, including 
astrocytes. However, our data suggests that cART-mediated synaptic damage may involve direct 
mechanisms occurring specifically in neurons, such as oxidative stress, and that neurons, and not 
astrocytes, are the primary targets of cART-mediated damage in the CNS.  
 
It is most likely that chronic exposure to cART regimens including neurotoxic ARVs over many years is 
associated with a slower, nonetheless insidious changes including synaptic damage in the absence of 
neuronal loss, and these neuronal perturbations may contribute to, and may even precipitate, some of the 
clinical and pathological changes observed in the chronic course of HAND in the cART era. While 
detrimental, such slow damage also suggests that alterations in cART regimens to include ARVs with low 
neurotoxicity profiles, such as NRTIs or nNRTIs may halt synaptic damage, and provide a point where 
previous damage may be reversed, either due to the withdrawal of the toxic drug, or with the help of an 
adjuvant, such as fumaric acid esters. Future studies, first in primates, then in humans, will be crucial to 
explore the specific impact of treatment interruption on recovery from cART-mediated neuronal damage 
and to determine the efficacy of potential adjunctive therapies necessary to mitigate the side effects of 
cART in the CNS. 
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Figure 3.1 Antiretroviral drugs induce neuronal damage in vivo 
(A, B, C and D) Formalin-fixed, paraffin-embedded tissue sections from hippocampus of pig-tailed 
macaques that were either uninfected (n=6), SIV-infected but not cART-treated  (n=7), or SIV-infected and 
treated with cART (Tenofovir, Atazanavir, Saquinavir, and L-870812a) (n=4) were prepared for 
immunofluorescent analysis and were triple-labeled for MAP2 (red), synaptophysin (green) and GFAP. 
Sections were visualized by laser confocal microscopy and images were quantified for MAP2, 
synaptophysin and GFAP expression.  (A) Representative composite images of two cases per group which 
were stained with MAP2 and synaptophysin are shown. Scale bar = 30µm.  (B) Quantification shows the 
resolution of GFAP immunoreactivity in SIV(+)/cART group, compared with SIV(+)/placebo group (One-
Way ANOVA, *p<0.05). No changes were observed in MAP2 expression between groups (C), but there 
were statistically significant decreases in synaptophysin immunoreactivity (D) in SIV(+)/cART group, as 
compared with SIV(+)/untreated and uninfected groups (One-Way ANOVA, *p<0.05, ns: not significant). 
(E and F) Fresh-frozen tissue sections from the frontal cortex of pig-tailed macaques that were either 
uninfected (n=3), SIV-infected but not cART-treated (n=6), or SIV-infected and cART-treated (n=6) were 
used for standard protein extraction and subsequent immunoblotting for the expression of CaMKII. Actin 
was used as a loading control. A representative immunoblot is shown. Quantification shows statistically 
significant decreases in CaMKII in the cART-treated group, as compared with the uninfected group or the 
SIV(+)/untreated group (One-Way ANOVA, *p<0.05) (G) Whole-cell lysates prepared from hippocampus 
of rats treated for 7 days with AZT/Rit/Saq (n=4) or vehicle (n=2) were immunoblotted for synaptophysin 
and MAP2. A band from the coomassie blue staining is included to control for equal loading and protein 
degradation.  
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Figure 3.2 Therapeutically relevant combination antiretroviral drug treatments are neurotoxic in 
vitro 
 (A, B, and C) Primary rat cortical neuroglial cultures aged 21 days in vitro (DIV) on coverslips were 
exposed to Rit (A), Saq (B), or AZT (C) at increasing doses for 48 hours, followed by hand-counting for 
MAP2-positive cells. (n=3, vehicle: 0.04% DMSO, *p<0.05, One-Way ANOVA with post-hoc Newman-
Keuls). (D, E and F) 21DIV primary neuroglial cultures grown in 96-well plates were treated with 
increasing doses of Rit (D), Saq (E), or AZT (F) for 48 hours, followed by MAP2 cell-based ELISA (n=2, 
vehicle: 0.04% DMSO, *p<0.05, One-Way ANOVA with post-hoc Newman-Keuls). (G) Primary 
neuroglial cultures were treated with AZT (25 mM), Rit (10 mM), or Saq (1 mM) at day zero.  90% of the 
media was changed with conditioned media supplemented with a fresh drug stock every two days and 
cultures were analyzed by MAP2 cell-based ELISA at days 4 and 8 (n=2, vehicle: 0.04% DMSO, *p<0.05, 
One-Way ANOVA with post-hoc Newman-Keuls). (H and I) Cultures grown on coverslips were exposed 
to the indicated treatments and synaptophysin-positive puncta were determined (n=3, vehicle: 0.04% 
DMSO, *p<0.05, One-Way ANOVA with post-hoc Newman-Keuls). (J and K) Primary neuroglial 
cultures were exposed to the indicated drug combinations (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) for 48 
hours, followed by hand-counting for MAP2-positive cells (J) or MAP2 cell-based ELISA (K) (n=2, 
vehicle: 0.04% DMSO, *p<0.05, # p<0.01, One-Way ANOVA with post-hoc Newman-Keuls). (L) Primary 
neuroglial cultures that were exposed to the indicated drug combinations (AZT: 25 mM, Rit: 10 mM, Saq: 
1 mM) for 16 hours were analyzed for synaptophysin-positive puncta (n=2, vehicle: 0.04% DMSO, 
*p<0.05, One-Way ANOVA with post-hoc Newman-Keuls). 
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Figure 3.3 Activation of Calpain in antiretroviral drug-treated neurons 
Whole cell lysates were prepared from neuroglial cultures treated with the indicated single or combination 
drugs (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM), or with Thapsigargin (1mM) as a positive control, for 48 
hours. Calpain activation was assessed using an antibody to detect the accumulation of calpain-cleaved 
spectrin and an antibody raised against the cleaved and active form of caspase-3 was used for detection of 
caspase activity. A band revealed by coomassie staining of the gel was used as a loading control (n=2, 
vehicle: 0.04% DMSO). 
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Figure 3.4 Combination antiretroviral drug treatments induce oxidative stress in neurons. 
(A and D) Cortical neuroglial cultures grown on coverslips were treated for 6 hours with the indicated 
drugs (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) and the presence of reactive oxygen species was detected by 
DHE staining (red fluorescence)  
(A) The images were captured with epifluorescent microscopy with uniform settings. (D) Quantification of 
DHE fluorescence was generated by measurement of DHE pixel intensity per DAPI area (n=3; *p<0.05, 
#p<0.01, One-Way ANOVA, post-hoc Newman-Keuls).    
(B) Cortical neuroglial cultures grown on coverslips for 21 days and exposed to the indicated treatments 
(AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) were immunofluorescently labeled for MAP2 (green) and GFAP 
(red). Note that the cultures are enriched for neurons.  
(C) 21DIV pure cortical neuronal cultures grown on coverslips were treated with AZT (25 mM), Rit (10 
mM), or Saq (1 mM) for 2, 12 or 24 hours. The presence of reactive oxygen species was detected by DHE 
staining (red fluorescence) and MAP2 was used to stain neurons (green fluorescence). (E) The images 
captured with confocal microscopy with uniform settings were analyzed for DHE pixel intensity per DAPI 
area (n=3; *p<0.05, One-Way ANOVA, post-hoc Newman-Keuls).   
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Figure 3.5 Antiretroviral drugs do not induce an endogenous antioxidant response in astrocytes. 
(A) Pure astrocytic cultures grown on coverslips were treated with AZT (25 mM), Rit (10 mM), or Saq (1 
mM) for 2, 12 or 24 hours. The accumulation of reactive oxygen species was detected by DHE staining 
(red fluorescence) and GFAP was used to label astrocytes (green fluorescence). (B) The images captured 
with confocal microscopy with uniform settings were analyzed for DHE pixel intensity per DAPI area 
(n=3; *p <0.05, One-Way ANOVA, post-hoc Newman-Keuls). (C, D and E) Whole-cell lysates from pure 
astrocytic cultures treated with the indicated drugs (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) for 16h were 
immunoblotted for HO-1 and NQO-1. Representative blots from 3 independent experiments are shown in 
(C). Coomassie staining of gels were used as loading controls and fold changes over untreated lysates were 
determined. The quantification of HO-1 and NQO-1 band intensities from three independent experiments is 
shown in (D) and (E) (n=3; *p <0.05, One-Way ANOVA, post-hoc Newman-Keuls).   
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Figure 3.6 Combination antiretroviral drug treatments induce the endogenous antioxidant response 
(A and B) Cortical neuroglial cultures were exposed to the indicated treatments (AZT: 25 mM, Rit: 10 
mM, Saq: 1 mM) for 6 hours to determine changes in NQO-1 (A) and HO-1 (B) mRNA levels. A 
representative of three experiments is shown. Actin was used as internal control and fold changes were 
determined by the ΔΔCT method (*p<0.0001, One-Way ANOVA, post-hoc Newman-Keuls). (C and D) 
Whole-cell lysates from cortical neuroglial cultures treated with the indicated drug combinations (AZT: 25 
mM, Rit: 10 mM, Saq: 1 mM) for 16 and 48h were immunoblotted for NQO-1 (C) and HO-1 (D). 
Representative blots from 3 independent experiments are shown. Coomassie staining of gels were used as 
loading controls and fold changes over untreated lysates are indicated below each band of interest. (E and 
F) Whole-cell lysates prepared from hippocampus of rats treated for 7 days with AZT/Rit/Saq (n=4) or 
vehicle (n=2) were immunoblotted for HO-1 and NQO-1 (E) and fold change in HO-1 protein levels in the 
cART group compared with the vehicle group is shown (F) (*p<0.05, Student’s t-test).  
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Figure 3.7 MMF induces activation of a cellular antioxidant response and blocks neuronal 
damage/death 
 (A) In the absence (upper panel) or presence (lower panel) of MMF (100 mM), 21 DIV rat neuroglial 
cultures on coverslips were treated for 6 hours with the Rit/Saq, AZT/Rit/Saq (AZT: 25 mM, Rit: 10 mM, 
Saq: 1 mM), or were left untreated. ROS generation was detected by DHE staining (red fluorescence). (B) 
Quantification of nuclear DHE was done as described above (n=3, *p<0.01, One-Way ANOVA with post-
hoc Newman-Keuls). (C) Whole cell lysates of cultures exposed to Rit/Saq or AZT/Rit/Saq treatments 
(AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) in the absence or presence of MMF (100 mM) for 4 or 16 hours 
were immunoblotted for HO-1. A representative blot from 3 independent experiments is shown. A 
coomassie band from the gel was used as loading control. Quantification of band intensities is shown under 
each corresponding lane. (D) Primary cortical neuroglial cultures were either pretreated with MMF (100 
mM) for 30 min or received no pre-treatment; cultures were then treated with Rit/Saq or AZT/Rit/Saq 
(AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) for 72 hours to assess neuronal damage/death by MAP2 ELISA 
(n=3; vehicle=0.04% DMSO; *p<0.05 vs. untreated, @p<0.05 vs. Rit/Saq, #p<0.05 vs. AZT/Rit/Saq, One-
Way ANOVA with post-hoc Newman-Keuls). (E) Primary cortical neuroglial cultures were pre-incubated 
with SnMP (20 mM) and/or MMF (100 mM) for 30 min before the addition of the indicated antiretroviral 
drugs (AZT: 25 mM, Rit: 10 mM, Saq: 1 mM) and were assessed for nuclear DHE accumulation at 16 
(n=3; *p<0.01 vs. untreated, **p<0.05 vs. untreated, @p<0.01 vs. Rit/Saq, #p<0.05 vs. AZT/Rit/Saq, One-
Way ANOVA with post-hoc Newman-Keuls).  
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Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of 
Antiretrovirals in HIV-Associated Neurocognitive Disorders 
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4.1 ABSTRACT 
Despite effective viral suppression through combined antiretroviral therapy (cART), approximately half of 
HIV(+) individuals suffer from HIV-Associated Neurocognitive Disorders (HAND). Studies of 
antiretroviral treated patients have revealed persistent white matter pathologies including diffuse myelin 
pallor, diminished white matter tracts, and decreased myelin protein mRNAs. Loss of myelin can contribute 
to neurocognitive dysfunction, as the myelin membrane generated by oligodendrocytes is essential for rapid 
signal transduction and axonal maintenance. We hypothesized that myelin changes in HAND are partly due 
to effects of antiretrovirals on oligodendrocyte survival and/or maturation. We showed that primary mouse 
oligodendrocyte precursor cell cultures treated with therapeutic concentrations of HIV protease inhibitors 
Ritonavir or Lopinavir displayed dose-dependent decreases in oligodendrocyte maturation. However, this 
effect was rapidly reversed following drug removal. Conversely, nucleoside reverse transcriptase inhibitor 
Zidovudine had no effect. Furthermore, in vivo Ritonavir administration to adult mice reduced frontal 
cortex myelin protein levels. Finally, prefrontal cortex tissue from HIV(+) individuals with HAND on 
cART showed a significant decrease in myelin basic protein compared with untreated HIV(+) individuals 
with HAND or HIV-negative controls. These findings demonstrate that antiretrovirals can impact myelin 
integrity, and have implications for myelination in juvenile HIV patients, and myelin maintenance in adults 
on lifelong therapy.  
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4.2 INTRODUCTION 
Approximately 50% of patients infected with human immunodeficiency virus-1 (HIV) present with a broad 
spectrum of cognitive, motor, and behavioral disturbances collectively termed HIV-Associated 
Neurocognitive Disorders (HAND) (Kaul, 2005, Ozdener, 2005) despite effective viral control through 
combined antiretroviral therapy (cART) (Heaton, 2010, McArthur et al., 2010, Heaton, 2011, Sacktor and 
Robertson, 2014). cART is designed to simultaneously target multiple stages of HIV replication, thereby 
delaying viral mutational selection to acquire drug resistance. Most commonly prescribed regimens include 
viral reverse transcriptase inhibitors (nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs)), and 
HIV protease inhibitors (PIs) which prevent maturation of viral precursor proteins (WHO, 2013). While 
cART successfully reduces peripheral viral loads to undetectable levels in adherent individuals, 
inflammation and latent viral reservoirs remain in the central nervous system (CNS) (Chun, 1997, Finzi, 
1997, Wong, 1997, Anthony, 2005, Persidsky, 2006).  
 
Although pathology has shifted from subcortical to cortical manifestations since cART introduction, 
dendritic pruning and astrogliosis persist (Gray, 2003, Brew, 2004, Heaton, 2011, Sacktor and Robertson, 
2014). Notably, white matter pathologies are prevalent, with the degree of neurocognitive impairment 
correlating with the amount of damage (Muller-Oehring et al., 2010, Tate et al., 2010). Imaging studies 
have revealed cortical myelin disruption, volume loss, and diminished structural integrity of the corpus 
callosum in HAND patients, which were even more pronounced in cART-treated individuals (Ragin et al., 
2004, Tate et al., 2011, Kelly et al., 2014). Furthermore, transcriptome analysis in HAND patients on cART 
revealed dysregulation of genes critical to oligodendrocyte maturation and myelination, including myelin-
associated oligodendrocyte basic protein, myelin transcription factor 1, and myelin basic protein (Borjabad 
et al., 2011).  
 
In pediatric HIV patients, neurological complications such as encephalopathy and progressive multifocal 
leukoencephalopathy are frequent, with data suggesting emerging neurocognitive deficits and 
developmental delays (Wilmshurst et al., 2006, Crowell et al., 2014, Wilmshurst et al., 2014). WHO 
guidelines urge that all infected children be treated, with those under 3 years of age receiving a 
110	  
Lopinavir/Ritonavir first-line regimen (WHO, 2013). Importantly, this PI-based therapy is advised during 
the critical period for myelination (Miller et al., 2012), yet an understanding of the effects of HIV and 
antiretroviral drugs on myelin formation and maintenance is lacking.   
 
The myelin membrane is critical for axons to transmit rapid neuronal impulses as well as axonal 
maintenance (Lappe-Siefke et al., 2003, Edgar and Garbern, 2004). Conversely, impaired myelination can 
disrupt proper signaling, and hasten axonal degeneration, resulting in neurological dysfunctions (Criste et 
al., 2014, Mighdoll et al., 2015). Although sustained effects of continuing viral replication and treatment 
noncompliance are suggested to underlie continuing neurocognitive impairment, antiretrovirals themselves 
may contribute to HAND pathogenesis (Marra, 2009, Joska et al., 2010, Kahouadji et al., 2013). Crucially, 
while antiretroviral-mediated toxicity has been reported in primary rat cortical neurons (Robertson et al., 
2012, Akay et al., 2014), to date there are no published studies addressing the effects of antiretrovirals on 
oligodendrocytes, the myelin forming cells of the CNS. Here we examine whether antiretrovirals affect the 
survival and maturation of developing oligodendrocytes using a well-established primary mouse cortical 
cell culture model (See et al., 2004) and the effects of cART compounds on myelin maintenance in a mouse 
model and in patients with HAND. Our results support a role for a subset of cART agents in the white 
matter changes seen in HIV(+) individuals with HAND. 
 
4.3 MATERIALS AND METHODS 
Chemicals and Reagents 
Abcam (Cambridge, United Kingdom): rabbit polyclonal anti-inositol-requiring enzyme 1 antibody 
(IRE1α, ab37073), rabbit polyclonal anti-inositol-requiring enzyme 1 antibody (IRE1α, phospho S724, 
ab48187), rabbit polyclonal anti-NAD(P)H:quinone oxidoreductase antibody (NQO1, ab34173). 
Affymetrix (Santa Clara, CA): terminal deoxynucleotidyl transferase, recombinant (rTdT). AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH: antiretroviral reagents. BD Transduction 
Laboratories: mouse monoclonal anti-BiP/Grp78 antibody (610978). Cell Signaling Technology (Beverly, 
MA): rabbit polyclonal anti-eukaryotic initiation factor 2 alpha antibody (eIF2α, 9722S), rabbit polyclonal 
anti-phospho-eukaryotic initiation factor 2 alpha (Ser51) antibody (p-eIF2α, 9721S). Chemicon 
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International (Temecula, CA): mouse monoclonal anti-cyclic-nucleotide-3’phosphodiesterase antibody 
(CNPase, MAB326R), mouse monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase antibody 
(GAPDH, MAB374). Covance Laboratories (Conshohocken, PA): mouse monoclonal anti-myelin basic 
protein antibody (MBP, SMI-99). Enzo Life Sciences (Plymouth Meeting, PA): rabbit polyclonal anti-
Heme Oxygenase-1 antibody (HO-1, SPA-896). Life Technologies (Carlsbad, CA): B27 Supplement, 4-
12% Bis-Tris gradient gels, CAS-block,  dihydroethidium,  Dulbecco’s Modified Eagle’s Medium 
(DMEM), DMEM/F12, Deoxyribonuclease 1 (Dnase), Ham’s F12, L-glutamine, Hank’s Balanced Salt 
Solution (HBSS), rabbit polyclonal anti-small/large myelin-associated glycoprotein antibody (S/L MAG), 
Neurobasal Medium, Penicillin/Streptomycin. Jackson Immunoresearch Laboratories (West Grove, PA): 
Rhodamine-conjugated goat anti-mouse IgM, FITC-conjugated goat anti-mouse IgG3, Rhodamine-
conjugated goat anti-rat IgG, FITC-conjugated goat anti-rat IgG, Rhodamine-conjugated streptavidin. 
LiCOR (Lincoln, NE): Odyssey goat anti-mouse IRdye 800CW, goat anti-mouse IRdye 680RD, goat anti-
rat IRdye 800CW, goat anti-rat IRdye 680RD, goat anti-rabbit IRdye 800CW, goat anti-rabbit IRdye 
680RD. Peprotech (Rocky Hill, NJ): neurotrophin-3 (NT-3). Peptide International: poly-D-lysine. 
Proteintech (Chicago, IL): rabbit polyclonal anti-activating transcription factor 6 beta antibody (ATF6β, 
15794-1-AP).  R&D Systems (Minneapolis, MN): basic fibroblast growth factor (bFGF), platelet-derived 
growth factor -AA (PDGF-AA). Roche Diagnostics (Basil, Switzerland): biotin-16-dUTP. Sigma Aldrich 
(St. Louis, MO): mouse monoclonal anti-α-tubulin antibody (T5168), biotin, dimethyl sulfoxide (DMSO), 
fast green FCF, insulin, monomethyl fumarate (MMF), TRITC-conjugated phalloidin, progesterone, 
protease inhibitor cocktail, putrescine, sodium cacodylate, selenium, tert-Butyl hydroperoxide (tBHP), 
thyroxine (T4), transferrin. Thermo Fisher Scientific (Waltham, MA): Restore Western Blot Stripping 
Buffer. Vector Laboratories (Burlingame, CA): Vectashield with DAPI.  
 
Additional antibodies: anti-A2B5 mouse hybridoma supernatant (ATCC (Eisenbarth et al., 1979)), anti-
galactocerebroside mouse hybridoma supernatant (GalC H8H9, (Ranscht et al., 1982)), anti-myelin 
oligodendrocyte glycoprotein (MOG, (Piddlesden et al., 1991), anti-myelin basic protein rat hybridoma 
supernatant (MBP, gift of Virginia Lee, University of Pennsylvania), anti-proteolipid protein rat hybridoma 
(AA3, gift of Dr. Alex Gow, Wayne State University). 
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Primary Cortical Oligodendrocyte Cultures 
All experiments were performed in accordance with the guidelines set forth by The Children's Hospital of 
Philadelphia and The University of Pennsylvania Institutional Animal Care and Use Committees (IACUC). 
Primary mouse oligodendrocyte precursor cell (OPC) cultures were isolated from postnatal day 1 CD1 pups 
obtained from Charles River Laboratories, with modifications from previously described protocols (See et 
al., 2004). Briefly, cortical cell suspensions isolated from mouse pups using standard protocols were plated 
on poly-D-lysine coated T-75 flasks in Neurobasal medium with B27 supplement at 37°C with 5% CO2. 
After 24 hours, cultures were switched to growth medium consisting of Neurobasal medium with B27 
which contained 10 ng/ml bFGF, 2 ng/ml PDGF-AA, and 1 ng/ml NT-3. Within 7 days, confluent cells 
were purified to 90-95% OPCs and 5-15% astrocytes using a gentle wash-down procedure (Feigenson et 
al., 2009), and sub-cultured onto poly-lysine-coated flasks, coverslips, or Petri dishes. For differentiation 
experiments, growth medium was replaced with differentiation medium, consisting of 50% DMEM, 50% 
Ham’s F12, Pen/Strep and 2 mM glutamine with 50 µg/ml transferrin, 5 µg/ml putrescine, 3 ng/ml 
progesterone, 2.6 ng/ml selenium, 12.5 µg/ml insulin, 0.4 µg/ml T4, 0.3% glucose, and 10 ng/ml biotin 
(Feigenson et al., 2009).  
 
Immunofluorescence 
Cells on coverslips were processed for detection of specific antigens as described previously (Grinspan and 
Franceschini, 1995, See et al., 2004). Prior to fixation, live cells were labeled for cell surface marker 
detection using anti-A2B5 (mouse hybridoma supernatant, undiluted), and anti-GalC (mouse hybridoma 
supernatant, undiluted). For detection of internal antigens following acid alcohol fixation and 
permeabilization, antibodies used were anti-MBP (rat hybridoma supernatant, 1:2 dilution) or anti-PLP (rat 
hybridoma supernatant, 1:2 dilution). Secondary antibodies used at a 1:100 dilution were Rhodamine or 
Fluorescein conjugated. Vectashield with DAPI was used to mount coverslips, and to stain all nuclei. 
Antigen-positive and DAPI-positive cells were counted in 10 fields in each of 3 to 4 coverslips from at 
least 3 biologically separate preparations of cells using a Leica DM6000B fluorescence microscope at 40x 
magnification. A total of approximately 2000 cells were counted per condition. The chosen and accepted 
standard method for quantification of differentiation determines the number of cells progressing through 
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various stages using well-defined stage-specific markers (Scherer et al., 1994, Miller, 2002, Feigenson et 
al., 2009). For phalloidin staining, cell surface markers were stained as above. Next, cells were fixed with 
4% paraformaldehyde for 8 minutes, washed with PBS, solubilized with 0.5% Triton X-100 in PBS, and 
blocked for 30 minutes with a 1:1 dilution of 100 mg/ml BSA and CAS-block. Cells were then incubated 
with TRITC-conjugated phalloidin at a final concentration of 500 nM for 2 hours. Cells were mounted and 
visualized as described above. To assess cells committed to apoptotic cell death, a TUNEL staining 
protocol adapted from that of Gavrieli et al. was utilized (Gavrieli et al., 1992). Cells were fixed with ice-
cold acetone for 10 minutes, washed with PBS, and solubilized with 0.5% Triton X-100 in PBS for 15 
minutes. Positive control coverslips were generated during this period by incubating in DN buffer (30 mM 
Trizma base pH 7.2, 140 mM Na cacodylate, 4 mM MgCl, and 0.1 mM DTT) for 2 minutes, followed by 
DNase (1:200) in DN buffer for 10 minutes. All coverslips were washed with PBS then placed in TDT 
buffer for 2 minutes (30 mM Trizma base pH 7.2, 140 mM Na cacodylate, 1 mM CoCl). Cells were 
incubated for 1 hour with TdT and biotin-UTP in TDT buffer (8 µL of each in 1mL TDT Buffer). 
Following a subsequent PBS wash, cells were placed in TB buffer for 15 minutes (300 mM NaCl, 30 mM 
sodium citrate), and then a 2% BSA solution for 30 minutes. Finally cells were incubated with Rhodamine-
conjugated streptavidin for 20 minutes prior to a final PBS wash and mounting on slides with Vectashield 
containing DAPI. Visualization and counting were performed as described above.  
 
Jugular Vein Antiretroviral Administration Mouse Model 
Surgical procedures were performed with the approval of the Institutional Animal Care and Use Committee 
of the University of Pennsylvania. Adult male C57BL/6 mice were catheterized via jugular vein, as 
described previously (Thrivikraman et al., 2002, Briand et al., 2012). Briefly, mice were anesthetized prior 
to surgery with 80 mg/kg ketamine and 12 mg/kg xylazine. An indwelling silastic catheter (Strategic 
Applications, Inc.) was placed into the right jugular vein and sutured in place. The catheter was connected 
to a mesh platform which was subcutaneously placed on the animals back and sutured in place. Catheters 
were flushed daily with 0.1 ml of the antibiotic Timentin dissolved in heparinized saline (0.93  mg/ml). 
Treatment regimens were composed of Vehicle (DMSO) or Ritonavir (20 mg/kg), administered twice daily 
for 14 days by continuous intravenous injection (Vehicle n= 6, Ritonavir n= 7). This drug dose was based 
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on previously published pharmacokinetic studies (Kageyama et al., 2005, Pistell et al., 2010, du Plooy et 
al., 2011). At time of euthanasia, catheter patency was verified by response to pre-euthanasia sedation (80 
mg/kg ketamine and 12 mg/kg xylazine). Brains were removed, the frontal cortex, cerebellum, and 
hippocampus were dissected on ice, and tissue samples were stored at -80 °C until immunoblot analyses 
were performed.  
 
Human Subjects 
For immunoblotting analyses, samples from a cohort of individuals were obtained from the National 
NeuroAIDS Tissue Consortium (NNTC) and the Texas NeuroAIDS Research Center. The cohort 
encompasses 20 HIV(-), 20 HIV(+) cART-naïve, and 20 HIV(+) cART-medicated for greater than 12 
months (HIV(+)/ART) cases. Six HIV(+) cART-naïve and 14 HIV(+) cART-medicated subjects had 
clinically diagnosed HAND. The pathological diagnosis of HIV encephalitis was established in six HIV(+) 
cART-naïve and one HIV(+) cART-medicated patients. Diagnosis of HAND by neuropsychological 
assessment was based on the results from the NNTC neurocognitive test panel guided by Frascati Criteria, 
which entails evaluation of seven domains of cognitive functioning at six-month intervals prior to death 
(Antinori, 2007). NNTC site pathologists rendered nosological diagnoses of HIVE according to established 
criteria (Budka et al., 1991). Evaluation of regimen history determined that 85% of cART-medicated 
patients were HIV protease inhibitor (PI) experienced, and 100% were nucleoside reverse transcriptase 
inhibitor (NRTI) experienced. Table 4.1 contains complete cohort demographics and clinical data. 
 
The human studies were conducted in accordance with human subject protection protocols, with written 
consent obtained at four collections sites within the USA. The following institutions maintained the IRBs 
set forth to provide oversight for the protection of human subjects: 1) The University of Texas Medical 
Branch Office of Research Subject Protections (Galveston, TX), 2) Mount Sinai Medical Center Program 
for the Protection of Human Subjects (New York, NY), 3) University of California (San Diego, CA), 4) 
University of California Los Angeles, Office of the Human Research Protection Program (Los Angeles, 
CA).  
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Immunoblotting 
Whole cell extracts of primary mouse oligodendrocyte cultures were prepared with ice-cold cell lysis buffer 
(50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 10 mM EDTA, 0.5 mM Na3VO4, and 1:100 protease 
inhibitor cocktail), followed by centrifugation at 14,000 rpm at 4°C for 30 minutes. Whole cell extracts of 
mouse and human tissue samples were prepared by homogenization of 100 mg dissected frontal cortex 
tissue in ice-cold tissue extraction buffer (50 mM Tris pH 7.5, 0.5 M NaCl, 1% NP-40, 1% SDS, 2 mM 
EDTA, 2 mM EGTA, 5 mM NaF, 0.4 mM Na3VO4, 1 mM DTT and 1:100 protease inhibitor cocktail), 
followed by centrifugation at 14,000 rpm at 4°C for 30 minutes. Protein concentrations of collected 
supernatants were determined by the Bradford Method. 10-25 µg of protein was loaded into each lane of 4-
12% Bis-Tris gradient gels for separation. For detection of PLP, gels were run under non-reducing 
conditions due to antibody specificity. A broad-spectrum molecular weight ladder was run on each gel. 
Following separation, proteins were transferred onto Millipore Immobilon-FL membranes, and blocked in 
PBS with 0.1% Tween-20 (PBST) and 5% milk for 20 minutes at 4°C. Membranes were incubated 
overnight at 4°C with primary antibodies in PBST + 5% milk. The following primary antibodies were used: 
MBP (SMI-99, 1:1000 dilution), PLP (1:1000 dilution), MAG (1:500 dilution), CNPase (1:1000 dilution), 
HO-1 (1:1000 dilution), NQO1 (1:1000 dilution), BiP (1:1000 dilution), phospho-eIF2α (1:1000), total 
eIF2α (1:1000), phospho-IRE1α (1:1000), total IRE1α (1:1000), and ATF6β (1:1000). Membranes were 
washed with PBST, re-blocked for 20 minutes in PBST+ 5% milk, and incubated with corresponding 
antigen-specific fluorescent probe-conjugated secondary antibodies (1:10,000 dilution) in PBST + 5% milk. 
Membranes were visualized using an Odyssey Infrared Imaging System (LiCOR). Loading controls were 
obtained by reblotting for GAPDH (1:1000 dilution), α-tubulin (1:1000 dilution), or FastGreen FCF. To 
obtain ratios of phosphorylated to total protein levels for eIF2α and IRE1α, first phosphorylated proteins 
were detected. Following visualization, membranes were stripped using Restore Western Blot Stripping 
Buffer and re-examined using the Odyssey to ensure all detectable first-round antibodies were removed. 
Membranes were then re-blocked and incubated with the corresponding primary antibodies for total eIF2α 
or IRE1α.  Bands of interest were specified to determine pixel intensities for each treatment using the NIH 
ImageJ program (V 1.36b, Bethesda, MD), and the band intensities were normalized to loading controls to 
ensure equal loading. Proteins of interest were quantified by analyzing bands corresponding to the 
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appropriate molecular weight reported by the manufacturers and observed in our previous studies. In mouse 
and human brain tissue in which myelin proteins are found in high abundance, MBP and MAG present as 
doublets, which were evaluated simultaneously and quantified. FastGreen staining was used for samples 
from in vivo tissue, to ensure protein integrity as well as equal loading. To quantify FastGreen 
densitometry, a horizontal section of the membrane spanning a broad molecular weight range was scanned 
together, and overall intensity was determined for each lane. This method allows for normalization across 
lanes within gels without bias towards a single representative protein loading control. Due to large sample 
size in the human studies, a standard combined sample was run on each gel, and values were then 
normalized across gels. 
 
Measurement of Reactive Oxygen Species 
The superoxide indicator dihydroethidium (DHE) was used to detect the presence of reactive oxygen 
species (ROS) in vitro. Fifteen minutes prior to conclusion of treatments, 3 µM DHE was added to the 
culture medium. Oxidation of DHE to ethidium allows for ethidium intercalation with nuclear DNA, 
emitting a quantifiable red fluorescence (Zhao, 2003). Cells were washed with F12 medium, and fixed with 
4% paraformaldehyde at room temperature for 8 minutes. The coverslips were then washed with F12 
medium, mounted on slides with DAPI-containing Vectashield, and visualized using fluorescent 
microscopy, as described above. The oxidant tert-Butyl hydroperoxide (tBHP, 2.5 µM) was used as a 
positive indicator of ROS in culture. Post-acquisition analysis was performed using MetaMorph 6.0 
software (Molecular Devices, Sunnyvale, CA) to determine the fluorescence intensity of nuclear 
intercalated DHE normalized to the area of DAPI signal. 
 
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) 
The expression of HO-1, NQO1, spliced X-box Binding Protein-1 (XBP-1), total XBP-1, Binding 
Immunoglobulin Protein (BiP), C/EBP homologous protein (CHOP), IRE1α, ATF6β and activating 
transcription factor 4 (ATF4) mRNA in oligodendrocyte cultures were quantified by qRT-PCR. OPC 
cultures were grown on 100-mm dishes and harvested after treatment with specified antiretrovirals for 6 
hours. RNA was extracted with Trizol, and 5 µg of RNA was converted to cDNA by the Invitrogen 
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Superscript First-strand kit. q-PCR was performed using Power SYBR Green, as previously described 
(French et al., 2009, Feigenson et al., 2011). Samples were measured in triplicate for each experiment from 
three biological replicates (n=3). Data were normalized using Protein Kinase Gene 1 (PKG1), and analyzed 
according to the ΔΔCT method. Primer pairs obtained from Integrated DNA Technologies for each gene 
can be found in Table 4.2.  
 
Statistical Analysis 
All data were analyzed by Prism 5.0 software (GraphPad Software, San Diego, CA). Values are expressed 
as mean ± SEM. All statistical tests compared Zidovudine (AZT) to untreated as it was dissolved in water, 
and Lopinavir and Ritonavir to the vehicle (DMSO) in which they were resuspended. Following 
differentiation, untreated and vehicle do not statistically differ in the number of cells staining with GalC, 
which marks immature oligodendrocytes, or MBP and PLP, which mark mature oligodendrocytes (data not 
shown). One-way ANOVA with post-hoc Newman-Keuls multiple comparison test, One-way ANOVA 
with post-hoc Dunnett’s multiple comparison test or Student’s t-test were performed where indicated. For 
comparison of specific treatment groups at two time-points, One-way ANOVA with post-hoc Bonferroni 
correction was performed. Values of p < 0.05 were considered significant for all analyses. 
 
4.4 RESULTS 
HIV Protease Inhibitors Prevent Oligodendrocyte Differentiation 
The potential impacts of antiretroviral compounds on oligodendrocyte survival, maturation, or myelination 
have not been determined to date. We chose to test three widely prescribed antiretroviral drugs: Zidovudine 
(AZT), a nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI), and Ritonavir and Lopinavir, two 
protease inhibitors (PI). We based our range of antiretroviral doses on previously reported plasma and 
cerebrospinal fluid (CSF) levels in humans, as measurements from human brain parenchyma have not been 
performed (Wynn et al., 2002, Noor et al., 2006, Cusini et al., 2013, Tiraboschi et al., 2014, Decloedt et al., 
2015). Many antiretrovirals are thought to have limited CNS penetrance due to pharmacological properties 
which impair transport across the blood brain barrier (BBB) and promote active exclusion through efflux 
transporters (McGee et al., 2006, Cysique and Brew, 2009, Varatharajan, 2009). However, there is 
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extensive evidence of HIV-mediated disruption of the BBB resulting in increased entry of normally 
excluded small molecules and serum proteins (Toborek et al., 2005, Wang et al., 2008, Nakagawa et al., 
2012). In addition to HIV-mediated effects, even in the absence of virus, CNS accessibility is not 
necessarily as restricted as anticipated, as brain entry can be facilitated if drugs are given in combination 
(Marzolini et al., 2013). Importantly, animal studies predict that parenchymal concentrations reach levels 
equal to, or greater than those found in the CSF, suggesting that concentrations attained in human brain 
may be higher than current clinical estimates (Anthonypillai et al., 2004, Anderson and Rower, 2010). 
 
We first determined the dose-dependent effects of these compounds on differentiation utilizing our 
previously described paradigm (See et al., 2004). Primary mouse oligodendrocyte precursor cells (OPCs) 
were purified and grown in the presence of bFGF, PDGF-AA, and NT-3 to 75% confluence, at which time 
growth factors were removed and thyroid hormone was added to initiate differentiation, allowing OPCs to 
progress first to immature then mature oligodendrocytes. OPCs were allowed to differentiate for 72 hours 
in the presence of Vehicle (DMSO) or the antiretrovirals tested: AZT (1 µM, 10 µM, or 25 µM), Ritonavir 
(100 nM, 1 µM, or 3 µM), or Lopinavir (150 nM, 1.5 µM, or 15 µM). Oligodendrocyte maturation is well 
defined and regulated; therefore, cellular markers correlating to specific stages of differentiation are 
commonly used to illustrate lineage progression (Miller, 2002). A2B5 was used as a marker of OPCs, 
galactocerebroside (GalC) as a marker of immature oligodendrocytes, and myelin basic protein (MBP) or 
proteolipid protein (PLP) as markers of mature oligodendrocytes.  
 
Immunofluorescent staining following treatments revealed that the PIs Ritonavir and Lopinavir but not 
NRTI AZT resulted in fewer cells expressing differentiation markers, compared with controls. 
Representative images of oligodendrocytes after 72 hours in differentiation medium demonstrate dose-
dependent maturation decreases with PIs (Figure 4.1A), with the extent of maturation determined by 
comparing the percentage of GalC+ cells and MBP+ cells across treatments (Figure 4.1B-C). Following PI 
treatment, the number of cells expressing the immature marker GalC after three days of differentiation was 
reduced by 69.43% ± 6.07% for the highest dose of Ritonavir and by 95.63% ± 0.96% with the highest 
dose of Lopinavir, compared with vehicle controls (p < 0.001) (Figure 4.1B). Similarly, the number of 
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MBP+ cells was significantly reduced by 75.14% ± 4.94% with Ritonavir and by 97.62% ± 1.03% with 
Lopinavir treatments compared with vehicle (p < 0.001) (Figure 4.1C). In contrast, AZT treatment did not 
alter the number of GalC+ or MBP+ cells, compared with controls (Figures 4.1B-C). Quantification of 
PLP+ cells mirrored that of MBP+ cells for all conditions (data not shown).  
 
Changes in the number of cells expressing markers of oligodendrocyte differentiation could be attributed to 
cell death, altered precursor proliferation, or inhibition of differentiation. To address changes in cell death 
or OPC proliferation, we determined the number of total cells (DAPI+ cells) (Figure 4.2A) and A2B5+ 
OPCs (Figure 4.2B) following treatments. AZT, which did not cause a loss of GalC+ or MBP+ 
oligodendrocytes compared to controls, did not lead to a loss of OPCs or total cells at any dose as expected. 
Interestingly, Ritonavir, at any dose, also did not lead to loss of OPCs or total cell number in culture, 
suggesting that Ritonavir treatment decreased GalC+ and MBP+ oligodendrocytes by inhibition of the 
differentiation process. In contrast, Lopinavir treatment trended towards a reduction in total cell number at 
the 1.5 µM dose (81.5% ± 5.52%) and significantly decreased total cell numbers at the 15 µM dose 
(73.9%± 6.29% of vehicle total) (p < 0.05) (Figure 4.2A). A significant reduction between the 1.5 µM and 
15 µM concentrations was not observed. Lopinavir did not alter A2B5 precursor cell number at any 
concentration (Figure 4.2B). These observed decreases, although statistically significant, are modest 
compared to the near total loss of GalC+ and MBP+ cells with 15 uM Lopinavir treatment. To verify that 
the dramatic reductions observed in expression of GalC and MBP following Lopinavir treatment were due 
to inhibition of differentiation and not apoptotic cell death, we assessed whether remaining cells were 
committed to the apoptotic cell death cascade using the TUNEL assay, which labels double-stranded DNA 
breaks in extensively damaged cells. Treatment with 15 µM and 1.5 µM concentrations of Lopinavir 
resulted in negligible TUNEL+ cells, similar to vehicle treatment (Figure 4.2C). Together, these results 
suggest that Lopinavir inhibits proper oligodendrocyte maturation in a dose-dependent manner. The modest 
reductions in GalC+ and MBP+ cells observed at 1.5 µM (57.0% ± 12.43% and 56.7% ± 12.72% of control 
differentiation levels) plummets to 4.37% ± 0.96% and 2.38% ± 1.03%, respectively, at 15 µM without 
activation of the apoptotic cascade or a significant reduction in cell number between these two 
concentrations. 
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Lopinavir Reduces the Expression of Myelin Proteins 
Given that PI-treated cultures contained fewer GalC+, MBP+ and PLP+ cells, as compared with vehicle by 
immunofluorescence, next we determined whether this effect resulted from decreased protein levels. The 
cultures were treated as described above for 72 hours, and protein lysates were prepared for immunoblot 
analysis. The highest dose of Lopinavir (15 µM) led to a significant decrease in MBP levels when 
compared with vehicle (p < 0.01) (Figure 4.3C). In contrast, neither AZT nor Ritonavir significantly altered 
MBP expression levels (Figure 4.3A-B). Additionally, PLP and cyclic-nucleotide-3’phosphodiesterase 
(CNP), two other major myelin proteins, were also decreased in 15 µM Lopinavir-treated cells compared 
with controls, whereas no change in either protein was observed following high dose (25 µM) Azt or (3 
µM) Ritonavir treatments (Figure 4.3D-E). This immunoblotting analysis of Lopinavir treated cells 
parallels that of the immunofluorescence results in Figure 1, with dramatic reductions in protein markers of 
maturation observed between the 1.5 µM and 15 µM concentrations of Lopinavir (Figure 4.2A). 
Intriguingly, all doses of Ritonavir and the intermediate dose of Lopinavir (1.5 µM) decreased the number 
of GalC+ and MBP+ cells by immunofluorescence, but not myelin protein levels by immunoblot. 
 
Protease Inhibitor-Mediated Reduction of Differentiation is Reversible 
Our observation that at low doses of PIs there were significantly fewer mature oligodendrocytes, despite 
unchanged levels of myelin proteins prompted us to determine whether oligodendrocyte processes were 
elaborated but myelin proteins were not being properly localized. Therefore, we utilized phalloidin staining 
to visualize actin microfilaments. Cells were treated with vehicle, 3 µM Ritonavir, or 15 µM Lopinavir and 
allowed to mature for 72 hours, followed by phalloidin staining. As shown in the representative images of 
Figure 4.4A, cells maintained normal differentiated geometry and process extension after treatment, 
however the immature oligodendrocyte stage marker GalC did not appear to correctly localize to the cell 
surface.  
 
To determine if the effects of the PIs were permanent, or if cells were still capable of proper myelin protein 
production and localization, we differentiated OPCs in the presence of 3 µM Ritonavir or 15 µM Lopinavir 
and allowed 72 hours for maturation. At this time, a subset of cultures was switched into fresh 
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differentiation medium lacking further treatment for an additional 24 hours. Cultures that underwent a drug 
washout period were analyzed for markers of oligodendrocyte differentiation and compared with the 
cultures that did not undergo drug washout but were exposed to PI treatments for 72 hours. As we have 
shown in Figure 4.1, while 72 hour treatment with 3 µM Ritonavir or 15 µM Lopinavir resulted in fewer 
GalC+ cells compared with vehicle, this effect was completely reversed after the removal of both PIs 
(Figure 4.4B). Similarly, drug washout for 24 hours resulted in the reversal of the deficit in MBP levels 
following treatment with 15 µM Lopinavir (0.28 ± 0.12 fold of control levels, p < 0.05), as detected by 
immunoblotting (Figure 4.4C). In 15 µM Lopinavir treated cultures, the rapid restoration of maturation to 
vehicle-treated levels following drug washout further corroborates the findings from Figures 4.1-4.3, which 
together substantiate that cell death did not cause the original reduction in myelin proteins and cell surface 
markers of differentiation following Lopinavir treatment. 
 
Antiretroviral Drugs Induce Oxidative Stress 
Previous work from our laboratory has shown that oxidative stress is capable of halting oligodendrocyte 
differentiation (French et al., 2009, Reid et al., 2012). We have also demonstrated in primary neuroglial 
cultures that antiretroviral compounds (PIs and NRTIs) evoke the generation of reactive oxygen species 
(ROS) (Akay et al., 2014). In light of this, we postulated that oxidative stress could be the instigating factor 
for altered differentiation in the presence of Ritonavir and Lopinavir. OPCs were exposed to AZT, 
Ritonavir, and Lopinavir for 30 minutes, 1 hour, 2 hours, 6 hours, 12 hours, or 24 hours at the doses used in 
previous experiments, followed by staining with dihydroethidium (DHE) as an indicator of ROS. This 
method is a readout for cellular ROS levels, as oxidation of DHE to ethidium allows for ethidium 
intercalation with DNA, emitting a quantifiable red fluorescence which overlaps with DAPI area (Zhao, 
2003). Tert-butyl hydroperoxide (tBHP, 2.5 µM) treatment was used as positive indicator of ROS 
generation for each timepoint. Following the timecourse outlined above, we found that Ritonavir produced 
a dose-dependent, rapid and robust accumulation of ROS by 1 hour (1756% ± 360.8% compared with 
vehicle, p < 0.001), while AZT produced a more modest effect, which was not observed until 2 hours post-
treatment (505% ± 80.4% compared with control, p < 0.001) (Figure 4.5). Interestingly, Lopinavir did not 
produce detectable ROS levels at any time-point up to 24 hours (not shown).  
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The Endogenous Antioxidant Response is not Activated with Antiretroviral Drugs in Developing 
OPCs 
Robust ROS were rapidly detectable following Ritonavir and AZT treatments. The typical cellular response 
to such an imbalance in redox homeostasis is activation of the endogenous antioxidant response (EAR) (Li, 
2009). Therefore, we investigated whether exposure of antiretroviral compounds to developing 
oligodendrocytes activated this cellular stress signaling pathway. OPCs were treated with the highest dose 
of each antiretroviral at the time of differentiation. Then, mRNA or protein was extracted 6 or 16 hours 
later, respectively. The analysis of principle cellular targets of the EAR: Heme Oxygenase-1 (HO-1) and 
NAD(P)H:quinone oxidoreductase (NQO1), revealed no changes in mRNA levels after 6 hours of 
treatment with AZT. Surprisingly, Lopinavir led to a decrease in HO-1 mRNA levels to 0.654 fold 
compared with vehicle, with a range between 0.331 and 1.294 fold (p < 0.001). In contrast, NQO1 levels 
were significantly increased with both Ritonavir to 1.716 fold (1.474-2.00 fold range, p = 0.015) and 
Lopinavir to 1.272 fold (0.554-2.921 fold range, p < 0.001) (Table 4.3). The incremental changes in NQO1 
in our treatments, as compared with the robust increases normally seen with EAR activation with classical 
pathway inducers suggest that the response may not be functionally significant (Table 4.3). Consistent with 
this interpretation, immunoblotting for HO-1 and NQO1 showed no alterations in protein levels following 
16 hours of treatment with any of the compounds tested (Figure 4.6A-B). 
 
Effective Reduction of Reactive Oxygen Species Does not Rescue Maturation Defects 
Robust oxidative stress was evident following treatment with Ritonavir, yet the EAR was not activated 
following treatment with any of the antiretroviral drugs tested. Therefore, we sought to determine if 
decreasing the accumulation of ROS would rescue the observed differentiation defects. To do this, we 
utilized the fumaric acid ester, monomethyl fumarate (MMF). MMF is the active metabolite of dimethyl 
fumarate (DMF), which is now approved for treatment of the demyelinating disorder Multiple Sclerosis 
(FDA, 2013, Limmroth, 2013). Importantly, we have previously shown that MMF successfully ameliorates 
ROS accumulation and antiretroviral-induced toxicity in neuroglial cell cultures (Akay et al., 2014). To 
determine whether MMF was effective at reducing ROS accumulation triggered by antiretrovirals in 
oligodendrocyte cultures, OPCs were pre-treated with 10 µM MMF for 6 hours, followed by 
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supplementation with MMF and/or treated with 25 µM AZT or 3 µM Ritonavir for 2 hours or 15 µM 
Lopinavir for 6 hours. DHE staining revealed that MMF pre-treatment significantly attenuated ROS 
accumulation after AZT and Ritonavir treatments (Figure 4.7A). As we previously established, Lopinavir 
did not induce ROS at 6 hours, and MMF had no effect on endogenously detectable ROS levels (Figure 
4.7A). We next assessed if reducing oxidative stress by attenuating ROS accumulation by MMF would 
increase the number of mature oligodendrocytes in the presence of PIs. OPCs were pre-treated with MMF 
for 24 hours prior to switching to differentiation medium, and were treated with 3 µM Ritonavir or 15 µM 
Lopinavir. MMF was replenished at the time of PI treatment and again every 24 hours. After 72 hours in 
differentiation medium, cells were stained for GalC and compared with vehicle or cells incubated with 
MMF without PIs. There was no difference between the number of GalC+ cells in cultures treated with 
Ritonavir +MMF or Lopinavir +MMF (Ritonavir 35.2%  ± 0.77%, Lopinavir 36.4%  ± 18.2% of vehicle) 
and those exposed to Ritonavir or Lopinavir alone (Ritonavir 29.9% ± 5.90%, Lopinavir 19.9% ± 14.5%) 
(Figure 4.7B). Thus MMF decreased oxidative stress but did not improve oligodendrocyte differentiation. 
  
The Unfolded Protein Response is Not Triggered by Antiretroviral Drugs in Maturing 
Oligodendrocytes 
We and others have demonstrated that antiretroviral drugs induce the unfolded protein response (UPR) in 
neuroglial and somatic cell types (Gannon and Jordan-Sciutto, personal communication, Zhou, 2005, 
2006). It has also been well documented that the UPR plays an important role in a variety of demyelinating 
disorders (Gow and Wrabetz, 2009). This complex signaling pathway is modulated by the actions of three 
branches, PKR-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription 
factor 6 (ATF6), all of which complex with ER-resident chaperone protein Binding Immunoglobulin 
Protein ((BiP)/GRP78) in the absence of ER stress (Reviewed in (Hetz et al., 2015)). Activation of these 
pathways leads to attenuation of global protein translational in conjunction with selective upregulation of 
pro-survival proteins (Bertolotti et al., 2000, Lee and Ozcan, 2014, Hetz et al., 2015).  
 
Therefore, we analyzed whether the UPR was activated in OPCs treated with antiretroviral drugs for 6 or 
16 hours by assessing mRNA and protein levels of markers of UPR activation. Upon disruption of 
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endoplasmic reticulum homeostasis and activation of the UPR, X-box binding protein 1 (XBP-1) mRNA is 
spliced to promote the production of the active XBP-1 protein (Yoshida et al., 2001, Calfon et al., 2002). 
The relative ratio between spliced and total XBP-1 mRNA is an accepted standard for UPR activation 
(Yoshida et al., 2001, Calfon et al., 2002). The analysis of this ratio revealed no increases in XBP-1 mRNA 
splicing in antiretroviral treated cells at 6 hours, suggesting that UPR activation did not occur upon 
treatment of OPCs with these drugs (Table 4.4). While Lopinavir treatment led to a significant decrease in 
XBP-1 mRNA splicing (0.398 fold as compared with vehicle, with a range of 0.297-0.534 fold (p < 0.001)) 
(Table 4.4), this effect is negligible compared with biologically relevant changes, and does not correspond 
to the robust increases in the ratio of spliced-to-total XBP-1 mRNA which would indicate UPR activation. 
Additional genes targeted by the UPR pathway were also examined by this method. No significant 
alterations in transcript levels were noted for CHOP, BiP, ATF6, or ATF4 with any antiretroviral tested 
(Table 4.4). IRE1α was not altered with AZT or Ritonavir, but was highly upregulated following Lopinavir 
treatment (8.664 fold compared with vehicle, with a range of 8.532-8.797 fold). Binding immunoglobulin 
protein (BiP) served as an indicator of UPR activation at the protein level. As the primary sensor of 
endoplasmic reticulum stress, its cellular levels are tightly regulated by transcription, translation, and 
selective stabilization during stress conditions (Brown and Naidoo, 2012). Additionally, BiP is known to be 
upregulated in oligodendrocytes under conditions promoting UPR activation (Cortopassi et al., 2006). 
Immunoblotting for BiP protein showed no difference between PI-treated and vehicle cultures (Figure 
4.8A). To further examine the individual arms of the UPR, western blotting was performed for post-
translational modifications of representative proteins. As eIF2a phosphorylation was not increased 
following 16 hours of treatment with any antiretroviral, the PERK pathway is likely not involved at this 
timepoint (Figure 4.8B). ATF6β cleavage was also not observed; suggesting these antiretrovirals do not 
modulate ATF6-mediated transcriptional activity (Figure 4.8C). Finally, despite a significant increase in 
IRE1α mRNA observed by RT-PCR following Lopinavir treatment, total protein IRE1α protein level was 
not increased in this condition compared to vehicle (Figure 4.8D). More importantly, activation of the 
IRE1α branch of the UPR is dependent on protein dimerization facilitated by phosphorylation status. IRE1α 
phosphorylation status was not increased with Lopinavir or any antiretroviral condition (Figure 4.8E). 
Functional activation of the IRE1α pathway arm leads to the splicing event of XBP1 (Bertolotti et al., 2000, 
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Lee and Ozcan, 2014, Hetz et al., 2015). Rather than increasing, we observed that XBP1 splicing was 
significantly decreased following Lopinavir treatment, suggesting potential IRE1 pathway suppression, 
complete with compensatory increase of regulator IRE1α transcription as was also observed by RT-PCR 
(Table 4.4). In summary, these findings suggest that neither the EAR nor the UPR are activated in OPCs by 
any of the antiretrovirals tested during the timeframe that was previously determined to induce responses 
within these pathways neuroglial culture. Thus we do not currently ascribe the observed negative 
maturation effects to actions of either of these pathways. 
 
Myelin Protein Expression In Vivo is Reduced after Treatment with a Ritonavir Regimen 
After investigating how antiretrovirals altered oligodendrocyte maturation in vitro, we asked whether these 
compounds also had detrimental effects to established myelin in vivo. To this end, we examined the effects 
of a repeated/chronic antiretroviral exposure. We administered Ritonavir or vehicle intravenously to adult 
male mice through implanted jugular vein catheters over a two-week period, according to the same protocol 
followed in our previous studies (Briand et al., 2012, Akay et al., 2014). Recommendations for treatment 
regimens are constantly changing to improve patient outcomes while reducing adverse effects, as well as 
incorporating new drug classes and next-generation therapeutics. For our purposes, Ritonavir was chosen as 
a representative antiretroviral compound for our in vivo study. Ritonavir is globally used clinically as a 
boost for other antiretrovirals to increase bioavailability, as it is a potent inhibitor of cytochrome P450 
which metabolizes these compounds (Moyle, 2001). Increased bioavailability of co-administered 
compounds with high CNS penetrance likely leads to higher brain levels of these compounds (Marzolini et 
al., 2013). Additionally, Ritonavir-boosted regimens are still commonly prescribed in resource-limited 
settings as first-line treatment, making it globally among the most-prescribed treatment options 
(AIDSTAR-One, 2012). The dose of Ritonavir was based on previously published pharmacokinetic studies 
(Kageyama et al., 2005, Pistell et al., 2010, du Plooy et al., 2011). The animals showed no signs of distress 
or gross phenotypic alterations over the course of treatment. To determine the effects of Ritonavir on 
established myelin, myelin protein levels were assessed by immunoblotting cellular lysates prepared from 
frontal cortex. In addition to myelin basic protein (MBP), other components of mature myelin were also 
evaluated in vivo: myelin oligodendrocyte glycoprotein (MOG), cyclic-nucleotide-3’phosphodiesterase 
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(CNPase), myelin-associated glycoprotein (MAG), and proteolipid protein (PLP). We observed that protein 
levels of MOG and CNPase were significantly decreased with Ritonavir compared with vehicle treatment 
(p < 0.05), whereas MBP, MAG, and PLP levels were not significantly altered (Figure 4.9). 
 
Myelin Protein Expression in Humans is Altered by HIV- and Antiretroviral Treatment-Status 
To address potential translational relevancy of our observations, we examined prefrontal cortex autopsy 
specimens from cohort of HIV-infected patients who were exposed to antiretroviral agents. To date, 
diffusion tensor and magnetic resonance imaging studies and a single transcriptome study have been 
performed to examine white matter dysfunction in HIV and HAND patients (Borjabad et al., 2011, Tate et 
al., 2011, Kelly et al., 2014), but changes in post-mortem myelin protein levels have not been reported. The 
cohort contained age-matched HIV(-), HIV(+) patients who were cART-naïve (HIV(+)), and HIV(+) 
cART-medicated >12 month individuals (HIV(+)/ART) (n = 20 for each group). The HIV(+) cART-naïve 
group was comprised of six individuals with diagnosed HAND, one who was neurocognitively normal, five 
with neuropsychological impairment that was potentially due to factors other than HIV infection. Eight of 
the cases did not undergo a structured ante-mortem neurocognitive assessment. The HIV(+) cART-
medicated >12 month group (HIV(+)/ART) contained 14 individuals with HAND, two who were 
neurocognitively normal, and four with neuropsychological impairment potentially due to factors other than 
HIV infection. The full details of their demographics and clinical data are in Table 4.1. The prefrontal 
cortex was selected for analysis for the following reasons: 1) This brain region is utilized in performing the 
functional modalities in which HAND patients display impairments (Antinori, 2007), 2) Synaptodendritic 
damage has been previously reported in this region in affected patients (Ellis et al., 2007), and 3) A region 
of mixed white and grey matter was desired for analysis as is seen in the cortex, so that the overall myelin 
contribution and relative protein amounts could be assessed. Previous studies have shown that the volume 
of the corpus callosum is reduced in HIV and with antiretroviral treatment, however as this is an extremely 
myelin-rich environment, to observe a quantitative change in immunoblot analysis would require a sizable 
loss of myelination. For all cases, the myelin proteins MBP, MOG, CNPase, and MAG were examined by 
immunoblot analysis. When subdivided according to HIV status alone, no statistically significant 
alterations were noted in the myelin protein levels between uninfected controls and the HIV(+) patients 
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(Figure 4.10). However, when the cohort was stratified into categories based on antiretroviral therapy 
status, CNPase protein was significantly increased in the HIV(+) cART > 12 month group (HIV(+)/ART) 
compared with the HIV(-) group (p < 0.01) (Figure 4.11A). Finally, individuals for whom neurocognitive 
data was not known, who were neurocognitively normal, or who had neuropsychological impairment due to 
factors other than HIV-infection were excluded from analysis to remove potential confounding factors, and 
to allow us to examine only those cases with known HAND diagnosis in relation to cART-medication 
status. This analysis revealed a statistically significant decrease in MBP protein levels in the HIV(+)/ART 
group, as compared with the HIV(-) (p <  0.05), and HIV(+) groups (p < 0.05) (Figure 4.11B). On the other 
hand, a significant increase in CNPase protein was observed in the HIV(+)/ART group, compared with the 
HIV(-) group (p < 0.001) (Figure 4.11B). These results indicate that HIV infection compounded with the 
effects of antiretroviral therapy can lead to alterations in myelin protein levels in patients. 
 
4.5 DISCUSSION 
Despite effective viral suppression through antiretroviral therapy, HIV-Associated Neurocognitive 
Disorders (HAND) persists in infected individuals and is frequently accompanied by white matter 
pathologies (Tate et al., 2010, Kelly et al., 2014, Sacktor and Robertson, 2014). Here, we investigate the 
effects of antiretrovirals in vitro on oligodendrocyte survival and maturation, and in vivo on myelin 
maintenance in both adult mice and HIV(+) individuals and provide novel, compelling evidence that the 
protease inhibitors Ritonavir and Lopinavir impair both the maturation of oligodendrocyte precursors into 
myelin-producing cells, and the maintenance of myelin proteins in vivo. Furthermore, human brain 
specimens demonstrated a reduction in MBP and an increase in CNPase in HAND patients who had been 
cART-medicated for greater than one year, suggesting a loss of myelin integrity yet failure of successful 
remyelination. These novel observations of the effects of a subset of antiretrovirals on oligodendrocyte 
development and maintenance may have critical clinical repercussions for both pediatric and adult HIV-
patients.  
 
Utilizing stage-specific markers, we have shown that PIs Ritonavir and Lopinavir prevent oligodendrocyte 
maturation in vitro while NRTI AZT does not. Interestingly, myelin protein levels as evaluated by 
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immunoblotting remained unchanged under most conditions, except at the highest dose of Lopinavir. 
During normal maturation, OPCs enter into differentiation and proceed with upregulation of myelin 
component mRNAs (Miller, 2002). During this progression, cells extend actin filaments to elaborate 
processes. Most myelin proteins are then translated in the perinuclear endoplasmic reticulum and trafficked 
through the secretory pathway to be inserted into the forming myelin membrane (Colman et al., 1982). An 
exception is MBP, in which mRNA is trafficked to sites proximal to membrane insertion where the protein 
is then translated on free-ribosomes (Colman et al., 1982, Ainger et al., 1997). In that context, our data 
suggest that treatment with PIs prevents proper membrane insertion of both myelin proteins traversing the 
secretory network and locally synthesized MBP as we have detected by immunofluorescence; however, in 
these conditions, protein levels remain unchanged, as determined by immunoblotting. Specifically, even at 
the highest Ritonavir dose where we observed substantial decreases in maturation by immunofluorescence, 
we did not detect parallel changes at the protein level. This finding, while unusual, is not unprecedented in 
oligodendrocytes. Maier et al. (2009) demonstrated that reduction in cellular cholesterol levels can result in 
decreased PLP surface expression with minimal reduction at the protein level. Along these lines, a recent 
study also suggested that myelin membrane lipid composition may be altered under two models of 
demyelination. In this work, MBP surface localization to myelinated processes by immunohistochemistry 
was diminished, while total MBP levels remained unchanged (Frid et al., 2015). Additionally, a study 
investigating the role of mammalian target of rapamycin in oligodendrocyte differentiation observed 
maintenance of normal myelin protein levels despite a significant reduction in the number of maturing 
oligodendrocytes (Wahl et al., 2014). Further, we observed that cells treated with either PI adopted properly 
elaborated mature oligodendrocyte morphology, as evidenced by normal actin cytoskeleton morphology 
despite reduction in myelin protein expression at the cell surface. The effect of PIs was reversible, as cells 
proceeded to differentiate rapidly following drug removal, with both cell surface marker expression and 
myelin protein levels indistinguishable from controls after 24 hours. The accelerated rescue of maturation 
deficits further suggests that required components are already present within the treated cells, and that these 
PIs are most probably suppressing maturation on a post-translational level. Drug removal alleviates this 
blockade, resulting in appropriate protein localization to the myelin membrane.  
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We have observed differences in the effects of Ritonavir and Lopinavir. While both are PIs, their differing 
chemical structures likely result in disparate cellular uptake, metabolism, and intracellular interactions. In 
agreement with this notion, other commonly prescribed PIs behave differently within cells of the same 
lineage. For example, inhibition of differentiation was observed with Nelfinavir and Indinavir, but not 
Amprenavir in adipocytes (Caron et al., 2003). Similarly, in CNS-derived astrocytes, Nelfinavir and 
Indinavir displayed striking differences in ROS production, glutathione export, and toxicity (Brandmann et 
al., 2012). Regardless of the differing subcellular effects that Lopinavir and Ritonavir invoke, it is clear 
based on our observations that properly functioning myelin would not arise following exposure to either PI 
even at low concentrations. 
 
Several antiretroviral drugs induce ROS, mitochondrial depolarization and neurotoxicity in mixed 
neuroglial cultures (Robertson et al., 2012, Akay et al., 2014), and we have shown that oxidative stress can 
hinder the process of oligodendrocyte differentiation (French et al., 2009). While both AZT and Ritonavir 
induced robust ROS accumulation, Lopinavir did not, even at extended timepoints. When we assessed 
whether the EAR, which is triggered by cellular redox imbalance, was activated following antiretroviral 
exposure, no biologically relevant increases in target gene mRNAs or proteins, such as HO-1 or NQO1 
were detected (Li, 2009). Furthermore, scavenging of ROS with the antioxidant compound MMF did not 
rescue PI-induced decreases in oligodendrocyte differentiation despite previously demonstrated 
neuroprotection (Akay et al., 2014). PIs have also been shown to activate the UPR in non-CNS cells, which 
potently suppresses protein translation while upregulating stress-response proteins (Zhou, 2005, 2006, 
Brown and Naidoo, 2012). However, we found no evidence of UPR activation in oligodendrocytes 
following antiretroviral treatments at two timepoints where such activation was evident in neuroglial 
cultures (Akay et al., 2014), although we acknowledge that there may be activation at earlier or later time 
points. Thus, our data suggest that PIs inhibit oligodendrocyte maturation through an alternate mechanism. 
An intriguing possibility is whether PIs disrupt the crucially important myelin-lipid balance, which may 
result in inappropriate organization of myelin components, as previously reported (Maier et al., 2009, 
Chrast et al., 2011, Lee et al., 2014, Frid et al., 2015). Since PIs have been shown to cause dyslipidemia in 
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patients and in non-CNS cell types (Carr, 1998, Haughey et al., 2004, Zhou, 2005), this could contribute to 
the white matter loss seen in HAND patients (Tate et al., 2010, Kelly et al., 2014). 
 
The effects of antiretrovirals on myelin in vivo using both a mouse model and human autopsy cases also 
indicate alterations in myelin proteins. In mice, we detected reduced levels of less abundant myelin proteins 
in as little as 14 days of chronic exposure. Levels of the abundant structural myelin components MBP and 
PLP were not affected in this short-term administration model. Changes in these critical proteins may be 
unexpected in such a short time frame, as gross changes in myelin may be necessary to result in detectable 
alterations. In our human cohort, we did observe a reduction in MBP in cART-experienced individuals with 
HAND compared with cART-naïve individuals with HAND, and HIV(-) controls. This finding correlates 
with a transcriptome analysis of virally controlled patients with HAND, which showed reduction of MBP 
mRNA (Borjabad et al., 2011). The HIV(+)/ART group also displayed a significant increase in the amount 
of CNPase over both HIV(-) and HIV(+) cART-naïve individuals, regardless of their neurocognitive status. 
CNPase is the earliest myelin protein to be expressed during maturation (Scherer et al., 1994), and our 
observation may reflect a remyelination attempt that is prematurely halted, failing to form mature myelin. 
 
Current WHO guidelines urge immediate treatment of all infected children under the age of 5 years, and 
adults with a CD4 count ≤ 350 cells/mm3. Guidelines suggest that first-line cART consist of two NRTIs 
and a non-nucleoside reverse-transcriptase inhibitor (nNRTI). When second-line cART is necessary due to 
acquired drug resistance, recommended regimens are composed of two NRTIs plus a Ritonavir-boosted PI, 
either Lopinavir or Atazanavir. All infected children under 3 years of age are recommended a 
Lopinavir/Ritonavir first-line regimen (WHO, 2013). As is clear from these guidelines, PI-based regimens 
are extensively used in HIV treatment, particularly in children, during a time of critical cortical myelination 
which primarily occurs from the postnatal period until late adolescence (Miller et al., 2012). Neurological 
complications are common in infected children, with documentation of encephalopathy, progressive 
multifocal leukoencephalopathy, cerebrovascular events, and emerging neurocognitive deficits leading to 
developmental delays, motor, cognitive, and behavioral deficits (Wilmshurst et al., 2006, Crowell et al., 
2014, Wilmshurst et al., 2014). Our results showing an effective disruption in myelination following PI 
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exposure may underlie these clinical presentations, and therefore have important ramifications for the 
future treatment of pediatric HIV infection.  
 
PI-supplemented regimens are generally prescribed to adults as second-line options. However, as lifelong 
cART adherence is necessary, over the course of regimen alterations, most patients will be exposed to a 
boosted PI. The maintenance and replacement of myelin in the brain is an active and ongoing process, 
which is critical for proper neuronal functioning and survival (McLaurin and Yong, 1995). Remyelination 
of neurons in the adult has been well documented, particularly through investigation into pathology and 
potential treatments for Multiple Sclerosis (Hartley et al., 2014, Kutzelnigg and Lassmann, 2014). 
Additionally, while traditionally viewed as an early life event, active myelin formation in adulthood is 
required for motor learning (Long and Corfas, 2014, McKenzie et al., 2014). We have shown through our 
mouse model that prolonged PI exposure may lead to reductions in adult cortical myelin proteins. More 
importantly, human patients with HAND who had been treated with antiretrovirals for at least a year 
demonstrated a significant reduction in MBP compared with uninfected individuals and HAND patients 
who were cART-naïve. Therefore, therapeutics which will preserve the capacity for myelin formation and 
the integrity of existing structures are of vital importance.   
 
In summary, this study implicates antiretrovirals as a contributor to HAND pathology and its persistence in 
virologically suppressed individuals. In human patients, the underlying viral infection complicates analysis 
of consequences solely due to antiretrovirals. Our observed effects of antiretrovirals in conjunction with the 
potential contribution of HIV-induced pathogenesis on oligodendrocytes highlight the necessity for 
strategic drug development for new therapeutics with fewer deleterious side effects. While this study has 
highlighted the effects of antiretroviral compounds, future work investigating the consequences of HIV 
infection in the CNS on the oligodendrocyte population are also essential for a more complete 
understanding of the changes to white matter in HIV-positive patients. 
 
Furthermore, we must consider adjunctive therapies designed not only to alleviate neuronal dysfunction, 
but also to preserve myelin formation and maintenance by oligodendrocytes. Persistent ROS elevation and 
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oxidative damage are seen in treated HIV(+) individuals (Roc et al., 2007, Blas-Garcia et al., 2011). HO-1 
deficiency has recently been reported in HIV(+) and HAND patients, suggesting inactivity of the EAR 
pathway (Gill et al., 2014). Supporting this notion, we have reported that EAR and HO-1 upregulation by 
the antioxidant MMF was successful in preventing ARV-induced oxidative stress and neuronal toxicity in 
neuroglial cultures (Akay et al., 2014). Unfortunately, based on our current findings, while neurons may be 
initially protected by adjunctive antioxidant therapy, oligodendrocytes would remain vulnerable and 
neuronal pathology caused by myelin disruption would still persist. Thus, the effects of antiretrovirals on 
oligodendrocyte maturation and myelin unveiled in this study illuminate the need for greater understanding 
of viral- and therapy-mediated repercussions to the critically important oligodendroglial cell population in 
order to attenuate neurocognitive deficits in HIV(+) individuals in the cART era.   
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Table 4.1: Demographics of Human Subjects 
Summary of human cohort demographics, antiretroviral therapy history, and clinical data utilized for post-
mortem analysis. Abbreviations: Antiretroviral Therapy (ART), standard deviation (SD), HIV-Associated 
Neurocognitive Disorders (HAND), Antiretroviral (ARV), HIV protease inhibitor-experienced (PI-
experienced), nucleoside reverse transcriptase inhibitor-experienced (NRTI-experienced), HIV encephalitis 
(HIVE). aAnalysis of Variance (ANOVA) p-value, bChi-square test p-value, c Student’s t-test p-value. 
Table 1: Demographics of Human Subjects 
Characteristic: HIV (-) HIV (+) 
ART-
naïve 
HIV (+) 
ART-
medicated 
>12mo 
p-value 
     
Number of Subjects 20 20 20 - 
     
Age at death, mean ± SD 42.8 ± 5.6 39.7 ± 7.3 45.3 ± 6.7 0.032a 
     
Hours post-mortem, mean ± SD   9.9 ± 5.7 10.0 ± 6.4 12.4 ± 7.9 0.455a 
     
Sex     
     Male (%) 80% 90% 80% 0.619b      Female (%) 20% 10% 20% 
     
Race     
     White (%)  11 (55%) 12 (60%) 15 (75%)  
     Black (%) 7 (35%) 8 (40%) 5 (25%) 0.498b 
     Other/Unknown (%) 2 (10%) 0 (0%) 1 (5%)  
     
Ethnicity     
     Hispanic (%) 5 (25%) 3 (15%) 3 (15%) 0.641b      Non-Hispanic (%) 15 (75%) 17 (85%) 17 (85%) 
     
Neurocognitive Impairment Status     
     HAND (%) - 6 (30%) 14 (70%) 
0.009b      Neuropsych. Impair. Other Origin (%) - 5 (25%) 4 (20%)      Neurocognitively Normal (%) - 1 (5%) 2 (10%) 
     No Neurocognitive Data (%) - 8 (40%) 0 (0%) 
     
ARV Treatment Status     
     PI-Experienced (%) - - 17 (85%)  
     PI-Naïve (%) - - 3 (15%)  
     NRTI-Experienced (%) - - 20 (100%)  
     NRTI-Naïve (%) - - 0 (0%)  
     
Disease Parameters     
     HIVE (%) - 6 (30%) 1 (5%)  
     Log Plasma HIV c/mL, mean ± SD - 4.1 ± 1.4 4.7 ± 1.1 0.196c 
     Log Brain HIV g/mL, mean ± SD - 3.4 ± 1.9 4.1 ± 0.9 0.358c 
     Log CSF HIV c/mL, mean ± SD - 3.4 ± 1.8 2.8 ± 1.1 0.261c 
     CD4+lymphocytes/mm3, mean ± SD - 108 ± 118 85 ± 118 0.624c 
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Table 4.2 Primers Used for q-RT PCR 
Primer pairs used for qRT-PCR are shown, which were obtained from IDT. Abbreviations are: PKG1, 
Protein Kinase Gene 1; HO-1, Heme Oxygenase-1; NQO1, NAD(P)H:quinone oxidoreductase; XBP-1, X-
box Binding Protein 1; BiP, Binding Immunoglobulin Protein; CHOP, C/EBP homologous protein; Ire1α, 
inositol-requiring enzyme 1 alpha; ATF6, activating transcription factor 6; ATF4, activating transcription 
factor 4. 
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Table 4.3 mRNA alterations in Endogenous Antioxidant Response Genes Following Antiretroviral 
Application in Primary OPCs 
Extracted RNA (5 µg) was converted to cDNA using the Superscript First-strand kit and q-PCR was 
performed using Power SYBR Green. All measurements were normalized first to the oligodendrocyte 
housekeeping gene PKG1, and then to controls. Analysis was performed by the ΔΔCT method. 
Endogenous Antioxidant Response genes: HO-1 and NQO1 were probed. ΔΔCT ±SEM, fold change, and 
fold change range are presented from 3 independent biological replicates (n = 3). P-values are indicated, 
(*= p< 0.05). 
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Table 4.4 mRNA alterations in Unfolded Protein Response Genes Following Antiretroviral 
Application in Primary OPCs 
Extracted RNA (5 µg) was converted to cDNA using the Superscript First-strand kit and q-PCR was 
performed using Power SYBR Green. All measurements were normalized first to the oligodendrocyte 
housekeeping gene PKG1, and then to controls. Analysis was performed by the ΔΔCT method. Unfolded 
Protein Response genes: XBP-1 spliced, XBP-1 total, BiP, CHOP, Ire1α, ATF6, and ATF4 were probed. 
ΔΔCT ±SEM, fold change, and fold change range are presented from 3 independent biological replicates (n 
= 3). P-values are indicated, (*= p< 0.05). 
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Figure 4.1: Antiretrovirals Inhibit Oligodendrocyte Differentiation 
Primary mouse OPCs plated on coverslips were put into differentiation medium and treated with vehicle 
(DMSO), doses of AZT (1 µM, 10 µM, or 25 µM), Ritonavir (100 nM, 1 µM, or 3 µM), or Lopinavir (150 
nM, 1.5 µM, or 15 µM). After 72 hrs, cells were fixed and stained with antibody to MBP (green) with 
DAPI (blue) for total cell nuclei. Epifluorescent images were captured, with 10 fields on three coverslips 
per condition. Results from n= 4 independently prepared cultures. 
A) Representative images from immunofluorescent staining, scale bar indicates 25 µm. 
B-C) Immature oligodendrocytes (GalC+ cells) (B) and mature oligodendrocytes (MBP+ cells) (C) were 
counted using ImageJ software, represented as percentage normalized to untreated. Results from AZT are 
in the top row, Ritonavir in the center, and Lopinavir in the bottom row respectively. Data are presented as 
mean ±SEM. One-way ANOVA followed by post-hoc Newman-Keuls determined statistical significance.  
Significance compared with control (###= p< 0.001, ##= p< 0.01).
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Figure 4.2: Antiretrovirals Do Not Alter Oligodendrocyte Precursor Number or Induce Apoptotic 
Cell Death 
A-B) Primary mouse OPCs plated on coverslips were put into differentiation medium and treated with 
vehicle (DMSO), doses of AZT (1 µM, 10 µM, or 25 µM), Ritonavir (100 nM, 1 µM, or 3 µM), or 
Lopinavir (150 nM, 1.5 µM, or 15 µM). After 72 hrs, cells were fixed and stained with antibody to A2B5 
with DAPI (blue) for total cell nuclei. Results from AZT are in the top row, Ritonavir in the center, and 
Lopinavir in the bottom row respectively. Epifluorescent images were captured, with 10 fields on three 
coverslips per condition.  
A) Total cell number (DAPI+ nuclei) were counted using ImageJ software from the biological replicates 
utilized for the dose curves in Figures 1 and 2 (n=8). Results are represented as percentage normalized to 
untreated. Significance compared with control (#= p< 0.05). Data are presented as mean ±SEM. One-way 
ANOVA followed by post-hoc Newman-Keuls determined statistical significance.  
B) Oligodendrocyte precursor cells (A2B5+ cells) were counted using ImageJ software and are represented 
as percentage normalized to untreated. Data are presented as mean ±SEM. Results from n= 3 independently 
prepared cultures. One-way ANOVA followed by post-hoc Newman-Keuls determined statistical 
significance.  
C) Primary mouse OPCs plated on coverslips were put into differentiation medium and treated with vehicle 
(DMSO), or doses of Lopinavir (1.5 µM, or 15 µM). After 72 hrs, cells were fixed and stained using a 
TUNEL assay to label cells with double-stranded DNA breaks indicative of activation of the apoptotic 
cascade. DNase was used as a positive control. Epifluorescent images were captured at 40x magnification, 
with 10 fields on three coverslips per condition. Results from n= 2 independently prepared cultures. Data 
are presented as mean ± SEM. One-way ANOVA followed by post-hoc Dunnett’s comparison determined 
statistical significance. Significance compared with control (###= p< 0.001). 
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Figure 4.3: Lopinavir Reduces Myelin Proteins but AZT and Ritonavir Do Not 
OPCs were treated with vehicle, AZT (1 µM, 10 µM, or 25 µM), Ritonavir (100 nM, 1 µM, or 3 µM) or 
Lopinavir (1.5 µM or 15 µM) at the time of differentiation. After 72 hrs cells were harvested for protein, 
undifferentiated OPCs were harvested at time 0. Cell lysates were immunoblotted for MBP protein (A-C), 
CNP protein (D), or PLP protein (E). 
A) Representative Western blot image and quantification of band intensities normalized to loading control 
GAPDH from 5 separate culture groups (n= 5) reveals the typical increase in MBP expression over 72 
hours between OPC and untreated, however no significant change with any dose of AZT.  
B) Analysis as in A) from n= 5 reveals the typical increase in MBP expression over 72 hours between OPC 
and vehicle treatment, however no change with any dose of Ritonavir.  
C) Representative Western blot image and quantification of band intensities normalized to loading control 
GAPDH from n= 4 reveals treatment with 15 µM Lopinavir resulted in significantly less MBP expression 
over 72 hours than with vehicle alone or with the lower 1.5 µM dose of Lopinavir. 
D) Representative Western blot images with loading control GAPDH reveals less CNP expressed at 72 
hours following treatment with 15 µM Lopinavir than with the vehicle alone, 25 µM AZT, or 3 µM 
Ritonavir. 
E) Representative Western blot images with loading control GAPDH reveals less PLP expressed at 72 
hours following treatment with 15 µM Lopinavir than with the vehicle alone, 25 µM AZT, or 3 µM 
Ritonavir. 
Data are presented as mean ± SEM. One-way ANOVA followed by post-hoc Newman-Keuls determined 
statistical significance across concentrations. Undifferentiated and controls (untreated or vehicle) were 
compared by Student’s t-test (##= p< 0.01, #= p< 0.05).   
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Figure 4.4: Antiretroviral Inhibition of Differentiation is Reversible 
A) OPCs were treated with vehicle, 3 µM Ritonavir, or 15 µM Lopinavir at the time of differentiation. 
After 72 hrs, cells were fixed and stained for GalC (green) with DAPI (blue) and Phalloidin (red) for actin. 
Sample images reveal that cells in Ritonavir and Lopinavir treatments have elaborated morphology but lack 
the appropriate maturation marker GalC co-staining. Scale bar indicates 25 µm.  
B) OPCs were treated as in A. After 72 hrs, the washout group received new differentiation medium 
without antiretrovirals and was allowed to further mature for 24 hrs. Cells were fixed and stained for GalC 
with DAPI. Cells were counted as in Figure 1 for 15 fields in 3 coverslips per condition at 40x 
magnification. Data are presented as mean ± SEM, n= 4. One-way ANOVA followed by post-hoc 
Bonferroni correction compared vehicle and treatment conditions at the two time-points (#= p< 0.05, ##= 
p< 0.01, ###= p< 0.001, ns= not significant).  
C)  OPCs were treated with Vehicle or 15 µM Lopinavir at the time of differentiation. After 72 hrs, the 
washout group received new differentiation medium without treatment and was allowed to further mature 
for 24 hrs. Cell lysates were immunoblotted for MBP protein. Representative Western blot image shown. 
Quantification of band intensities normalized to a loading control reveals that Lopinavir-treated cells 
expressed less MBP protein compared with vehicle; however this level rose to be comparable to vehicle 24 
hours after washout. Data are presented as mean ± SEM, n= 3. One-way ANOVA followed by post-hoc 
Bonferroni correction compared vehicle and treatment conditions at the two time-points (#= p< 0.05).  
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Figure 4.5: Antiretrovirals Induce Oxidative Stress  
OPCs were treated with vehicle, AZT (1 µM, 10 µM, or 25 µM), Ritonavir (100 nM, 1 µM or 3 µM), 
Lopinavir (150 nM, 1.5 µM, or 15 µM), or positive control tBHP (2.5 µM) for 30 min, 1 hr, 2 hrs, 6 hrs, 12 
hrs, and 24 hrs to determine if reactive oxygen species (ROS) were generated. DHE staining was used as an 
indicator of ROS, with DAPI staining for cell nuclei. Epifluorescent images were captured at 40x 
magnification, with 10 fields on three coverslips per condition at the time-point where ROS began to 
accumulate for each antiretroviral compound. Scale bar indicates 25 µm. In treatments up to 24 hrs, 
Lopinavir produced no accumulation. Analysis using Metamorph determined fluorescence intensity of 
DHE normalized to nuclear DAPI area. Representative experiments shown, values are presented as mean 
±SEM, n= 2 for each time-point tested. One-way ANOVA followed by post-hoc Newman-Keuls 
determined statistical significance (##= p< 0.01, ###= p< 0.001).  
A)  Representative images of 1 hr tBHP- and Ritonavir-treated and 2 hr AZT-treated OPCs, with DHE 
fluorescence (red) and cell nuclei stained with DAPI (blue). 
B)   Quantification of these experiments.  
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Figure 4.6: The Endogenous Antioxidant Response is Not Triggered by Antiretrovirals in Developing 
OPCs 
OPCs were treated with vehicle, 25 µM AZT, 3 µM Ritonavir, or 15 µM Lopinavir at the time of 
differentiation. After 16 hrs cells were harvested for protein. Cell lysates were immunoblotted for Heme 
Oxygenase-1 (HO-1) (A) and NAD(P)H:quinone oxidoreductase (NQO1) (B), target proteins upregulated 
following activation of the endogenous antioxidant response. Representative Western blot images shown, 
with quantification of band intensities normalized to GAPDH loading controls revealing no change with 
any treatment condition. Data are presented as mean ± SEM from 3 separate cultures (n= 3). One-way 
ANOVA followed by post-hoc Dunnett’s multiple comparison determined statistical significance. 
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Figure 4.7: Effective Reduction of Reactive Oxygen Species Does not Rescue Maturation Defects 
A) OPCs were pre-treated with 10 µM monomethyl fumarate (MMF) for 6 hrs. Cultures were then 
supplemented with MMF and/or treated with vehicle, 25 µM AZT or 3 µM Ritonavir for 2 hrs or 15 µM 
Lopinavir for 6 hrs. DHE staining, imaging and analysis was performed as in Figure 4. Representative 
experiment shown, values are presented as mean ± SEM, n= 2. Student’s t-test determined significance for 
direct comparisons (#= p< 0.05, ##= p< 0.001). 
B)  OPCs plated on coverslips were pre-treated with 10 µM MMF for 24 hrs. Cells were then switched into 
DM, supplemented with MMF and/or treated with vehicle, 3 µM Ritonavir or 15 µM Lopinavir. MMF was 
replenished at 24 and 48 hrs. After 72 hrs, cells were fixed and stained for GalC and DAPI, and were 
imaged and analyzed as in Figure 1. Data are presented as mean ± SEM, from 3 separate cultures (n= 3). 
Student’s t-test determined significance for direct comparisons (##= p< 0.01, ###= p< 0.001).  
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Figure 4.8: The Unfolded Protein Response is Not Triggered by Antiretrovirals in Developing OPCs 
OPCs were treated with vehicle, 25 µM AZT, 3 µM Ritonavir, or 15 µM Lopinavir at the time of 
differentiation. After 16 hrs cells were harvested for protein. Cell lysates were immunoblotted for protein 
alterations indicating activation of the unfolded protein response.  
A)  Representative Western blot images shown of BiP, with quantification of band intensities normalized to 
GAPDH loading controls from 3 independent biological replicates graphed.   
B-E) Levels of phosphorylated compared to total eIF2a protein B), cleaved compared to total ATF6β 
protein C), total IRE1α protein D), and phosphorylated compared to total IRE1α protein E), were each 
analyzed from three separate biological replicates (n=3). Quantification of band intensities normalized to 
GAPDH loading controls revealed no changes in any of these proteins following treatment with the 
antiretrovirals tested. Data are presented as mean ± SEM. One-way ANOVA followed by post-hoc 
Dunnett’s multiple comparison test determined statistical significance. 
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Figure 4.9: In Vivo Ritonavir Administration Leads to Reduction in Myelin Proteins  
Brain lysates derived from our jugular vein administration model were immunoblotted for various myelin 
proteins: MBP, Myelin Oligodendrocyte Glycoprotein (MOG), CNP, Myelin-Associated Glycoprotein 
(MAG), and PLP. The drug regimen was composed of vehicle (DMSO) or 20 mg/kg/day of Ritonavir for 
14 days. 
A)  Western Blot images from frontal cortex lysates are shown (vehicle n= 6, Ritonavir n= 7).  
B) Quantification of band intensities normalized to FastGreen FCF reveals statistically significant 
decreases in MOG and CNP protein levels. Data are presented as mean ± SEM. Student’s t-test determined 
statistical significance for direct comparisons (#= p< 0.05). 
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Figure 4.10: Myelin Protein Expression in Humans is Not Affected by HIV Status 
Lysates from prefrontal cortex specimens of HIV(-) controls, HIV(+) cART-naïve, and HIV(+) cART-
medicated >12mo (HIV(+)/ART), were immunoblotted for myelin component proteins MBP, MOG, CNP, 
and MAG (n=20 for each group). Protein expression levels were determined by quantification of band 
intensities normalized to a FastGreen total protein loading control. Patient samples were stratified by HIV 
status with HIV(-) individuals compared with the HIV(+) cases, both cART-naïve and cART-medicated 
combined, with red data points indicating patients diagnosed with HAND. Black lines indicate mean ± 
SEM. Student’s t-test determined statistical significance for direct comparisons, result was not statistically 
significant. 
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Figure 4.11: Myelin Protein Expression in Humans is Affected by cART-Medication Status 
Lysates from prefrontal cortex specimens of HIV(-) controls (n= 20), HIV(+) cART-naïve (n= 20), and 
HIV(+) cART-medicated >12mo (HIV(+)/ART) (n= 20), were immunoblotted for myelin component 
proteins MBP, MOG, CNP, and MAG. Protein expression levels were determined by quantification of band 
intensities normalized to a FastGreen total protein loading control.   
A) Patient samples were stratified by HIV-treatment status, with red data points indicating patients 
diagnosed with HAND. Black lines indicate mean ± SEM. One-way ANOVA followed by post-hoc 
Newman-Keuls determined statistical significance (##= p< 0.01). 
B)  Individuals satisfying criteria for HAND diagnosis were stratified by HIV-treatment status, Black lines 
indicate mean ± SEM. One-way ANOVA followed by post-hoc Newman-Keuls determined statistical 
significance (#= p< 0.05, ###= p< 0.001).  
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5.1 ABSTRACT  
Events leading to autoimmune targeting of myelin in Multiple Sclerosis (MS) patients remain unknown, yet 
chronic oxidative stress is a pervasive disease feature. Tecfidera, (dimethyl fumarate), a recently released 
drug that reduces MS relapse rates is thought to target oxidative stress. Tecfidera is rapidly metabolized to 
monomethyl fumarate (MMF), which effectively promotes transcription factor Nrf2-mediated activation of 
the endogenous antioxidant response (EAR) in neurons and macrophages. Effects of MMF have not been 
examined in oligodendrocytes. Effective therapy will require both prevention of myelin loss and promotion 
of re-myelination through maturation of oligodendrocyte precursors. We have previously demonstrated that 
oxidative stress can halt oligodendrocyte differentiation. Also, we have shown that MMF can attenuate 
oxidative stress-induced neurotoxicity through EAR upregulation. We hypothesized that MMF may reverse 
stress-induced differentiation deficits in oligodendrocytes by EAR upregulation and subsequent attenuation 
of oxidative stress. Treatment of mouse oligodendrocyte precursors and mature oligodendrocytes with an 
oxidant resulted in accumulation of reactive oxygen species (ROS) and significant reduction in 
differentiation; however, EAR target genes were not upregulated. MMF significantly reduced ROS 
accumulation induced by multiple oxidants, but did not coincide with EAR activation. MMF also did not 
rescue maturation defects, as comparable significant decreases were evident in oxidant alone and oxidant+ 
MMF conditions. Our results suggest that oligodendrocytes do not properly activate the EAR to restore 
redox homeostasis, even after treatment with antioxidants such as MMF. As such, the therapeutic effect of 
MMF in patients is likely due a mechanism other than direct antioxidant effects on oligodendrocytes.  
 
5.2 SUMMARY STATEMENT 
The biological metabolite of Multiple Sclerosis drug Tecfidera neither activates the endogenous antioxidant 
response in oligodendrocytes, nor rescues oxidative stress-mediated differentiation deficits. These findings 
suggest that Tecfidera reduces relapse rates in patients via a mechanism other than direct antioxidant 
activity in oligodendrocytes, or that antioxidant effects are mediated through indirect actions of other cell 
populations. 
  
163	  
5.3 INTRODUCTION 
Multiple Sclerosis (MS) affects 2.3 million people worldwide, yet precipitating events leading to the 
autoimmune targeting of myelin in patients are not well understood. Symptoms arise from disruption of 
myelin integrity within white matter tracts in the brain, as the myelin membrane synthesized by CNS 
oligodendrocytes is vital for proper transmission of rapid neuronal impulses through their axons (For recent 
reviews see (Markowitz, 2013) and (Mallucci et al., 2015)). Cellular pathology includes both destruction of 
myelin sheaths and death of the associated oligodendrocytes, as well as axonal damage and neuronal cell 
death (Criste et al., 2014, Mallucci et al., 2015). In addition to disruption of proper action potential signal 
facilitation, impaired myelination can alter the trophic support provided to neurons from oligodendrocytes, 
hastening axonal degeneration (Lappe-Siefke et al., 2003, Edgar and Garbern, 2004, Criste et al., 2014, 
Mighdoll et al., 2015).  
 
Despite the unknown etiology of MS, two well-documented pathological observations are chronic oxidative 
stress and inflammation (reviewed in (Friese et al., 2014, Mahad et al., 2015)). Studies have also identified 
oxidative damage as one of the key driving elements in the aberrant loss of myelination observed in 
children who suffer from periventricular white matter injury (PWMI) (Back and Rosenberg, 2014). This 
brain damage occurring in pre-term infants targets white matter in particular, and is a major contributor to 
subsequent neurological dysfunctions, which commonly includes cerebral palsy (Volpe, 1981, 2001). 
While PWMI can be triggered by several independent events, one of the principal causes is lack of cerebral 
oxygenation, which leads to the generation of oxidative stress and cell death of the particularly vulnerable 
oligodendrocyte precursor cells (OPCs) (Back and Rosenberg, 2014). In several perinatal rat 
hypoxia/ischemia models, reactive oxygen species generated by the insult resulted in injury and death of 
OPCs, which led to subsequent decreased numbers of mature oligodendrocytes and hypomyelination of 
white matter (Levison et al., 2001, Reid et al., 2012). Additionally, in vitro studies have demonstrated 
maturation-stage specific vulnerability to oxidative stress, with OPCs and developing immature 
oligodendrocytes displaying significantly more sensitivity than mature oligodendrocytes due to lower levels 
of glutathione and antioxidant enzymes, as well as higher rates of oxygen consumption (Halliwell, 1992, 
Back et al., 1998, Fern and Moller, 2000, Baud et al., 2004).  
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In the developing brain, loss of this critical OPC population profoundly impacts the total capacity of initial 
myelination. Potential depletion of the pool of OPCs in the adult from chronic oxidative stress has similar 
repercussions for the capability for effective re-myelination of affected areas in MS. In addition to OPC 
dropout due to oxidative stress-induced toxicity, we have previously demonstrated that at sub-toxic levels, 
oxidative stress generated by multiple compounds halts oligodendrocyte differentiation (French et al., 
2009). Together, these reports highlight the necessity for reduction of oxidative stress to facilitate recovery 
of function in demyelinating conditions, as the pool of cells responsible for re-myelination are negatively 
affected both by functional and toxicity-based mechanisms.   
 
The recently FDA-approved drug Tecfidera (BG-12, (dimethyl fumarate)) has been demonstrated to reduce 
relapse rates in MS patients (FDA, 2013, Limmroth, 2013, Fox et al., 2014, Dubey et al., 2015, English and 
Aloi, 2015). Intriguingly, while suspected to act as an antioxidant, the mechanism of action by which this 
compound is effective has not been elucidated. The chemical formulation of this drug is dimethyl fumarate 
(DMF), a fumaric acid ester, which is rapidly metabolized to monomethyl fumarate (MMF) (Litjens et al., 
2004, Schmidt et al., 2007, Limmroth, 2013, Fox et al., 2014). Within minutes of administration, MMF is 
the primary metabolite found in blood plasma, with DMF no longer detectable (Schmidt et al., 2007). 
Critically, marked reduction of macrophage recruitment into actively demyelinating brain regions was 
observed following oral DMF administration in a rodent experimental autoimmune encephalomyelitis 
model of MS, demonstrating that therapeutic levels of MMF cross the blood brain barrier (Schilling et al., 
2006). In neurons and macrophages, antioxidant effects of MMF have been reported, through NF-E2 
(nuclear factor (erythroid-derived 2))-related factor-2 (Nrf2) mediated activation of the endogenous 
antioxidant response (EAR) and upregulation of target antioxidant and detoxifying genes (Cross et al., 
2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et al., 2012, Akay et al., 2014). We have 
demonstrated successful MMF amelioration of oxidative stress-mediated neuronal toxicity through such 
activation (Akay et al., 2014). Surprisingly, the direct effects of MMF on signaling pathways of primary 
oligodendrocytes, the initially affected cell population in MS pathology, have not been explored. 
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Here, we investigated whether MMF was capable of reducing oxidative stress and upregulating the EAR in 
oligodendrocytes, and if this led to a reversal of stress-induced deficits in differentiation. Our results 
indicate that oligodendrocytes do not activate the EAR under conditions of oxidative stress to restore redox 
homeostasis. Furthermore, in contrast to other CNS-resident cell populations, MMF does not upregulate 
this pathway in oligodendrocytes through Nrf2-mediated transcription of canonical EAR target genes. 
These findings suggest that the beneficial effect of Tecfidera in MS patients is likely due to a mechanism 
other than direct antioxidant effects on oligodendrocytes, either through alternative anti-inflammatory 
pathway actions, or through upregulation of EAR proteins in other cell types which act cell non-
autonomously to provide protection to mature oligodendrocytes and OPCs differentiating to restore 
insufficient myelination.    
 
5.4 MATERIALS AND METHODS 
Chemicals and Reagents 
Abcam: rabbit polyclonal anti-NAD(P)H:quinone oxidoreductase antibody (NQO1, ab34173). Chemicon 
International (Temecula, CA): mouse monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase 
antibody (GAPDH, MAB374). Covance Laboratories (Conshohocken, PA): mouse monoclonal anti-myelin 
basic protein antibody (MBP, SMI-99). Enzo Life Sciences (Plymouth Meeting, PA): rabbit polyclonal 
anti-Heme Oxygenase-1 antibody (HO-1, SPA-896). Life Technologies (Carlsbad, CA): B27 Supplement, 
4-12% Bis-Tris gradient gels, dihydroethidium, Dulbecco’s Modified Eagle’s Medium (DMEM), 
DMEM/F12, Ham’s F12, L-glutamine, Hank’s Balanced Salt Solution (HBSS), Neurobasal Medium, 
Penicillin/Streptomycin. Jackson Immunoresearch Laboratories (West Grove, PA): FITC-conjugated goat 
anti-mouse IgG3, Rhodamine-conjugated goat anti-rat IgG, LiCOR (Lincoln, NE): Odyssey goat anti-
mouse IRdye 800CW, goat anti-mouse IRdye 680RD, goat anti-rabbit IRdye 680RD. Peprotech (Rocky 
Hill, NJ): neurotrophin-3 (NT-3). Peptide International: poly-D-lysine. R&D Systems (Minneapolis, MN): 
basic fibroblast growth factor (bFGF), platelet-derived growth factor AA (PDGF-AA). Sigma Aldrich (St. 
Louis, MO): L-Buthionine-sulfoximine (BSO), biotin, dimethyl sulfoxide (DMSO), hydrogen peroxide 
solution, insulin, monomethyl fumarate (MMF), progesterone, protease inhibitor cocktail, putrescine, 
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selenium, tert-Butyl hydroperoxide (tBHP), thyroxine (T4), transferrin. Vector Laboratories (Burlingame, 
CA): Vectashield with DAPI.  
 
Additional antibodies: anti-galactocerebroside mouse hybridoma supernatant (GalC H8H9, (Ranscht et al., 
1982)), anti-myelin basic protein rat hybridoma supernatant (MBP, gift of Virginia Lee, University of 
Pennsylvania). 
 
Primary Mouse Oligodendrocyte Cultures 
All experiments were performed following the guidelines set forth by The Children’s Hospital of 
Philadelphia Institutional Animal Care and Use Committee (IACUC). Primary oligodendrocyte precursor 
cell cultures were generated from postnatal day 1 CD1 mouse pups with modifications from previously 
described methods (See et al., 2004). Briefly, cortical cell suspensions isolated from pups obtained from 
Charles River Laboratories were plated on poly-D-lysine (PDL) coated flasks in Neurobasal Medium with 
B27 supplement at 37°C with 5% CO2. Cells were switched into growth medium consisting of Neurobasal 
Medium +B27 supplemented with 10 ng/ml bFGF, 2 ng/ml PDGF-AA, and 1 ng/ml NT-3 24 hours after 
isolation. After growing to confluence, cultures were purified to 90-95% oligodendrocyte precursor cells 
(OPCs) and 5-15% astrocytes using a wash-down procedure (Feigenson et al., 2009), after which cells were 
sub-cultured onto PDL-coated coverslips or Petri dishes. To facilitate transition of OPCs into maturing 
oligodendrocytes, growth medium was replaced with differentiation medium, consisting of 50% DMEM, 
50% Ham’s F12, Pen/Strep, 2 mM glutamine, 50 µg/ml transferrin, 5 µg/ml putrescine, 3 ng/ml 
progesterone, 2.6 ng/ml selenium, 12.5 µg/ml insulin, 0.4 µg/ml T4, 0.3% glucose, and 10 ng/ml biotin 
(Feigenson et al., 2009).  
 
Detection of Reactive Oxygen Species 
Dihydroethidium (DHE) was used to detect the presence of reactive oxygen species in vitro for cells grown 
on coverslips, as oxidation of DHE by superoxide allows for intercalation with nuclear DNA, and emission 
of a quantifiable red fluorescence (Zhao, 2003). 3 µM DHE was added to the culture medium 15 minutes 
prior to the end of treatments. Cells were then washed with F12 medium, fixed with ice-cold acid alcohol 
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for 8 minutes, re-washed, and then mounted on slides with Vectashield containing DAPI to stain nuclei. 
Ten non-overlapping fields per coverslip were imaged from 3 independent wells for each treatment from at 
least 3 biologically independent primary cell preparations. The Advanced Fluorescence Leica Application 
Suite was used for image acquisition, coupled with a Leica DM6000B fluorescence microscope equipped 
with a DFC240 camera at 40x magnification (HCX PL APO 40x/0.85 CORR objective). MetaMorph 6.0 
software (Molecular Devices, Sunnyvale, CA) was used for post-acquisition analysis, which determined the 
fluorescence intensity of nuclear intercalated DHE normalized to the total DAPI area.  
 
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) 
The expression of Heme Oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase (NQO1), NF-E2 
(nuclear factor (erythroid-derived 2))-related factor-2 (Nrf2), and Myelin Basic Protein (MBP) mRNA were 
quantified by qRT-PCR. For endogenous antioxidant response targets HO-1, NQO1, and Nrf2, OPC 
cultures or 72 hour matured oligodendrocytes grown on 100-mm dishes were harvested 6 hours following 
treatment. To isolate RNA for myelin component protein MBP, cells were treated at the time of 
differentiation and harvested 72 hours later. Following Trizol extraction, 5 µg of RNA was converted to 
cDNA (Invitrogen Superscript First-strand kit). q-PCR was performed as previously described using Power 
SYBR Green, with samples measured in triplicate from three independent biological replicates (n=3) 
(French et al., 2009, Feigenson et al., 2011). Data was analyzed according to the ΔΔCT method, with 
normalization to Protein Kinase Gene 1 (PKG1). Table 5.1 details the primer pairs for each gene, obtained 
from Integrated DNA Technologies (IDT).  
 
Immunoblotting 
Whole-cell extracts were prepared from primary mouse oligodendrocyte cultures using ice-cold lysis buffer 
(50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 10 mM EDTA, 0.5 mM Na3VO4, and 1:100 protease 
inhibitor cocktail), followed by centrifugation at 14,000 rpm at 4°C for 30 minutes. Protein concentrations 
were determined using a NanoDrop 1000 Spectrophotometer A280 absorbance assay. A broad spectrum 
molecular weight ladder was run alongside treatment samples containing 25-50 µg of protein per lane of 4-
12% Bis-Tris gradient gels for separation. Following electrophoresis, proteins were transferred onto 
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Immobilon-FL membranes (Millipore), and blocked in PBS with 0.1% Tween-20 (PBST) and 5% milk for 
20 minutes at room temperature (RT). Membranes were then incubated overnight with primary antibodies 
in PBST+ milk at 4°C. The following primary antibodies were utilized: HO-1 (1:1000 dilution), NQO1 
(1:1000 dilution), and MBP (SMI-99, 1:500 dilution). Membranes were rinsed with PSBT, re-blocked for 
20 minutes at RT in PBST+ milk, then incubated with secondary antibodies with corresponding antigen-
specific fluorescent probes (1:10,000 in PBST+ milk). An Odyssey Infrared Imaging System (LiCOR) was 
used to visualize membranes. Re-blotting for GAPDH (1:1000 dilution) obtained loading controls for each 
membrane. Pixel intensities for each treatment were determined by quantifying specified bands of interest 
using the NIH ImageJ program (V1.36b, Bethesda, MD). These values were normalized to those obtained 
from analysis of loading control GAPDH.  
 
Immunofluorescence 
Detection of specific antigens for primary oligodendrocyte lineage cells grown on coverslips was 
performed as previously described (Grinspan and Franceschini, 1995, See et al., 2004). Live cells were 
labeled for cell surface marker detection prior to fixation using anti-GalC (mouse hybridoma supernatant, 
undiluted) followed by FITC-conjugated goat anti-mouse IgG3 (1:100 dilution). Following acid alcohol 
fixation and permeabilization, internal antigens were detected using anti-MBP (rat hybridoma supernatant, 
1:2 dilution) followed by Rhodamine-conjugated goat anti-rat IgG (1:100 dilution). Vectashield with DAPI 
was used to mount slides while also staining all cell nuclei. Images were acquired as previously described 
for DHE staining, with 10 non-overlapping fields in each of 3 coverslips per condition from at least 3 
independent primary cell isolations. Antigen-positive and DAPI-positive cells were counted from each 
sampled field, with approximately 2000 cells counted per treatment condition.  
 
Statistical Analysis 
Prism 5.0 software (GraphPad Software, San Diego, CA) was used to analyze all data. Values are 
expressed as mean ± SEM, with p < 0.05 considered significant. Student’s t-test or One-way ANOVA with 
post-hoc Dunnett’s multiple comparison test were performed where indicated.   
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5.5 RESULTS 
Reactive oxygen species accumulate in oligodendrocytes following oxidant treatment 
There is a large body of evidence gathered from in vitro, animal, and human patient studies to suggest that 
oligodendrocyte precursor cells (OPCs) and immature oligodendrocytes are particularly vulnerable to 
oxidative stress (Halliwell, 1992, Back et al., 1998, Fern and Moller, 2000, Levison et al., 2001, Baud et 
al., 2004, Back and Rosenberg, 2014). It critical to understand how oxidative stress affects the processes of 
differentiation and myelination of these susceptible precursor cells. The process of oligodendrocyte 
maturation is well defined, with tightly regulated transcription factor activity and characteristic cellular 
markers corresponding to specific stages of differentiation utilized to track lineage progression (Miller, 
2002). Previous work within our laboratory determined that oligodendrocyte differentiation is halted 
following oxidant treatment using these established methods (French et al., 2009, Reid et al., 2012).  
 
Surprisingly, the mechanism by which oligodendrocytes respond to oxidative stress is not understood. To 
model oxidative stress in an in vitro model of oligodendrocyte differentiation, we used the oxidant tert-
butyl hydroperoxide (tBHP), a cell-permeable compound that generates tert-butoxyl radicals, resulting in 
depletion of intracellular glutathione and lipid peroxidation (Back et al., 1998, Zhao et al., 2005, French et 
al., 2009). Oligodendrocyte lineage cells were isolated as OPCs and induced to differentiate over a 72 hour 
period into maturing oligodendrocytes (OLs) following our previously described maturation paradigm (See 
et al., 2004). OPCs and 72hr differentiated OLs were exposed to 2.5 µM tBHP for 30 minutes, 1 hour, 2 
hours, 6 hours, 12 hours, or 24 hours. Cells were then stained with the ROS indicator dihydroethidium, a 
cell-permeable fluor that intercalates into DNA when oxidized to ethidium (Zhao, 2003). Following the 
timecourse outlined above, we found that tBHP treatment produced robust ROS accumulation by 1 hour in 
both OPCs (677% ± 76.2%, p < 0.01) (Figure 5.1A), and in OLs (3451% ± 1454%, p < 0.01) when 
compared with untreated (Figure 5.1B).  
 
Oxidative insult does not upregulate the EAR in oligodendrocytes 
High levels of ROS were evident following application of the oxidant tBHP in both OPCs and mature OLs. 
In many cell types including neurons and astrocytes, when such a cellular imbalance in redox homeostasis 
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occurs, there is activation of the endogenous antioxidant response (EAR) (Chen et al., 2009, Li, 2009). We 
next examined whether oligodendrocyte lineage cells activated this cellular signaling pathway following 
exposure to oxidants and subsequent ROS accumulation. OPCs or OLs were treated with tBHP for 6 or 16 
hours and assayed for EAR targets by qPCR and immunoblot analysis. Quantification of mRNA following 
tBHP application to OPCs revealed no significant changes after 6 hours in the principle targets of the EAR: 
Nrf2, Heme Oxygenase-1 (HO-1), and NAD(P)H:quinone oxidoreductase (NQO1) (Table 5.2). Consistent 
with these results, immunoblotting for HO-1 and NQO1 following 16 hours of treatment also revealed no 
significant changes in protein levels (Figure 5.2A-B). In mature OLs, analysis of the EAR targets also 
revealed no changes in mRNA levels after 6 hours of tBHP treatment (Table 5.2). Similarly, following 16 
hours of treatment, no significant alterations in HO-1 or NQO1 protein levels were observed (Figure 5.2C-
D). Therefore, in contrast to many other cell types, both oligodendrocyte precursors and mature OLs do not 
appear to activate the EAR despite robust accumulation of ROS.  
 
Oxidative Insult Inhibits Oligodendrocyte Maturation 
In our previous work we described alterations in levels of transcription factors responsible for induction of 
oligodendrocyte differentiation, and a consequent reduction in the number of cells expressing immature 
oligodendrocyte cell surface marker Galactocerebroside (GalC) following treatment with 5 µM tBHP 
(French et al., 2009). Here we have expanded on those findings to encompass markers for mature 
oligodendrocytes by immunofluorescent staining, mRNA, and protein evidence using our differentiation 
paradigm. Following tBHP treatment for 72 hours in differentiation medium, immunofluorescent staining 
reveals that the lower dose of 2.5 µM tBHP used in the present study significantly reduced the number of 
cells expressing differentiation markers, while not reducing total cell number. Representative images of 
untreated and tBHP treated oligodendrocytes 72 hours after differentiation illustrate differentiation deficits, 
with extent of maturation determined by quantifying the percentage of GalC+ and MBP+ cells across 
treatments (Figure 5.3A). Following tBHP treatment, the number of cells expressing the immature marker 
GalC was significantly reduced by 23.11% ± 5.4% (p < .01). Similarly, the number of MBP+ mature 
oligodendrocytes was significantly reduced by 22.42% ± 6.71% (p < .05). The number of total cells in the 
tBHP treated condition was not significantly affected (Figure 5.3A).   
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We next examined whether this reduction in maturation at the cell surface was reflected in a reduction in 
myelin basic protein (MBP) mRNA and protein. OPCs were treated with tBHP at the time of 
differentiation, with mRNA and protein harvested 72 hours later. Analysis determined that while a 
significant upregulation of MBP mRNA was observed between undifferentiated OPCs and 72 hour mature 
OLs (p < .05), the levels of MBP mRNA were comparable between the untreated OLs and the tBHP treated 
condition (Figure 5.3B). At this same point in differentiation, the amount of MBP protein in the untreated 
oligodendrocytes had significantly increased by approximately 2 fold over OPCs (p < 0.05). Notably, tBHP 
treatment resulted in a dramatic reduction in MBP protein expression levels when compared with untreated 
(p < 0.05) and no significant increase observed when compared with OPCs (Figure 5.3C). Taking these 
results together, we conclude that oxidative stress induced by tBHP halts oligodendrocyte maturation by 
altering expression of myelin component proteins levels. 
 
MMF reduces ROS accumulation induced by various oxidant compounds 
Oxidative stress generated by tBHP caused the accumulation of ROS and differentiation deficits in 
maturing OPCs without activation of the EAR. Therefore, we next determined if attenuating ROS would 
prevent the oxidant-induced maturation blockade. We utilized the fumaric acid ester monomethyl fumarate 
(MMF), which is the active metabolite of the FDA approved MS therapeutic compound dimethyl fumarate 
(FDA, 2013, Limmroth, 2013). In neurons and macrophages, MMF behaves as an antioxidant through 
Nrf2-mediated EAR activation (Cross et al., 2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et 
al., 2012, Akay et al., 2014). We have previously demonstrated MMF-mediated protection from oxidative 
stress-induced toxicity in neurons through EAR pathway activity (Akay et al., 2014). In order to determine 
whether MMF is effective at reducing oxidant-induced ROS accumulation, OPCs were pre-treated with 10 
µM MMF for 6 hours to allow for potential upregulation of EAR target proteins. Cells were then treated 
with oxidants for an additional 2 hours. In addition to 2.5 µM tBHP, 100 µM hydrogen peroxide, and 100 
µM L-buthionine sulfoximine (BSO) were utilized. Hydrogen peroxide is a strong, oxidizing agent which 
will generate abundant highly reactive hydroxyl radicals within the cell (Sies, 1993). BSO was selected as 
it is a selective inhibitor of γ-glutamylcysteine synthetase, the enzyme which catalyzes the rate-limiting 
step of glutathione synthesis (Meister, 1992, French et al., 2009). This set of compounds allows for analysis 
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of oxidants with various properties, and can potentially differentiate between effects caused by tBHP and 
BSO-mediated glutathione depletion versus whole-cell effects caused by hydroxyl radical-based 
modifications. Following treatment, DHE staining revealed that MMF pre-treatment significantly reduced 
the amount of ROS accumulation induced by tBHP (Figure 5.4A), hydrogen peroxide (B), and BSO (C).  
 
MMF fails to rescue differentiation defect caused by oxidative insult 
MMF was successful at reducing the accumulation of ROS in OPCs induced by multiple oxidant 
compounds. We next assessed whether this reduction of oxidative stress would increase the number of 
mature oligodendrocytes following oxidant treatment. OPCs were pre-treated with MMF for 24 hours, after 
which they were switched into differentiation medium and treated with the oxidants as previously 
described. MMF was replenished at the time of differentiation, and at 24 and 48 hours. After 72 hours of 
differentiation, cells were stained for GalC and MBP to assess maturation. Significantly fewer cells 
expressed the immature marker GalC following treatment with each oxidant, with significantly fewer cells 
expressing the mature marker MBP with tBHP and hydrogen peroxide treatment (Figure 5.5A-B). Notably, 
concomitant treatment with MMF did not rescue the observed maturation deficits caused by any of the 
oxidants. The effects of BSO were milder than that of the other two oxidants, with modest though not 
significant reduction in percentage of cells maturing to the MBP+ stage (Figure 5.5B). At this dose, 
hydrogen peroxide appears to cause both a significant loss of cells due to toxicity (Figure 5.5C) as well as 
an oxidant-mediated inhibition of differentiation, as a negligible number of the remaining cells progressed 
to either the GalC+ or MBP+ maturation stages (Figure 5.5A-B). Together these results suggest that despite 
effectively reducing ROS accumulation and oxidative stress, MMF failed to rescue the oligodendrocyte 
differentiation deficits caused by several oxidant compounds.  
 
MMF does not upregulate components of the EAR in developing oligodendrocytes 
While MMF has been shown to upregulate components of the EAR in other CNS cell populations (Cross et 
al., 2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et al., 2012, Akay et al., 2014), the direct 
effects of this compound on the EAR pathway of primary oligodendrocytes have not been examined. In 
order to investigate if MMF acts to stimulate the EAR pathway in oligodendrocytes, we examined 
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expression of downstream EAR targets in maturing oligodendrocytes following MMF application over 
time. OPCs were treated with 10 µM MMF at the time of differentiation. Lysates were harvested for protein 
analysis at 0, 2, 6, 12, and 24 hours. Surprisingly, neither HO-1 (Figure 5.6A) nor NQO1 (Figure 5.6B) 
protein levels were increased in MMF treated cells at any time point tested. We do not discount that EAR 
upregulation may occur at a later time interval. We feel that this is unlikely however, as in our neuroglial 
culture studies we saw effects within 6 hours, and MMF replenishment was required every 24 hours to 
maintain efficacy (Akay et al., 2014). Therefore, in contrast to other CNS cell types, MMF does not 
upregulate the EAR in oligodendrocytes. 
 
5.6 DISCUSSION 
Multiple Sclerosis is a devastating demyelinating condition for which the etiology is still not understood. 
At present, therapies which reduce chronic levels of oxidative stress and inflammation have been aimed at 
restoring quality of life and reducing relapse rates in patients (Friese et al., 2014, Mahad et al., 2015). Here, 
we investigate the consequences of oxidative stress on oligodendrocyte maturation, and the potential 
actions of an FDA approved MS therapeutic compound, which has been proposed to act through 
antioxidant means. This compound, Tecfidera, potentially works by boosting activation of Nrf2 
transcription factor-mediated induction of the endogenous antioxidant response (EAR) element in the 
promoters of a specific cohort of genes which clear excess reactive oxygen species (ROS) from cells. The 
regulation of this pathway in oligodendrocytes and its role in directly decreasing oxidative damage in 
oligodendrocytes has not previously been tested. We provide compelling evidence that exposure to 
oxidants produces ROS accumulation in both oligodendrocyte precursors and mature oligodendrocytes, yet 
unlike other neural cell types fails to elicit a consequential activation of the endogenous antioxidant 
response element. As a possible result of this failure, when OPCs are exposed to an oxidant at the time of 
differentiation, they are unable to differentiate into immature and then mature oligodendrocytes and do not 
express myelin proteins nor traffic them appropriately for insertion into their cell membranes. We have 
shown that MMF, the active metabolite of Tecfidera (BG-12, dimethyl fumarate), successfully attenuated 
ROS accumulation in OPCs and mature oligodendrocytes caused by various oxidant compounds as 
anticipated. However, MMF failed to rescue oxidative-stress mediated differentiation deficits induced by 
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these compounds. Contrary to expectations, based on previously reported evidence in cells of a wide 
variety of neuroglial cell lineages (Cross et al., 2011, Linker et al., 2011, Albrecht et al., 2012, Scannevin et 
al., 2012, Akay et al., 2014), MMF did not upregulate EAR target genes at any time during an extended 
timecourse. These observations may suggest that the antioxidant effects of Tecfidera in reducing MS 
relapse rates by lowering oxidative stress levels to allow for oligodendrocyte survival and maturation are 
indirect and mediated through other neural cell types.  
 
The mechanism by which myelin is initially targeted in MS is not understood, however it is clear that once 
initiated, chronic inflammation and oxidative stress drive much of the pathology. Activated immune cells 
secrete a variety of pro-inflammatory cytokines and reactive oxygen species (Haider, 2015). Immature 
oligodendrocytes and oligodendrocyte precursors in particular are exceptionally vulnerable to oxidative 
insults due to high energy demands and low glutathione and antioxidant enzyme levels (Halliwell, 1992, 
Back et al., 1998, Fern and Moller, 2000, Baud et al., 2004). Disruption of myelin caused by the effects of 
oxidative stress on oligodendrocytes can then lead to degeneration, both of affected oligodendrocytes and 
the neurons they no longer effectively insulate. Concomitantly, oxidative stress stops OPCs from 
differentiating and replacing the damaged mature oligodendrocytes. The breakup of myelin and cellular 
loss can then lead to further macrophage recruitment to clear cellular debris, thus perpetuating the cycle 
(Friese et al., 2014, Mahad et al., 2015). The primary cellular response leading to attenuation of oxidative 
stress is the EAR pathway, through targeted Nrf2-mediated transcriptional upregulation of genes with an 
antioxidant response element in their promoter regions (Li, 2009). Activation of this pathway increases the 
expression of Phase II detoxifying enzymes and antioxidants, including NADP(H) quinone oxidoreductase 
(NQO1) and Heme oxygenase-1 (HO-1) (Li, 2009).  
 
The consistent observation of oxidative stress in active demyelinating MS lesions prompted investigation 
into whether cells within these regions upregulate their EAR in an effort to combat the persistently high 
levels of ROS. The Nrf2 target protein, NQO1, was found to be highly abundant in chronic and active 
lesions, though this was restricted to the astrocyte and macrophage cell populations (van Horssen et al., 
2006). In animal models of MS, HO-1 was found in high abundance in macrophages, microglia, and 
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astrocytes during the acute phase of injury, and in oligodendrocytes in early lesions (Stahnke et al., 2007). 
Recently, the presence of Nrf2 and its targets was identified in oligodendrocytes in MS lesions. Licht-
Mayer et al examined active demyelinating regions from MS patients and found strong nuclear expression 
of the transcription factor Nrf2 and its downstream target HO-1 in oligodendrocytes, though the highest 
enrichment of these proteins is found in degenerating cells (Licht-Mayer et al., 2015). The authors 
comment that because Nrf2 is already highly expressed in oligodendrocytes in active lesions, it is doubtful 
that further stimulating the ARE by fumarates would protect oligodendrocytes in any way. Additionally, it 
can be difficult to draw conclusions regarding stress response proteins in diseased tissue, as cells viewed 
from a single point in time can either be effectively combatting the unfavorable stressful situation, or fated 
for cell death after an unsuccessful attempt at overcoming such conditions.  
 
In contrast to other cell types examined, little is known about the protective effects of the EAR in 
oligodendrocytes. Studies using OLN-98 cells and primary rat oligodendrocytes exposed to hydrogen 
peroxide have demonstrated HO-1 upregulation by immunoblotting (Goldbaum and Richter-Landsberg, 
2001, Stahnke et al., 2007). However, the oxidative insult applied also culminated in loss of mitochondrial 
function and apoptosis, suggesting this upregulation was not sufficient to protect the cells (Goldbaum and 
Richter-Landsberg, 2001). In our current work, we have examined the role of the EAR in protecting 
oligodendrocytes from oxidative stress in more detail. We demonstrated that ROS accumulate in OPCs and 
mature OLs following oxidant exposure, yet this failed to promote upregulation of the EAR at the mRNA 
or protein level in either stage of the oligodendrocyte lineage. Furthermore, exposure of OPCs to an oxidant 
at the time of differentiation resulted in reduced maturation evaluated both by myelin protein expression, as 
well as characteristic maturation-stage specific surface marker levels. Within this background, we 
attempted to exogenously activate the EAR by directly treating oligodendrocyte lineage cells with a newly 
approved drug aimed at ameliorating the chronic inflammation and oxidative stress seen in MS. 
 
Tecfidera effectively reduces MS relapse rates (FDA, 2013, Limmroth, 2013, Fox et al., 2014, Dubey et al., 
2015, English and Aloi, 2015). This drug is composed of dimethyl fumarate (DMF), yet despite much 
investigation, the cellular mechanism by which this compound is effective remains elusive. Antioxidant 
176	  
effects of DMF have been reported from in vitro studies in neurons, with Nrf2-mediated upregulation of 
EAR target genes such as HO-1 conferring effective protection from oxidant challenge (Lehmann et al., 
2007, Albrecht et al., 2012, Wang et al., 2015). It is also suggested through these studies that DMF 
culminates in antioxidant effects by directly interacting with glutathione via Michael-addition and affecting 
glutathione recycling. Reduced to oxidized glutathione ratio serves as a critical redox homeostasis sensor 
within the cell, and modulates amounts of xenobiotic and antioxidant enzymes accordingly (Ishii and 
Mann, 2014, Espinosa-Diez et al., 2015). Normally, following electron donation oxidized glutathione is 
reduced back to its original form by glutathione reductase (Ishii and Mann, 2014, Espinosa-Diez et al., 
2015). In the process of Michael-addition however, such as that which occurs between the Michael-donor 
glutathione and Michael-acceptor dimethyl fumarate, a new carbon bond is formed between the nucleophile 
glutathione the α,β-unsaturated carbon bond present within the DMF molecule, preventing subsequent 
glutathione recycling (Lehmann et al., 2007, Albrecht et al., 2012, Wang et al., 2015). By depleting the 
cellular store of this critical redox regulator, DMF causes a transient oxidative stress within the cell and 
consequently an upregulation of EAR pathway activity (Lehmann et al., 2007, Albrecht et al., 2012).  
 
Within our present study, we chose to evaluate the effects of the primary metabolite of DMF, monomethyl 
fumarate (MMF). A critical and previously overlooked element of many studies aiming to determine the 
mechanism of action of Tecfidera, is that DMF is extremely rapidly metabolized when administered orally, 
so that a vast majority of the effects seen in animal models and in human patients are likely caused by 
metabolic byproducts and not DMF directly. In vivo animal studies have shown that DMF is rapidly 
hydrolyzed to MMF or adducted to glutathione via Michael-addition (Schmidt et al., 2007). In rodents, 
when given orally no detectable levels of free DMF are found in blood plasma (Schmidt et al., 2007), and 
similarly when administered directly to the small intestine none can be detected in the portal vein (Dibbert 
et al., 2013). MMF is the dominant metabolite generated by DMF breakdown (Litjens et al., 2004, Dibbert 
et al., 2013). Similar to the findings from DMF in vitro studies, MMF has also been demonstrated to 
upregulate Nrf2-mediated EAR activity in neurons and macrophages (Cross et al., 2011, Linker et al., 2011, 
Albrecht et al., 2012, Scannevin et al., 2012, Akay et al., 2014). Contrary to expectations, MMF did not 
upregulate Nrf2-pathway antioxidant genes HO-1 or NQO1 at any point during a 24-hour timecourse in 
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oligodendrocytes, and was unsuccessful at rescuing cells from an oxidant-induced maturation deficit. In an 
experimental model of MS, in which animals ingesting the copper chelator cuprizone develop a specific 
and reversible demyelinating lesion in the corpus callosum, boosting the Nrf2 pathway with either DMF or 
MMF had only minor effects on remyelination and were not protective against cell death (Moharregh-
Khiabani et al, 2010). While in vitro differentiation was not examined by this group, they also 
demonstrated that pre-application of DMF or MMF to an oligodendrocyte–like cell line that was then 
treated with hydrogen peroxide showed no rescue from oxidative stress-induced toxicity (Moharregh-
Khiabani et al, 2010). The lack of activation for this supposedly ubiquitous cellular stress response pathway 
to a variety of oxidant and antioxidant compounds which cause target gene upregulation in other cell types 
may help to explain the selective vulnerability of oligodendrocytes to oxidative stress.  
 
One possible explanation for the lack of EAR pathway activation observed in the current work regards the 
regulation of glutathione synthesis and recycling in oligodendrocytes. The oxidant utilized in the initial 
component of this study to investigate the effects of oxidative stress was tBHP, which has been 
demonstrated to deplete cellular glutathione (Back et al., 1998, Zhao et al., 2005, French et al., 2009). In 
later experiments, the oxidant BSO was used, which selectively inhibits glutathione synthesis (Meister, 
1992, French et al., 2009). Hydrogen peroxide was also used, which does not have as targeted effects with 
the cell, but rather generates highly reactive hydroxyl radicals which interact with proteins, lipids, as well 
as reducing agents such as glutathione (Sies, 1993). MMF was unable to rescue differentiation deficits 
caused by the cellular effects induced by any of these oxidants. While higher concentrations than DMF 
were required to attain comparable cellular effects, MMF itself has also been shown to reduce cellular 
glutathione levels in astrocytes (Schmidt and Dringen, 2010). The isoform of the enzyme responsible for 
glutathione conjugation to electrophilic compounds, glutathione s-transferase (GST), expressed in 
oligodendrocytes is GST-pi. Within the brain, this form of GST is uniquely found in oligodendrocytes 
(Cammer et al., 1989, Cammer and Zhang, 1992), and has been widely used as a marker for mature 
oligodendrocytes in vivo (Girolamo et al., 2011, Li et al., 2013, Yatomi et al., 2015). Furthermore, 
immunofluorescent studies have demonstrated that GST-pi is found in the nucleus of OPCs, and during 
differentiation attains a cytoplasmic distribution, which may account for some of the sensitivity of 
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oligodendrocytes to oxidative stressors during early lineage stages (Tamura et al., 2007). It may be that the 
glutathione system for monitoring redox homeostasis operates differently in oligodendrocytes, such that if 
levels are depleted the EAR is not effectively activated, particularly in OPCs and maturing cells. 
Interestingly, a recent study has demonstrated that DMF treatment can increase the glutathione level in a 
human oligodendrocyte cell line, suggesting that fumarate compounds can potentially impact cells of the 
oligodendrocyte cell lineage, although how metabolism in this cell line compares to primary cells is 
unknown (Huang et al., 2015). In our study, neither tBHP nor MMF caused EAR pathway upregulation. It 
will be intriguing to discover if alternative oxidants, which impact redox sensors other than glutathione, are 
capable of EAR upregulation in primary oligodendrocytes, or if the canonical pathway is not present in this 
cell lineage.  
 
With this in mind, the mechanism of action by which Tecfidera reduces MS relapse rates is likely not due 
to direct effects on oligodendrocytes. Alternatively, secondary effects from upregulation of the EAR in 
neurons and macrophages may play a role in oligodendrocyte protection (Cross et al., 2011, Linker et al., 
2011, Albrecht et al., 2012, Scannevin et al., 2012, Akay et al., 2014). Furthermore, while not examined in 
the present work, the effects of Tecfidera may also be modulated by a DMF-mediated reduction of secreted 
inflammatory cytokines (Lehmann et al., 2007, Albrecht et al., 2012) or inhibition of the NF-κB pathway 
(Gillard et al., 2015).   
 
Reducing levels of chronic oxidative stress is key to enabling functional recovery for affected patients, as 
remyelination will not proceed unless conditions are favorable. Our study suggests that reduction in 
oxidative stress will most likely require the concerted efforts of multiple CNS cell populations, with 
neurons, macrophages, and/or astrocytes together providing an environment free of oxidative stress with 
restored redox homeostasis for the susceptible oligodendrocyte cell population to survive, mature, and re-
myelinate affected areas.  
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Gene: Primer Sequences: 
PKG1 Forward: 5’ ATG CAA AGA CTG GCC AAG CTA C 3’ Reverse: 5’ AGC CAC AGC CTC AGC ATA TTT C 3’ 
HO-1 Forward: 5’ TGT AAG GGA GAA TCT TGC CTG GCT 3’ Reverse: 5' TGC TGG TTT CAA AGT TCA GGC CAC 3’ 
NQO1 Forward: 5’ AAG AGC TTT AGG GTC GTC TTG GCA 3’ Reverse: 5’ AGC CTC CTT CAT GGC GTA GTT GAA 3’ 
Nrf2 Forward: 5’ TCA CAC GAG ATG AGC TTA GGG CAA 3’ Reverse: 5’ TAC AGT TCT GGG CGG CGA CTT TAT 3’ 
MBP Forward: 5’ TGG TAC ACA CTA ACC TCG GTG GAA 3’ Reverse: 5’ AGC GAC TCG ATT CAG TGA CAG GAA 3’ 
 
Table 5.1: q-RT PCR Primers 
Primer pairs used for qRT-PCR are shown. Abbreviations are: PKG1, Protein Kinase Gene 1; HO-1, Heme 
Oxygenase-1; NQO1, NAD(P)H:quinone oxidoreductase; Nrf2, NF-E2 (nuclear factor (erythroid-derived 
2))-related factor-2; MBP, Myelin Basic Protein. Primers were obtained from IDT. 
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Oligodendrocyte Precursor Cells 
Gene: ΔΔCT ±SEM: P value: 
Nrf2 3.482 ± 1.189 0.1721 
HO1 2.423 ± 0.709 0.1824 
NQO1 3.655 ± 1.935 0.3037 
 
Mature Oligodendrocytes 
Gene: ΔΔCT ±SEM: P value: 
Nrf2 1.422 ± 0.322 0.3199 
HO1 2.357 ± 1.140 0.3560 
NQO1 0.499 ± 0.206 0.1354 
 
Table 5.2: mRNA alterations in Endogenous Antioxidant Response Genes Following 6hr tBHP Insult  
Extracted RNA (5 µg) was converted to cDNA using the Superscript First-strand kit and q-PCR was 
performed using Power SYBR Green. All measurements were normalized first to the oligodendrocyte 
housekeeping gene PKG1, and then to controls. Analysis was performed by the ΔΔCT method. 
Endogenous Antioxidant Response genes: Nrf2, HO-1, and NQO1 were probed. ΔΔCT ±SEM are 
presented from 3 independent biological replicates (n=3), with p-values indicated. 
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Figure 5.1: Oxidant tBHP Induces Reactive Oxygen Species in OPCs and Mature Oligodendrocytes 
Cells were treated with 2.5 µM tBHP for 1 hour to determine if reactive oxygen species (ROS) were 
produced. ROS accumulation was assayed by DHE staining, with cell nuclei stained by DAPI. Images were 
captured at 40x magnification, with 10 fields on 3 coverslips per condition. Scale bar indicates 25 µm. 
Metamorph image analysis determined DHE fluorescence intensity normalized to nuclear DAPI area.    
A) Representative images of 1 hr treated OPCs, with DHE fluorescence (red) and cell nuclei stained 
with DAPI (blue), and quantification of this experiment.  
B) Representative images of 1 hr treated mature oligodendrocytes, with DHE fluorescence (red) and 
cell nuclei stained with DAPI (blue), and quantification of this experiment. 
Representative experiments shown from n=2 biological replicates, values are presented as mean ±SEM. 
Student’s t-test determined statistical significance (##= p< 0.01). 
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Figure 5.2: Oxidative Insult does not Upregulate the EAR in Oligodendrocytes 
Protein was harvested from OPCs (A-B) or Mature Oligodendrocytes (C-D) 16 hours following 2.5 µM 
tBHP treatment. Cell lysates were immunoblotted for target proteins upregulated upon activation of the 
endogenous antioxidant response: HO-1 (A and C) and NQO1 (B and D). Representative Western blot 
images are shown, with quantification of band intensities normalized to GAPDH loading controls revealing 
no change between untreated and tBHP treated conditions. Data are presented as mean ± SEM from 4 
separate cultures (n= 4). Student’s t-test determined statistical significance. 
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Figure 5.3: Oxidative Insult Inhibits Oligodendrocyte Differentiation 
Primary mouse OPCs were put into differentiation medium (DM) and treated with 2.5 µM tBHP. After 72 
hours, cells were stained for stage-specific markers or RNA or protein was extracted to evaluate levels of 
myelin components.  
A) Cells on coverslips were stained with DAPI (blue) for total cell nuclei and with antibody to GalC 
(green) and MBP (red). Representative images are shown for untreated and tBHP treated conditions, with 
merged images in the rightmost column. Scale bar indicates 25 µm. Epifluorescent images were captured, 
with 10 fields on three coverslips per condition, from n=4 independently prepared cultures. Immature 
oligodendrocytes (GalC+ cells), mature oligodendrocytes (MBP+ cells), and total cell number (DAPI+ 
nuclei) were counted using ImageJ software, represented as percentage normalized to untreated. Data are 
presented as mean ±SEM. Student’s t-test determined statistical significance. Significance compared with 
control (##= p< .01, #= p< 0.05). 
B) RNA was extracted 72hours following addition of DM and tBHP treatment. cDNA conversion, 
qPCR, and analysis were performed as in Table 2. Expression of the gene for MBP was probed. ΔΔCT 
±SEM are presented from 3 independent biological replicates (n = 3). Student’s t-test determined statistical 
significance. A significant increase was found when precursor cells were compared with untreated-
differentiated cells (#= p< 0.05), however tBHP treatment did not significantly alter MBP mRNA 
compared with untreated (ns).  
C) Protein was harvested from oligodendrocytes at 72 hours post-treatment. Cell lysates were 
immunoblotted for MBP. Representative Western blot images are shown, with quantification of band 
intensities normalized to GAPDH loading controls. Data are presented as mean ± SEM from 4 separate 
cultures (n= 4). Student’s t-test determined statistical significance. A significant increase in MBP was 
found when OPCs were compared with untreated-differentiated cultures (###= p< 0.001). A significant 
reduction in MBP was observed when tBHP treated cultures were compared with untreated cultures (#= p< 
0.05). 
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Figure 5.4: MMF reduces ROS accumulation induced by various oxidant compounds 
OPCs were pre-treated with 10 µM monomethyl fumarate (MMF) for 6 hrs. Cultures were then treated with 
2.5 µM tBHP (A), 100 µM hydrogen peroxide (B), or 100 µM buthionine sulfoximine (BSO) (C) for an 
additional 2 hours. DHE staining, imaging and analysis was performed as in Figure 1. Representative 
experiments shown, values are presented as mean ± SEM, n= 2. Student’s t-test determined significance for 
direct comparisons (#= p< 0.05, ###= p< 0.001). Significant accumulation of reactive oxygen species was 
observed with each compound, and in treatment condition MMF pre-treatment significantly reduced this 
effect.   
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Figure 5.5: MMF fails to rescue differentiation defect caused by oxidative insult 
OPCs plated on coverslips were pre-treated with 10 µM MMF for 24 hrs. Cells were then switched into 
DM, supplemented with MMF and/or treated with tBHP, hydrogen peroxide, or BSO. MMF was 
replenished at 24 and 48 hrs. After 72 hrs, cells were fixed and stained for GalC and DAPI, and were 
imaged and analyzed as in Figure 4. Data are presented as mean ± SEM, from 3 separate cultures (n= 3). 
Student’s t-test determined significance for direct comparisons compared to untreated and MMF Vehicle 
(#= p< 0.05, ##= p< 0.01, ###= p< 0.001).  
A) GalC+ cell number was significantly reduced with tBHP, hydrogen peroxide, and BSO. No rescue 
was observed with concomitant MMF treatment. 
B) MBP+ cell number was significantly reduced with tBHP and hydrogen peroxide. No significant 
alterations in MBP cell number occurred with MMF co-treatment.  
C) Total cell number was significantly reduced with hydrogen peroxide. Simultaneous MMF 
treatment did not rescue this cell loss. 
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Figure 5.6: The EAR is not upregulated by MMF in maturing oligodendrocytes 
OPCs were treated with 10 µM MMF at the time of differentiation and harvested for protein analysis along 
a timecourse at the following intervals: 0hr, 2hr, 6hr 12hr and 24hr. Cell lysates were immunoblotted for 
HO-1 (A) and NQO1 (B), target proteins upregulated following activation of the endogenous antioxidant 
response. Representative Western blot images shown, with quantification of band intensities normalized to 
GAPDH loading controls revealing no change at any timepoint. Data are presented as mean ± SEM from 2 
separate cultures (n= 2). One-way ANOVA followed by post-hoc Dunnett’s multiple comparison 
determined statistical significance. 
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CHAPTER 6 
 
Discussion 
 
6.1 OVERVIEW 
Approximately half of HIV-positive individuals continue to suffer from some level of neurocognitive 
impairment within the spectrum of HIV-Associated Neurocognitive Disorders (HAND), despite effective 
suppression of viral replication through antiretroviral therapy (ART) to titers below the limits of detection 
(Gray, 2003, Brew, 2004, Heaton, 2010, 2011). Rigorous studies have demonstrated that dendritic pruning 
and synaptodendritic damage remain prevalent in patients (Masliah et al., 1997, Everall et al., 1999, Zheng 
et al., 2001, Langford et al., 2003, Everall et al., 2005, Ellis et al., 2007, Everall et al., 2009). Additionally, 
perturbations in white matter have been consistently demonstrated through evidence of disruption of myelin 
integrity, thinning of the corpus callosum, reduction of blood flow, and loss of volume in white matter 
structures (Pomara et al., 2001, Ragin et al., 2004, Gongvatana et al., 2009, Wohlschlaeger et al., 2009, 
Hoare et al., 2010, Tate et al., 2011, Kelly et al., 2014). Reproducible evidence of these pathologies in 
patients with well-controlled viral replication in the periphery suggests that within the CNS compartment, 
effects from inflammation, antiretroviral drugs, and viral reservoirs may all play roles in contributing to the 
persistence of HAND.  
 
Effects of antiretroviral compounds on cells of the CNS have not been well characterized, despite potential 
implications for the persistence of HAND in light of well-known peripheral toxicities (Carr, 1998, Dalakas, 
2001, Cohen, 2005, Parker, 2005, Ellis et al., 2008, Vidal et al., 2010). Activation of several cellular stress 
signaling pathways have been identified in peripheral cells in response to antiretroviral compounds, and are 
likely to also similarly affect cellular lineages exclusive to the brain, which may contribute to cognitive, 
behavioral, and motor deficits observed in HAND (Parker, 2005, Zhou, 2005, 2006, Gupta et al., 2007). In 
particular, even with the implementation of ART, studies indicate that oxidative stress is pervasive and 
abundant in HAND patients (Reviewed in Chapter 2). In addition to oxidative stress generated by the 
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presence of viral proteins and inflammatory responses of infected cells, antiretroviral compounds 
themselves had been previously shown to be capable of generating reactive oxygen species (ROS) in 
peripheral cell populations, macrophages, and astrocytes (Reviewed in Chapter 2). From this accumulated 
evidence, we hypothesized that ART compounds could activate cellular stress response pathways in 
neuroglial cells leading to cellular dysfunction, and that by counteracting the activation of these pathways 
the negative ART-induced effects could be ameliorated. Through our investigations exploring this 
hypothesis, we have contributed significant evidence to the effects of antiretroviral compounds on various 
neuroglial cell populations. Our findings, as discussed in the remainder of this chapter, have notable 
implications for the persistence of HAND in the ART era. 	  
 
We began by assessing the effects of antiretrovirals on neurons, through in vivo and in vitro models 
(Chapter 3). Similar to reports from human patients, we observed synaptodendritic damage in the brains of 
SIV-infected ART-treated pigtail macaques (Masliah et al., 1997, Everall et al., 1999, Zheng et al., 2001). 
Through an administration model in rats, we also demonstrated that this damage can occur in vivo due to 
ART compounds alone, in the absence of virus. In vitro studies determined that in neurons, exposure to 
antiretrovirals resulted in accumulation of ROS and slight EAR activation, yet culminated in cell death. 
Independent cultures of enriched neurons or astrocytes revealed that ROS accumulation occurred solely in 
neurons, with astrocytes neither accumulating ROS nor activating the antioxidant response. In our 
combined neuroglial cultures, monomethyl fumarate (MMF) potently activated the EAR, causing 
upregulation of antioxidant genes. In the context of antiretroviral exposure, this prevented ROS 
accumulation and subsequent neuronal death, suggesting that oxidative stress is a major contributor to 
ART-induced neuronal toxicity.  
 
Our next line of inquiry was to explore potential effects of ART compounds on oligodendrocyte survival, 
maturation, and myelin maintenance (Chapter 4). While not directly toxic at physiological doses, we 
definitively established that drugs from the PI class halt oligodendrocyte differentiation in a dose-
dependent, but reversible manner. Following antiretroviral exposure ROS accumulated, but unlike the 
rescue of neuronal toxicity observed in our previous study, co-administered MMF was unable to restore 
196	  
oligodendrocyte maturation deficits. Through an in vivo ART administration model performed in mice, 
Ritonavir treatment led to reduction in myelin protein levels in frontal cortex following two weeks of 
repeated exposure. Similarly, through an evaluation of human patient prefrontal cortex samples, we 
concluded that HIV-positive individuals with HAND who were ART-medicated displayed significant 
alterations in myelin proteins compared with both ART-naïve HAND individuals and seronegative 
controls.  
 
Finally, we decided to delve deeper into the activity of the endogenous antioxidant response (EAR) in 
oligodendrocytes, pursuing our finding that MMF failed to rescue oligodendrocyte maturation despite 
potently activating this pathway and providing protection from oxidant insults in neurons (Chapter 5). 
Oxidant application led to robust ROS accumulation in both OPCs and mature oligodendrocytes in vitro, 
yet expression of EAR target genes was not enhanced. This treatment also led to a reduction in cells 
progressing in differentiation from precursor cell to more mature lineage stages. MMF co-administration 
reduced the ROS accumulation induced by several oxidant compounds but did not activate the EAR or 
rescue the maturation deficits.  
 
Together our results provide some of the first evidence that antiretroviral compounds could be a major 
contributing factor to the persistence of HAND. In summary, we have shown that: 1) ART induces 
neuronal toxicity in vivo and in vitro, 2) Neuronal toxicity is primarily a result of oxidative stress, which 
can be rectified by an antioxidant promoting EAR activity, 3) PIs prevent oligodendrocyte maturation, 4) 
ART causes loss of myelin integrity in vivo, and 5) The EAR is not activated in oligodendrocytes under 
conditions which stimulate this pathway in other cell types. These findings advance our basic 
understanding of the neuronal and oligodendroglial responses to antiretroviral compounds and oxidative 
stress, and have important clinical implications for the treatment of HIV. These topics are considered in 
detail in this chapter. 
 
 
 
197	  
6.2 ANTIRETROVIRAL COMPOUNDS GENERATE OXIDATIVE STRESS AND INVOKE 
NEURONAL TOXICITY  
In many neurodegenerative diseases, including HAND, a hallmark indicator of neuronal damage and 
dysfunction is evidence of synaptic injury (Gupta et al., 2010). Reduction in synaptic density as indicated 
by dendritic pruning is a major pathological feature in HAND patients in the ART-era (Masliah et al., 1997, 
Everall et al., 1999, Zheng et al., 2001, Langford et al., 2003, Everall et al., 2005, Ellis et al., 2007, Everall 
et al., 2009, Xu and Ikezu, 2009). Elevated markers of oxidative stress such as lipid and protein oxidation, 
oxidative modifications to DNA, and depletion of the key antioxidant glutathione are still detectable in the 
brains of ART-treated patients despite effective control of viral replication (Reviewed in Chapter 2). 
Despite these findings, the small number of reported studies regarding antiretroviral compound 
pharmacokinetics and effects in the CNS did not examine pathological readouts of neuronal damage 
(Huisman et al., 2003, Anthonypillai et al., 2004, Anthonypillai et al., 2006).  
 
Through our work presented in Chapter 3, we have provided evidence for ART-induced synaptic injury in 
two animal models. In the first, adult rats received an NRTI-boosted PI ART-regimen 
(AZT+Saquinavir+Ritonavir) over the course of one week. Even in this short time span, analysis of brain 
sections derived from hippocampus revealed that repeated ART exposure led to significant reductions in 
synaptophysin, an essential component of synapses, and microtubule associated protein 2 (MAP2), a 
neuronal protein that stabilizes microtubules and which is used commonly as an indicator of neuronal 
processes. Our second in vivo model extended our findings to non-human primates, through an evaluation 
of brains from SIV-infected juvenile pigtail macaques. We observed decreased levels of synaptophysin in 
SIV-infected ART-treated animals, compared with either uninfected animals or infected animals receiving 
a placebo regimen. We acknowledge the caveat in the design of this study, that there is a lack of uninfected 
animals receiving ART. This prevented a strict determination of the effects of ART in the absence of viral 
infection, which is a topic of future investigation that will be addressed further in Section 6.5. Despite this, 
we did observe a definitive contribution of ART to neuronal damage, as SIV-infected ART-treated 
macaques had significantly less synaptophysin staining than their SIV-infected untreated counterparts. 
These studies demonstrating evidence of ART-associated synaptic damage in vivo warrant future 
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investigations into specific effects of individual drug classes, as well as the mechanisms through which 
neuronal damage occurs.  
 
Until recently, ART-induced toxicity had only been explored in cell lines, however Robertson and 
colleagues have now provided the first evidence for such toxicity in primary rat neurons (Cui et al., 1997, 
Robertson et al., 2012). Within our current study we have shown that the PIs Ritonavir and Saquinavir 
induce oxidative stress followed by subsequent neuronal damage/death in primary cultures at clinically 
relevant doses. We have also provided evidence that through activation of the EAR by MMF, we were able 
to prevent the generation of oxidative stress and neuronal toxicity induced by these antiretroviral 
compounds. Interestingly, application of the NRTI compounds AZT or stavudine (d4T) did not cause 
neuronal toxicity in our experimental paradigm. In agreement with these observations, a previous study in 
PC-12 neuron-like cells found that following extended exposure to either AZT or d4T no inhibition of cell 
growth or neurite regeneration were observed (Cui et al., 1997).  
 
We have demonstrated that ART-induced effects can be successfully blocked by MMF-mediated activation 
of the EAR. Only moderate activation of this pathway by ART compounds alone was seen through 
increased levels of both mRNA and protein of EAR target genes HO-1 and NQO1. Pre-treatment with 
MMF resulted in further increases in HO-1 protein and provided protection against ART-induced toxicity. 
We confirmed that this protection was the result of increased HO-1 activity by co-applying a heme 
oxygenase inhibitor at the time of MMF pre-treatment. With this inhibition, the protection provided by 
MMF was negated. We conclude that despite activation of the EAR in response to antiretroviral 
compounds, this response is either insufficient or too delayed to protect neurons from ART-mediated 
damage and death. In support of this interpretation, enhanced MMF-mediated activation of the EAR was 
strongly protective against the neurotoxic antiretroviral effects. Future studies utilizing this in vitro model 
could be very informative to determine if other clinically utilized ART combinations result in 
neurotoxicity, as well as to screen additional candidate compounds for potential use as adjunctive 
therapeutics prior to testing in in vivo models. The success of MMF in prevention of ART-induced neuronal 
toxicity in vitro is of particular interest for the potential of translation of our findings to the clinical setting. 
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MMF as a candidate for adjunctive therapy in patients with HAND will be discussed in detail in Section 6.6 
“Clinical Implications”.  
 
In our acute model of ART application in vitro, enriched astrocytes did not show evidence of ROS 
accumulation or EAR activation. Astrocytes have high levels of glutathione and antioxidant enzymes, and 
it is likely that our finding is reflective of efficient cellular buffering of the ROS produced by antiretroviral 
compounds so that no accumulation occurs and no upregulation of antioxidant proteins are required (Sagara 
et al., 1993, Bolanos et al., 1996). In SIV-infected macaques, we found that the astrogliosis normally 
present after infection was resolved in ART-treated animals. While these findings suggest that astrocytes 
may not be robustly impacted by ART compounds, the effects of long-term exposure cannot be predicted. 
Astrocytes have been well characterized in their ability to provide trophic support and stress buffering 
capabilities to neurons, including oxidative stress, and alterations in this capacity can precipitate damage in 
the already susceptible neuronal population (Sagara et al., 1993, Bolanos et al., 1996, Fernandez-Fernandez 
et al., 2012). In our in vitro model, enriched neuronal cultures succumb to antiretroviral-mediated toxicity 
in less than 6 hours. In neuroglial culture however, which contains approximately 95% neurons and 5% 
astrocytes, viability was sustained until mitochondrial depolarization and subsequent neuronal 
damage/death was observed at 48 hours post-treatment. These results indicate that while astrocytes do not 
themselves upregulate EAR proteins in response to antiretroviral agents, even when present in small 
numbers they are capable of buffering neuronal susceptibility to the oxidative stress generated by these 
compounds, at least for a time. Ultimately however, these neuroglial cultures do succumb to antiretroviral-
mediated toxic effects. Together, our data suggest that sustained oxidative stress and ROS accumulation 
due to extended ART exposure may lead to ART-induced neuronal injury in the CNS, leading to the 
persistence of clinically observed synaptodendritic damage in HIV patients in the ART-era. 
 
The persistence of HAND despite effective viral control outside of the CNS is accompanyied by a shift in 
pathology from severe dementia to more subtle neurocognitive impairments, implying a continuation of 
neuronal damage, albeit in a milder form. Through our results presented here, we propose that the 
mechanism of continued synaptic damage may be a combination of viral proteins and soluble factors 
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released from CNS reservoirs, as well as direct damage caused by ART compounds. Comprehensive 
studies have detailed neuronal and synaptic damage mediated by viral proteins and factors released from 
infected cells, by several direct as well as indirect mechanisms involving multiple cell types, including 
astrocytes (Gonzalez-Scarano, 2005). Our data suggest that additional synaptic damage may be caused by 
direct ART-mediated effects in neurons, through mechanisms involving oxidative stress. It is likely that 
longitudinal exposure to ART regimens including compounds which invoke this syanptic damage 
contribute to a slower, yet persistent alteration of neuronal function which contributes to the chronic course 
of progressive neurocognitive impairment observed in HAND patients in the ART-era. 
 
6.3: OLIGODENDROCYTE MATURATON AND MYELINATION ARE NEGATIVELY 
AFFECTED IN THE CONTEXT OF HIV AND ART 
Through our results presented in Chapter 4, we have been the first to evaluate oligodendrocyte maturation 
in the context of antiretroviral drug exposure. We have rigorously demonstrated that PIs produce significant 
deficits in the differentiation of cells from OPC to maturing oligodendrocytes, which is independent of the 
oxidative stress induced by ART compounds, despite ROS being produced. We were fortunate to be able to 
examine a human cohort containing HIV-positive individuals with and without antiretroviral drug 
experience, and measured a significant reduction in myelin basic protein and a significant increase in 
CNPase in the HAND patients who had been ART-medicated compared to seronegative controls and 
HAND patients who were ART-naïve. These data have enabled us to add cellular evidence of myelin 
protein perturbation to the persistence of white matter pathologies in ART-treated HAND patients, which 
corroborates previous reports utilizing non-invasive imaging studies (Pomara et al., 2001, Ragin et al., 
2004, Gongvatana et al., 2009, Wohlschlaeger et al., 2009, Hoare et al., 2010, Tate et al., 2011, Kelly et al., 
2014). Our data are also in accordance with the single transcriptome analysis study performed in patients to 
define genes altered in HIV infection that remained dysregulated following suppression of viral replication 
by antiretroviral therapy, which found that mRNA for myelin specific genes: myelin-associated 
oligodendrocyte basic protein and myelin basic protein (MBP) were reduced (Borjabad et al., 2011).  
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Given these findings, we propose the following model for the effects of antiretrovirals on the maturation of 
oligodendrocytes. Oligodendrocyte precursors treated with antiretroviral compounds enter into 
differentiation and proceed with transcription factor alterations and upregulation of myelin component 
mRNAs as has been well documented (Miller, 2002). During this progression, cells begin to extend actin 
filaments and adopt the morphology of mature, elaborated oligodendrocytes. A majority of myelin 
component proteins are translated in the perinuclear endoplasmic reticulum and are trafficked through the 
secretory pathway via the Golgi apparatus to be inserted into the forming myelin membrane (Colman et al., 
1982). An exception to this is MBP, in which mRNA is instead trafficked along microfilaments to sites 
proximal to the myelin membrane. Once in this vicinity, protein is translated from the mRNA on free-
ribosomes and is rapidly inserted into the neighboring membrane (Colman et al., 1982, Ainger et al., 1997).  
 
In the case of treatment with PIs we propose that either the translation or trafficking of myelin proteins is 
affected. The rapid rescue of maturation deficits suggest that required components are already present 
within treated cells, and that alleviation of cellular stress by drug removal allows for renewed translation 
and/or proper trafficking of myelin components. All myelin proteins examined, both those traversing the 
secretory pathway as well as MBP, are diminished at the cell surface. The most straightforward explanation 
for this result would be that PI treatment decreases protein synthesis. When this blockade is removed, rapid 
translation, trafficking, and membrane insertion can ensue. The caveat to this proposition is that protein 
levels remain normal as assessed by western blotting under most conditions where a deficit in membrane 
positivity already exists. This is particularly evident in the highest Ritonavir dose where no decreases are 
detected at the protein level, yet drastic decreases are seen by immunocytochemistry. While this finding is 
unusual, it is not unprecedented in oligodendrocytes and has been similarly reported by two independent 
laboratories (Maier et al., 2009, Wahl et al., 2014). Reduction in cholesterol levels can result in decreased 
surface expression of proteolipid protein (PLP) while maintaining normal protein level as assessed by 
western blotting (Maier et al., 2009). Similarly, investigations into the role of mammalian target of 
rapamycin in differentiation revealed a reduction in number of maturing oligodendrocytes yet maintenance 
of normal myelin protein levels (Wahl et al., 2014). Based on our findings and supporting evidence from 
these previous works, it is therefore more likely that a trafficking/membrane insertion problem exists for 
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myelin proteins which have already been synthesized.  
 
Alternatively, normal protein levels observed with Ritonavir at all concentrations and most doses of 
Lopinavir may indicate a failure of protein degradation under conditions which would normally promote 
destruction of myelin proteins which were synthesized but could not effectively be inserted into the 
membrane. PIs have been shown in non-CNS cells to have the off-target effect of inhibiting proteasomal 
degradation and activating the unfolded protein response (UPR) (Andre, 1998, Zhou, 2005, 2006). The 
UPR potently suppresses global protein translation while upregulating specific stress-response proteins 
(Brown and Naidoo, 2012). While we have provided evidence that the UPR is not activated in 
oligodendrocytes following antiretroviral application at timepoints where such activation was evident in 
neuroglial culture, we have not yet addressed potential effects on translational efficacy or inhibition of 
degradation machinery. Following this line of reasoning, the mechanism behind lower protein levels with 
highest dose Lopinavir would need to be explained, particularly if the proteasome is inhibited. 
 
Notable differences were observed in the effects of the two PIs Ritonavir and Lopinavir, which are likely 
the result of dissimilar metabolism and intracellular actions resulting from the unique properties of their 
chemical structures. There have been several previously reported instances where different effects are noted 
in the same cell population following exposure to independent PI compounds. Adipocyte differentiation 
was inhibited with Nelfinavir and Indinavir but not with Amprenavir (Caron et al., 2003). Additionally in 
astrocytes, ROS production, glutathione export, and toxicity differed dramatically following Nelfinavir 
versus Indinavir application (Brandmann et al., 2012). In spite of differing subcellular effects invoked by 
Ritonavir and Lopinavir, it is clear that exposure to either PI even at low concentrations would not result in 
the formation of a properly functioning myelin membrane based on reduced myelin protein localization to 
the cell surface and our observed deficit in myelin membrane elaboration. 
 
We have demonstrated that several antiretrovirals induce ROS, mitochondrial depolarization and 
neurotoxicity in astrocyte-supported neuronal culture (Chapter 3) and that oxidative stress hinders the 
process of oligodendrocyte differentiation (French et al., 2009, Reid et al., 2012). While both NRTI AZT 
203	  
and PI Ritonavir induce robust ROS accumulation, this is not a universal feature of antiretrovirals, as 
Lopinavir did not produce ROS accumulation even at greatly extended timepoints in oligodendrocytes. 
When we probed whether the EAR, which is triggered by cellular redox homeostasis imbalance, was 
activated in oligodendrocytes following antiretroviral exposure, no biologically relevant increases in 
pathway gene mRNAs or in target proteins HO-1 or NQO1 were detected (Li, 2009). Furthermore, 
scavenging of ROS through EAR upregulation via MMF did not rescue PI-induced decreases in 
oligodendrocyte differentiation despite previously demonstrated neuroprotection (Chapter 3). Thus, while 
PIs have been previously shown in other cell populations to induce oxidative stress and the UPR, we 
provide evidence that in oligodendrocytes PIs act through an alternate mechanism to affect maturation. An 
intriguing possibility is the potential for PIs to cause dyslipidemia, which has been demonstrated in patients 
and in non-CNS cell types (Carr, 1998, Haughey et al., 2004, Zhou, 2006). An effective myelin membrane 
is crucially dependent on proper lipid balance to ensure appropriate organization of myelin component 
proteins (Maier et al., 2009, Chrast et al., 2011, Lee et al., 2014). As was mentioned previously, reduction 
in cholesterol levels can result in decreased PLP at the surface of the myelin membrane with minimal 
reduction at the protein level, which mirrors our finding with MBP under conditions of Ritonavir treatment 
(Maier et al., 2009). Furthermore, PIs have been linked to altered regulation and localization of the master 
transcription factor of lipid metabolism sterol regulatory-element binding protein 1 (SREBP1), which may 
be involved in our differentiation phenotype (Zhou, 2006, Goulbourne and Vaux, 2010). In summary, while 
previous studies have implicated oxidative stress and activation of the UPR as cellular responses to 
antiretroviral compounds, in oligodendrocytes PIs do not seem to be acting through these pathways to 
induce a differentiation deficit and alternative mechanisms should be considered. 
 
Further investigation is needed to define the mechanism by which myelin proteins are dysregulated and 
prevented from reaching the myelin membrane following PI application. Several potential avenues of 
inquiry have been suggested by our results, including analysis of translational efficiency and protein 
turnover by the proteasome. In order to ascertain translational efficiency of myelin proteins in the presence 
or absence of PIs, pulse-chase experiments can be performed with radiolabeled methionine over a brief 
time interval in the context of proteasomal inhibition using the compound MG-132 to prevent breakdown 
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of newly synthesized proteins. At the endpoint of labeling, the myelin proteins would be pulled down using 
immunoprecipitation, and following gel electrophoresis the amount of newly synthesized protein could be 
quantified according to the amount of radioactive probe incorporated. To determine if proteasomal function 
is inhibited as a side effect of PI application in oligodendrocytes, cells can be treated and proteasomes 
specifically isolated through centrifugation in a glycerol gradient (Orino et al., 1991). Activity can then be 
assayed by measuring fluorescent emission of a synthesized probe engineered to emit 440-460 nm waves 
following specific proteasomal cleavage, allowing for comparisons under normal and treated conditions, as 
well as under MG-132 proteasomal inhibition. Secretory pathway function can also be assessed in our in 
vitro culture model. Isolation of individual cellular organelles by subcellular fractionation followed by 
western blotting will determine if myelin component proteins such as CNP and PLP are properly 
transitioning from the ER to the Golgi apparatus, or if unusual accumulations are occurring in these 
compartments. Immunocytochemistry followed by confocal imaging will address this question using a 
different approach, by co-staining with organelle markers in addition to one of the myelin proteins. 
Quantification of myelin proteins in each subcellular fraction will allow comparison of myelin protein 
localization to each cellular compartment under normal and PI-treated conditions. Finally, the lipid 
composition of the forming myelin membrane should be evaluated to determine if an imbalance or 
dysregulation of lipid rather than protein is preventing correct presentation of myelin proteins to the cell 
surface. Studies within the laboratory have begun to explore these possibilities, through mass spectrometry 
analysis of cellular lipid compositions during differentiation in the presence or absence of PIs, along with 
assessment of the activities and levels of the transcription factor SREBP1 and its downstream gene targets 
involved in lipid metabolism. 
 
Another area crucially in need of investigation is an exploration of the potential consequences of HIV-
infection on oligodendrocytes. In a recent publication, a model using inducible Tat-transgene expression in 
astrocytes began to address this important question. Following 3 months of Tat-expression, animals 
displayed significant abnormalities in myelin integrity, with aberrant morphology evident in the corpus 
callosum, anterior commissure, caudate-putamen, and striatum (Zou et al., 2015). Furthermore, application 
of exogenous Tat protein to oligodendrocytes in vitro culminated in reduced viability of immature 
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oligodendrocytes and significant reductions in oligodendrocyte maturation (Zou et al., 2015). While this 
foundational study has provided initial evidence that viral proteins can affect oligodendrocyte survival and 
extent of myelination, it is of upmost importance to understand the effects of HIV-infection on 
oligodendrocytes in the context of the entire virus and cell populations that undergo productive infection in 
vivo. Evidence has shown that in addition to factors secreted by infected cells, inflammatory activation of 
neighboring, uninfected macrophages, microglia, and astrocytes also contributes to release of cytotoxic 
factors into the cellular milieu. Therefore, we have begun to formulate studies using a model of HIV-
infection of isolated human monocyte-derived macrophages. Following infection with a CNS-isolated 
strain of HIV-1, supernatants will be collected at the peak of viral infection. These supernatants have been 
previously demonstrated to invoke neurotoxicity, at least in part through high levels of glutamate that 
promote N-methyl-D-aspartate receptor (NMDA) receptor-mediated excitotoxicity (O'Donnell et al., 2006). 
The oligodendrocyte study mentioned above from the Knapp laboratory also demonstrated a NMDA 
receptor-dependent mechanism of Tat-induced effects in their model, suggesting that in the context of full 
virus, high levels of extracellular glutamate may be negatively impacting oligodendrocytes as well as 
neurons. On the basis of these preliminary findings, it is expected that oligodendrocyte survival and 
maturation will be affected in the context of viral infection. Results investigating this possibility, in 
addition to the effects of antiretroviral compounds, will have great clinical and therapeutic implications.  
 
Through our work in Chapter 4 we have pioneered the investigation of the effects of antiretrovirals 
compounds on oligodendrocytes in vivo, through use of a rodent model as well as human patient samples. 
In mice, myelin alterations were evident in as little as two weeks of repeated exposure, with significant 
reductions observed in both CNPase and MOG. We also performed the first reported evaluation of myelin 
protein levels in individuals with HAND. None of the proteins MBP, CNP, MAG, or MOG were 
significantly altered when individuals were stratified solely into HIV-negative and HIV-positive groups. 
However, when only individuals with confirmed diagnosis of HAND were assessed, and were placed into 
categories based on whether they had received ART, a significant reduction in MBP was observed in 
patients with HAND who had been ART-medicated, when compared with either the untreated HAND 
individuals or the HIV-negative controls. Our findings reinforce the transcriptome analysis performed by 
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the Volsky group, which identified genes required for oligodendrocyte maturation including MBP as 
dysregulated in patients with HAND, even under effective suppression of viral replication (Borjabad et al., 
2011). While this could potentially be interpreted that synaptodendritic damage in HAND occurs with a 
subsequent loss of myelin, our results indicate that this is an insufficient explanation for all of our observed 
effects at the protein level. Our examination of patient samples also yielded an unexpected significant 
increase in CNPase in the HIV-positive ART-medicated group, over both the HIV-negative and HIV-
positive ART-naïve groups regardless of neurocognitive status. This observation could be indicative of an 
attempted cellular remyelination response that has been unsuccessful in restoring MBP levels, as CNPase is 
one of the earliest myelin proteins to be expressed during maturation from precursor cell to mature 
oligodendrocyte (Scherer et al., 1994). Together with our in vitro evidence, these results indicate that 
disruption of myelin in the ART era may occur as a direct effect of ART compounds on oligodendrocytes, 
rather than as a secondary consequence of neuronal damage. Our data suggests that in a reversal of roles, 
damage to myelin, coupled with oligodendrocyte precursors that cannot successfully remyelinate affected 
areas, may in turn lead to secondary synaptodendritic neuronal damage.   
 
Based on the evidence from our investigations and those previously performed, we have formulated the 
following model for the effects of HIV and antiretroviral compounds on oligodendrocytes in pediatric and 
adult settings (Figure 6.1). In children (A), throughout adolescence productive myelination occurs which 
allows for the ensheathment of neurons, axon potential conductivity, and plasticity of signaling networks 
throughout development. HIV-infection with concomitant suppressive ART and inflammation culminates 
in widespread neurological deficits including encephalopathy, leukoencephalopathy, cerebrovascular 
complications, neurocognitive deficits and developmental delays. These pathologies are likely a combined 
effect of reduction in effective myelin formation and disruption of myelin integrity of forming white matter 
tracts. In the adult (B), myelin is essential for the facilitation of action potentials, axonal maintenance, and 
neurotrophic support. Additionally, new myelin formation and plasticity/maintenance of formed myelin is 
crucial for maintained biological homeostatic function and for motor learning in adulthood. HIV-infection 
with persistent inflammation and treatment with lifelong ART together can result in HAND in patients. 
Pathologies including dendritic pruning, astrogliosis, loss of white matter volume and integrity, and 
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reduction in mRNA and protein for myelin components are evident in these individuals. Through the 
findings resulting from our our study, we propose that the myelin pathologies observed in patients are 
likely a combination of perturbed maintenance of formed myelin as well as an impairment of remyelination 
capability.  
 
6. 4 THE ENDOGENOUS ANTIOXIDANT RESPONSE IN OLIGODENDROCYTES 
It was quite intriguing that the EAR was not activated in oligodendrocytes in our investigations of effects of 
antiretroviral compounds despite robust oxidative stress, or following application of MMF which was 
known to upregulate this pathway in other cell populations. We decided to pursue this line of investigation, 
to examine the activity of the EAR in oligodendrocytes in Chapter 5.  
 
In contrast to the well-characterized pathway function of the EAR in many other cell types, very little is 
known about this pathway in oligodendrocytes. The sole reported study, using primary rat oligodendrocytes 
demonstrated upregulation of HO-1 by immunoblotting following exposure to hydrogen peroxide, however 
this insult culminated in loss of mitochondrial function and apoptosis, suggesting that the protein 
upregulation resulting from EAR pathway activity was not sufficient to protect the cells (Goldbaum and 
Richter-Landsberg, 2001). In our work, we provide compelling evidence that exposure to sub-toxic levels 
of oxidants produced ROS accumulation in both OPCs as well as mature oligodendrocytes in vitro. 
However, unlike other CNS cell types, in both the OPCs and mature oligodendrocytes this failed to elicit 
activation of the EAR. As a possible result of this failure, oxidant exposure at the time of differentiation 
prevented OPCs from progressing in differentiation to the more mature oligodendrocyte stages, and 
prevented appropriate levels of myelin protein expression for insertion into the cell membrane.  
 
In an attempt to better understand the unrectified level of oxidative stress in oligodendrocytes, we turned 
our focus to a demyelinating disease in which oxidative stress is a hallmark of disease and antioxidant 
treatment has benefited patients: Multiple Sclerosis (MS). Symptoms of MS arise from disruption of the 
integrity of myelin in white matter tracts in the brain, with cellular pathology including destruction of 
myelin sheaths and death of oligodendrocytes, as well as axonal damage and neuronal death (Criste et al., 
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2014, Mallucci et al., 2015). While initial steps leading to the autoimmune targeting of myelin are not well 
understood, it is evident in MS that once initiated; chronic inflammation and oxidative stress drive ongoing 
pathology (Friese et al., 2014, Mahad et al., 2015). Currently, therapies aimed at reducing relapse rates and 
restoring quality of life in patients have focused on attenuating these two persistently elevated forms of 
stress (Friese et al., 2014, Mahad et al., 2015). The drug Tecfidera effectively reduces relapse rates in MS 
patients (Fox et al., 2014, Dubey et al., 2015). This compound is suspected to act as an antioxidant, yet the 
mechanism by which it is effective has not been elucidated. Tecfidera is composed of the fumaric acid ester 
dimethyl fumarate (DMF), which is rapidly metabolized to MMF following ingestion (Litjens et al., 2004, 
Schmidt et al., 2007, Limmroth, 2013, Fox et al., 2014). Within minutes of administration, DMF is no 
longer detectable and MMF is the primary physiological metabolite (Schmidt et al., 2007). We and others 
have demonstrated antioxidant properties of MMF in neurons and macrophages through Nrf2-mediated 
EAR activation and upregulation of target genes (Chapter 3) (Cross et al., 2011, Albrecht et al., 2012, 
Scannevin et al., 2012). Remarkably, MMF effects on signaling pathways in oligodendrocytes have not 
been explored, despite the pivotal role these cells play in MS pathology.  
 
Within our in vitro model, we attempted to exogenously activate the EAR by treatment with MMF in 
oligodendrocyte lineage cells. Pre-treatment with MMF successfully attenuated ROS accumulation caused 
by various oxidant compounds in both OPCs and mature oligodendrocytes as anticipated. However, MMF 
did not upregulate Nrf2-mediated EAR target genes HO1 or NQO-1 at any point during an extended 24-
hour timecourse in oligodendrocytes, and was unsuccessful at rescuing the oxidant-induced maturation 
deficit in developing OPCs. Our finding is in line with that of the Stangel laboratory, in which animals 
were fed the copper chelator cuprizone to induce a specific, reversible demyelinating lesion in the corpus 
callosum. During the period of remyelination in this experimental model of MS, animals were given either 
DMF or MMF, yet only minor effects on remyelination were noted and the fumarate compounds did not 
protect against cell death (Moharregh-Khiabani et al., 2010). Additionally, while this group did not 
examine in vitro differentiation, they demonstrated that pre-application of either DMF or MMF failed to 
rescue an oligodendrocyte-like cell line from oxidative stress-induced toxicity following hydrogen peroxide 
treatment (Moharregh-Khiabani et al., 2010).  
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One possible explanation for the absence of EAR pathway activity in oligodendrocytes involves the 
regulation of glutathione synthesis and recycling. All of the oxidants utilized within our study impact 
cellular glutathione: tert-butyl hydroperoxide depletes levels of cellular glutathione, buthionine sulfoximine 
selectively inhibits glutathione synthesis, and hydrogen peroxide generates highly reactive hydroxyl 
radicals which interact with cellular proteins, lipids, and reducing agents such as glutathione (Meister, 
1992, Sies, 1993, Back et al., 1998, Zhao et al., 2005, French et al., 2009). MMF was unable to rescue 
maturation deficits induced following exposure to any of these oxidants. Glutathione s-transferase (GST) is 
the enzyme responsible for glutathione conjugation to electrophilic compounds. The isoform of GST 
expressed in oligodendrocytes is GST-pi, which within the brain is unique to this cell lineage and has been 
used as a marker for mature oligodendrocytes in vivo (Cammer et al., 1989, Cammer and Zhang, 1992, 
Girolamo et al., 2011, Li et al., 2013). Immunofluorescent studies have demonstrated that GST-pi is nuclear 
in OPCs and attains a cytoplasmic distribution during differentiation, which may account for some of the 
oxidative stress sensitivity of oligodendrocytes during early lineage stages (Tamura et al., 2007). It may be 
that in oligodendrocytes, the glutathione system for monitoring redox homeostasis operates differently than 
other CNS cell populations, such that if glutathione levels are depleted the EAR is not effectively activated, 
particularly in OPCs and maturing cells when components of this system are confined to the nucleus.    
 
Interestingly, both DMF and MMF have been reported to lower cellular glutathione levels in astrocytes and 
could potentially do the same in oligodendrocytes (Schmidt and Dringen, 2010). However in contrast to 
this idea, DMF has been recently reported to increase glutathione levels in a human oligodendrocyte cell 
line (Huang et al., 2015). Future investigation is certainly needed to resolve these conflicting theories, and 
will hopefully determine mechanistically how fumarate compounds affect glutathione regulation in primary 
oligodendrocytes. In addition to the fumarates, it will be important to determine if EAR upregulation occurs 
in oligodendrocytes using alternative oxidants and antioxidants which impact cellular redox sensors other 
than glutathione, or if this canonical pathway is truly not utilized in this cell lineage. 
 
Another possibility is that rather than the Nrf2 pathway playing the primary role in regulating redox 
homeostasis in oligodendrocytes, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
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κB) pathway may take the forefront in this cell population. These two pathways are extensively 
interconnected and normally antagonize each other (Li et al., 2008). It would not be surprising if a cell 
lineage which lacks activity in one pathway to have overly robust activity in the other in response to 
pathway initiation. This could be potentially harmful to oligodendrocytes, as NF-κB pathway activation 
leads to a pro-inflammatory state (Tobon-Velasco et al., 2014). Recent evidence from the Massa laboratory 
may help to support this theory. This group previously found that null mutation of Src homology 2 domain-
containing protein tyrosine phosphatase 1 (SHP-1) in mice resulted in reduced myelin gene expression and 
hypomyelination in the CNS (Massa et al., 2004). SHP-1 modulates ROS production by negatively 
regulating the NADPH oxidase complex (Krotz et al., 2005), which is inducible and toxic to 
oligodendrocytes (Johnstone et al., 2013). In their present study, SHP-1 deficient mice display a permanent 
shift away from redox homeostasis, with Nrf2 nuclear localization and upregulated HO-1 expression, but 
this is accompanied by irreversible protein damage both in vitro and in vivo, suggesting that the observed 
EAR pathway responses are insufficient to resolve the enhanced intracellular levels of ROS (Gruber et al., 
2015). Importantly, SHP-1 normally negatively regulates the activity of NF-κB (Mandal et al., 2010, 
Mariappan et al., 2010). This report also demonstrated that silencing of SHP-1 led to enhancement of 
downstream NF-κB pathway targets (Gruber et al., 2015). Investigating activity of this crucial protein 
which has the potential to impact both oxidative and inflammatory cellular states in oligodendrocytes could 
be very informative in regards to MS, where both of these stresses are key drivers of pathology. With these 
results in mind, future studies aimed at downregulating NF-κB pathway activity may be a more effective 
therapeutic approach than attempting to upregulate EAR activity.    
 
Overall, our results suggest that the source of selective vulnerability of oligodendrocytes to oxidative stress 
is two-fold. This cell lineage begins with endogenously low levels of antioxidant and detoxifying enzymes 
(Halliwell, 1992, Back et al., 1998, Fern and Moller, 2000, Baud et al., 2004), and this deficit in oxidant 
buffering capacity may be exacerbated by an inability to appropriately activate the supposedly ubiquitous 
EAR pathway under conditions of redox imbalance. Our results indicate that in vivo, oligodendrocytes 
likely rely on neighboring cells for protection from oxidative stresses, in much the same way that neuronal 
protection occurs via astrocyte involvement (Fernandez-Fernandez et al., 2012). In light of our findings, it 
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is not likely that Tecfidera reduces MS relapse rates through a direct effect on oligodendrocytes. Rather, it 
is more probable that secondary effects from EAR upregulation in neurons, macrophages, and possibly 
astrocytes play a role in conferring protection to the oligodendrocytes (Chapter 3 and (Cross et al., 2011, 
Scannevin et al., 2012)). While not examined in our present study, in addition to reducing overall levels of 
oxidative stress, Tecfidera may also be influencing levels of CNS inflammation through modulation of 
secreted cytokines and inhibition of the NF-κB pathway (Lehmann et al., 2007, Albrecht et al., 2012, 
Gillard et al., 2015). Functional recovery of patients with demyelination, as seen in MS and HAND, will be 
reliant on resilient reduction of oxidative stress. Our study has provided the foundational evidence that in 
order for this to succeed, the concerted efforts of multiple CNS cell populations will be required to provide 
an oxidative stress free environment, so that the susceptible oligodendrocyte population can effectively 
survive, mature, and re-myelinate affected areas.  
 
6.5 ANTIRETROVIRAL STUDIES GOING FORWARD 
The in vitro and in vivo models used throughout our studies have enabled great advances in the 
understanding of antiretroviral effects on CNS cell populations. Continuing forward in this line of 
investigation, it will be advantageous to consider: additional exploration of NRTI-based effects and initial 
investigation of the nNRTI and integrase inhibitor drug classees, responses to ART drugs on the whole-cell 
level, and advanced tools for evaluating CNS effects of ART compounds.   
 
6.5a Further Investigation of Antiretroviral Drug Classes 
In our detailed studies of the impacts of antiretroviral drugs in invoking neuronal toxicity and deficits in 
oligodendrocyte maturation, the candidate compound tested from the NRTI class, AZT, produced ROS 
accumulation but did not negatively impact the cellular functions that we assessed. NRTIs have been 
unequivocally implicated in peripheral neuropathy through mechanisms of mitochondrial dysfunction and 
oxidative stress, which made our negative findings rather unexpected (Dalakas, 2001, Ellis, 2008). NRTIs 
are formulated as pro-drugs, and must be tri-phosphorylated by thymidine kinases in vivo in order to 
effectively halt HIV replication. Expression of these enzymes is cell cycle-dependent, and while 
oligodendrocytes and OPCs possess the particular kinase required for NRTI phosphorylation, post-mitotic 
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neurons most likely do not (Nygard et al., 2003, Bazzoli et al., 2010). Therefore, it is highly likely that in 
our model used to study neurons, AZT is not converted to its active form. We did not test whether OPCs 
effectively phosphorylated AZT. Given our results, synthesized versions of tri-phosphorylated AZT and 
other NRTIs should be obtained and tested to see if our current results truly are representative of the drug 
class, or if antiretroviral-induced repercussions in neurons and oligodendrocytes would be different in the 
context of NRTIs which had been effectively activated by other CNS cell populations.  
 
Additionally, while we have evaluated cellular effects following application of representative candidate 
compounds from the NRTI and PI classes, we have not yet explored potential consequences of drugs from 
the nNRTI or Integrase Inhibitor families. Similar to the NRTI compounds, the efficacy of nNRTIs is based 
on prevention of viral reverse transcription from RNA to DNA (Pau and George, 2014). However, unlike 
the nucleoside/nucleotide analogs which compete as substrates for the reverse transcriptase enzyme, the 
nNRTI compounds directly bind to the catalytic domain of the enzyme to prevent its activity (de Bethune, 
2010, Pau and George, 2014). As the nNRTIs do not compete for endogenous cellular DNA or 
mitochondrial DNA synthesis, mitochondrial dysfunction may not be observed with this class. However, 
despite this differing mechanism of action, Efavirenz has been linked to the production of superoxide, 
glutathione depletion, and disruption of mitochondrial membrane potential and function in a human cell 
line (Apostolova et al., 2010). Furthermore, due to negative neurocognitive performance associated with 
use of Efavirenz, it has been removed from treatment recommendations (Decloedt and Maartens, 2013). 
Testing of Nevirapine and Rilpivirine in neuroglial cell populations is therefore imperative, as it remains to 
be seen if the other commonly prescribed nNRTIs have similar effects to Efavirenz. 
 
Another novel category of antiretroviral compounds, the integrase strand transfer inhibitors (INSTIs), has 
come to the forefront in treatment regimens following the introduction of Raltegravir in 2007 and 
subsequent approval of Dolutegravir and Elvitegravir (Pau and George, 2014, AIDSInfo, 2015). This drug 
class halts the HIV integrase enzyme from forming covalent bonds between host-cell and viral DNA, which 
prevents effective incorporation of the viral DNA into the host chromosome. Thus far, these drugs have 
been associated with less peripheral toxicities than other classes, which could translate to less neuroglial 
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toxicity. However preliminary evidence from our laboratory suggests that a dose-dependent reduction in 
oligodendrocyte maturation may occur with Raltegravir, a finding that should be verified and expanded 
upon.  
 
Antiretroviral regimens are constantly evolving, with new compounds and drug classes being introduced 
while others are eliminated. It is vital to screen these compounds in efficient ways to determine whether 
CNS toxicities occur, particularly with a continued focus on higher brain penetrance to eliminate viral 
reservoirs. Our current studies have demonstrated pronounced neuroglial effects following exposure to 
various antiretroviral compounds, with PIs having marked deleterious effects on neurons and 
oligodendrocytes. Future studies using the active form of NRTIs as well as initial examination of the 
nNRTIs and INSTIs, are necessary to more thoroughly understand the full range of effects of ART in 
patients who are exposed to regimens with a mix of these various classes.  
 
6.5b Cellular responses to Antiretroviral Compounds 
Through the combined efforts of many laboratories, oxidative stress, unfolded protein response activation, 
proteasome inhibition, lipid dysregulation, and release of cytokines have been well documented following 
exposure to antiretrovirals. These pathways have been implicated in various cell populations through 
clinical observations in patients, animal and cell culture models, and have been validated through a 
candidate pathway testing approach. The direct assessment of protein and mRNA changes in brain-resident 
cell populations in response to antiretroviral compounds of different classes is still crucially needed. 
Through DNA-microarray and RNA-Seq methods, specific pathways altered following antiretroviral 
exposure can be identified. This will greatly assist in informing which regimens would have the least 
negative impact on CNS-cells, and would allow for better targeting of deleterious side-effects through 
specific adjunctive therapies. 
 
6.5c Advanced Tools for Evaluating CNS Effects of Antiretroviral Compounds 
Primary isolated cortical cell populations have been our principal system for analyzing the effects of 
antiretroviral compounds. While we have gained much knowledge through evaluating effects on specific 
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cell lineages in isolation, the full extent of functional implications to cellular changes cannot be 
extrapolated by this method. An ex vivo method has been developed, where organotypic slice cultures can 
be isolated from brain regions of young rodents and maintained for several weeks (Gahwiler et al., 1997, 
Opitz-Araya and Barria, 2011). Performing ART studies on these cultures will allow for extension of 
current studies to include evaluation of synaptic transmission, as well as functional assessment of the 
formation and maintenance of myelin segments. Using this physiological model will enable normal cellular 
interplay between CNS-resident cell populations, and allow for high throughput screening of ART 
compounds for potential neuroglial effects, as well as potential adjunctive compounds prior to testing in a 
full-scale animal model.  
 
Our striking findings regarding the effects of PIs on oligodendrocyte maturation and myelin maintenance 
have prompted consideration for additional rodent models in which to study the effects of ART compounds 
in the absence of viral infection. The first of these would investigate the effects of ART on the process of 
remyelination in the adult animal. Our laboratory has experience performing the cuprizone model, which 
induces a specific demyelinated lesion in the corpus callosum that remyelinates in the weeks following 
cessation of cuprizone ingestion (Torkildsen et al., 2008). In a procedural advancement since our jugular 
vein administration model, animals could be outfitted with osmotic pumps to continually deliver specific 
ART drugs at a constant dosing during the remyelination period. Evaluation of remyelination will 
determine if PIs also prevent oligodendrocyte differentiation in vivo. This is an important question to 
resolve, as it would validate our conclusion that PIs produce loss of myelin integrity as well as prevent 
effective remyelination of the damaged areas in the adult. Furthermore, this procedure could also be 
merged with candidate adjunctive therapy studies to determine if ART-effects can be attenuated. At 
present, even less is known about viral and ART effects in children than in adults, with neurocognitive 
outcomes being unpredictable as they are the first generation to survive infection long-term. With our 
striking evidence for PI-based oligodendrocyte differentiation deficits, we would like to establish a model 
of pediatric ART administration in young mice. While current technology may limit when osmotic pumps 
may be installed, it is of critical importance to understand the effects of ART compounds on the developing 
brain. Treatment of pediatric animals with ART drugs of various classes followed by cognitive and 
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behavioral testing as well as pathological analysis will further aid in guiding treatment regimens and 
understanding ART-mediated effects in HIV-infected children.  
 
One of the most challenging aspects of HIV research is that animal models have been extremely limited 
due to the lack of membrane surface receptors required for HIV cellular entry in rodents. However, the 
well-developed model of SIV-infection in macaques as was described and utilized in Chapter 3 is a 
remarkable tool for researchers, as the disease course and outcomes mirror that of human patients (Dinoso, 
2009, Zink, 2010, Graham, 2011). While such studies are a large financial burden, well-designed 
experimental plans can allow for maximum data collection and translational relevance. Future studies in 
these animals with SIV-positive, SIV-positive/ART-treated, and SIV-negative/ART-treated groups will be 
instrumental in determining the independent contributions of virus versus therapy to synaptic damage, 
inflammation, and loss of myelin integrity. Additionally, studies in these animals can be performed over a 
longer duration than the available rodent ART-administration models, and will more faithfully report the 
longitudinal effects of viral and ART exposure in a primate. A final possibility to consider with this model 
is the potential for development of pre-clinical screening of adjunctive therapies, as neurocognitive 
function and post-mortem pathological assessment can determine efficacy in a more expedient manner than 
human clinical trials.   
 
6.6 CLINICAL IMPLICATIONS 
The studies contained within this body of work have unequivocally demonstrated that antiretroviral 
compounds, specifically those of the PI class, invoke neuronal toxicity through oxidative stress, halt 
oligodendrocyte differentiation, produce synaptodendritic damage, and lead to loss of myelin integrity. 
These findings necessitate crucial reconsiderations of recommended treatment regimens, as well as provide 
impetus to develop effective adjunctive therapies to attenuate these effects.  
 
In order to prolong anticipated lifespan and prevent viral effects, the World Health Organization urges that 
all children under the age of 5 receive ART, regardless of their CD4 counts (WHO, 2013). Of paramount 
concern is that the currently recommended first-line regimen for all children under 3 years of age is 
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Lopinavir/ritonavir (WHO, 2013). Increasing documentation has revealed that treated pediatric patients are 
developing neurocognitive deficits and developmental delays, as well as motor, cognitive, and behavioral 
deficits reminiscent of the hallmarks of HAND seen in adults (Crowell et al., 2014, Whitehead et al., 2014, 
Wilmshurst et al., 2014). With the currently suggested treatment guidelines, these young children are being 
exposed to the specific ART-compounds that we have shown propagate neuronal toxicity and prevent 
oligodendrocyte differentiation during the peak period of neuronal development and cortical myelination in 
humans (Miller et al., 2012). As these children will already have the lifelong burden of effects stemming 
from infection and therapy, we hope our findings will be noted by clinicians responsible for amending ART 
guidelines and alter the drug class of first-line pediatric therapy away from the PI-based regimens.  
 
Additionally, our studies have illuminated synaptodendritic damage and disruption of myelin integrity with 
PI compounds in rodent models, as well as with combination regimens given to SIV-infected macaques and 
HIV-infected human patients. These findings highlight that while effective at reducing viral replication, 
ART compounds can directly negatively affect the health and function of CNS cell populations. The 
persistence of viral reservoirs necessitates continued ART adherence, despite deleterious side-effects 
(Chun, 1997, Finzi, 1997, Wong, 1997, Persidsky, 2006). It is therefore of upmost importance to develop 
adjunctive therapies to ameliorate the damage caused by ART, viral enclaves, and lingering inflammation.  
 
We have demonstrated that MMF provides effective neuronal protection against ART-induced toxicity 
through Nrf2-mediated induction of the EAR. Importantly, in a study by one of our collaborators, the 
Kolson laboratory has shown that both MMF and DMF suppress HIV replication in macrophages, in 
addition to activating the EAR, potently upregulating HO-1 protein, and preventing neurotoxin release 
(Cross et al., 2011). The specific upregulation of HO-1 responsible for the protective effects of MMF in 
both our neuronal and their macrophage models may be a key element in attenuating the damage induced 
by chronic oxidative stress found in HAND patients. Preliminary evidence from our laboratory showed 
elevated cytoplasmic levels of Nrf2 in HIV-infected ART-treated patients with HAND compared with 
those patients who remained neurocognitively normal. This increase in cytoplasmic Nrf2 could indicate a 
failure of pathway activation, as nuclear localization indicates a proper stress-mediated response. To bolster 
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this finding, HO-1 deficiency has been recently reported in HAND patients (Gill et al., 2014). Additionally, 
it will be crucial to determine if MMF is capable of reducing oxidative stress in the brain as a whole, in the 
context of viral infection and ART medication. Unfortunately, based on our findings in oligodendrocytes, 
unless chronic oxidative stress is eliminated from the CNS compartment, neuronal pathology caused by 
myelin disruption would remain. In this setting, neurons may initially be protected by direct antioxidant 
effects of MMF, but unless oxidative stress levels are lowered to beyond the point of preventing 
oligodendrocyte damage and promoting remyelination, axonal and synaptodendritic damage would 
continue to persist. Together, these data also suggest that the drug Tecfidera which is currently approved 
for MS treatment may also be a promising adjunctive therapy for use in HAND and should be tested in 
animal models to determine if it would be efficacious in vivo. Going forward, the effects of antiretroviral 
compounds on neurons and oligodendrocytes have highlighted the need for future adjunctive therapies 
designed not only to alleviate neuronal damage, but also to preserve myelin integrity and remyelination 
capacity of oligodendrocytes in order to attenuate and potentially reverse the neuropathologic and 
neurocognitive deficits still observed in HIV-positive individuals in the ART-era.  
 
6.7 SUMMARY AND CLOSING REMARKS 
Taken together, the cumulative results from our studies indicate that specific antiretroviral compounds 
invoke drastic negative cellular consequences in multiple CNS cell populations, independent of virus 
infection. We demonstrated in rodent models of drug administration that synaptodendritic damage and 
myelin proteins are rapidly altered following repeated exposure in the absence of virus. Extending this 
finding to a non-human primate model, synaptodendritic damage was also observed in SIV-infected ART-
treated macaques. Furthermore, myelin proteins were significantly altered in human patients diagnosed 
with HAND who had received ART compared to those with HAND but who were ART-naïve, and control 
subjects without infection. No direct effect on myelin levels were noted when infected versus uninfected 
subjects were compared, suggesting a potential correlation to alterations of myelin proteins as a 
consequence of solely the antiretroviral drug exposure.  
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Through neuronal cultures in vitro, we established that antiretrovirals led to ROS accumulation, 
mitochondrial depolarization, and ultimately apoptotic cell death. Moderate activation of the EAR was 
noted by antiretrovirals alone, and when this response was boosted by supplementation with the fumaric 
acid ester MMF, neuronal toxicity was prevented. In addition to investigating cellular stress response 
signaling pathways and survival in response to antiretroviral exposure, studies in oligodendrocytes also 
extended our findings to the consequences of these compounds on cellular maturation. Antiretrovirals of 
the PI but not the NRTI class lead to dose-dependent, reversible reductions in oligodendrocyte 
differentiation that are independent of oxidative stress-mediated effects. Neither the UPR or EAR are 
activated in the maturing cells following antiretroviral application, in contrast to previous findings in 
neurons and peripheral cell types. According to cytoskeletal markers and rapid reversal of effects, we have 
concluded that oligodendrocytes are normally primed for maturation and enter into differentiation, but 
myelin proteins cannot effectively be trafficked and/or inserted into the forming myelin membrane in the 
presence of the antiretrovirals.  
 
Quite surprisingly, oligodendrocytes do not activate the EAR under conditions of oxidative stress induced 
by antiretroviral drugs, oxidants, or following stimulation with MMF. This may underlie the particular 
susceptibility of oligodendrocytes to oxidative stress-mediated toxicity and could help to explain the 
mechanism of action for therapeutics designed to alleviate oxidative stress in Multiple Sclerosis. The 
cellular milieu of the brain is an intricately interconnected system, where cell populations are critically 
dependent on one-another. Our results indicate that like neurons, which rely on neighboring cells such as 
astrocytes and macrophages for protection from oxidative stresses, oligodendrocytes likely behave in much 
the same way. It is also important to consider that while MMF is successful at rescuing ART-induced 
neuronal toxicity, it did not rescue the oligodendrocyte differentiation deficit. Even though the EAR was 
not upregulated, MMF did attenuate ROS in oligodendrocytes, suggesting that PI-based inhibition of 
maturation is through an independent mechanism. Future investigations will hopefully isolate the 
mechanism leading to this dysfunction, in order to effectively prevent the halt in differentiation.     
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We have discovered that PIs in particular have profound effects in perturbing oligodendrocyte maturation 
and invoking neuronal toxicity. We sincerely hope that our findings are used to inform decisions on the 
suggested pediatric ART-regimens, substituting Lopinavir/ritonavir with less toxic agents as frontline 
treatment during the critical period of development and myelination in children.  
 
Much work is still needed to facilitate a better understanding of the effects of antiretroviral compounds in 
CNS cell populations. Once cellular consequences to antiretroviral drug exposure are more thoroughly 
defined, appropriately targeted adjunctive therapies will be more likely to succeed in attenuating 
neurological complications and reducing the severity and prevalence of HAND in HIV-infected 
individuals.   
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Figure 6.1: Model of Antiretroviral Effects on Myelin in Humans 
A) Schematic of pediatric myelination and the negative consequences of HIV-infection & treatment  
B) Schematic of adult myelin maintenance and the negative consequences of HIV-infection & treatment  
 
Highlighted in red are hypothesized concepts supported through data within the Chapter 4 manuscript. 
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A1.1 EXPERIMENTAL RATIONALE 
In light of our findings regarding direct neuronal toxicity and altered oligodendrocyte function following 
antiretroviral drug exposure, we also wished to extend our findings to the possible indirect effects that 
secreted factors from astrocytes may have in each of these scenarios. To do this, enriched astrocytes and 
neurons were grown in vitro as described in Chapters 3, with oligodendrocytes generated from Sprague 
Dawley rat pups instead of mice following the same protocol as in Chapter 4 to maintain the same species 
throughout all experiments. Primary astrocyte cultures were then treated with a panel of antiretroviral 
compounds in a timecourse of 6, 12, and 24 hours (n=3 independent biological replicates). At each 
endpoint, supernatants were collected to determine potential effects on neurons and oligodendrocytes. The 
following antiretrovirals were tested: NRTIs AZT (25 µM), d4T (25 µM), ddC (25 µM); and Protease 
Inhibitors Ritonavir (10 µM), Saquinavir (1.0 µM), and Indinavir (25 µM). Thapsigargin at 1.0 µM served 
as a positive control, as release of ER-calcium stores should invoke the release of factors from astrocytes 
which may harm neurons.  
 
To begin, these supernatants were applied to 14DIV enriched neuronal cultures for 48 hours at a 1:20 
dilution. Following this period a MAP2 ELISA assay was performed to assess neuronal damage/death as 
described in Chapter 3. As can be seen in Figure A1.1, none of the supernatants from antiretroviral treated 
astrocytes at any point during the timecourse produced an effect on neuronal viability (n=3 biological 
replicates of neurons, each treated with the triplicate astrocytes derived samples). The only treatment which 
caused a significant decrease in MAP2 fluorescence was the sample group from 6 hour Thapsigargin 
treated-astrocytes (p <0.001), however this effect is resolved if samples are not taken until 12 or 24 hours 
suggesting that at later timepoints the astrocytes have successfully dealt with the ER-stress.  
 
To assess potential contributions to oligodendrocyte maturation and survival, astrocyte derived 
supernatants were also applied at the start of differentiation at a 1:20 dilution. After 72 hours in 
differentiation medium, maturation was assessed by immunofluorescence as in Chapter 4. Similar to the 
findings on neurons, no effects on oligodendrocyte differentiation or cell number were observed following 
exposure to supernatants from antiretroviral treated astrocytes at any point during the timecourse (n=3 
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biological replicates of oligodendrocytes, each treated with the triplicate astrocytes derived samples). 
Thapsigargin again produced a significant effect, with a reduction in cells progressing to express either 
immature (GalC) or mature (MBP) markers. This effect is found in oligodendrocytes treated with 
supernatants collected from all antiretroviral exposure times for the astrocytes. There is also a trend 
towards a significant decrease in total cell number, suggesting a potential toxic effect in addition to a halt in 
differentiation (Figure A1.2). 
 
A1.2 MATERIALS AND METHODS 
Chemicals and reagents. AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, 
NIH: antiretroviral reagents. Covance (Princeton, NJ): mouse monoclonal microtubule-associated protein 2 
(MAP2) antibody (SMI-52). Life Technologies (Carlsbad, CA): B27 supplement, Dulbecco’s Modified 
Eagle’s Medium (DMEM), goat anti-mouse beta-lactamase TEM-1 conjugate, fluorocillin green substrate, 
L-glutamine, Ham’s F12, Hank’s Balanced Salt Solution (HBSS), Neurobasal media, 
Penicillin/Streptomycin. Jackson Immunoresearch Laboratories (West Grove, PA): FITC-conjugated goat 
anti-mouse IgG3, Rhodamine-conjugated goat anti-rat IgG. Peprotech (Rocky Hill, NJ): neurotrophin-3 
(NT-3). Peptide International (Louisville, KY): poly-L-lysine, poly-D-lysine. R&D Systems (Minneapolis, 
MN): basic fibroblast growth factor (bFGF), platelet-derived growth factor -AA (PDGF-AA). Sigma 
Aldrich (St. Louis, MO): cytosine arabinoside (Ara-C), fetal bovine serum (FBS), progesterone, putrescine, 
thyroxine (T4), transferrin. Tocris Bioscience (Ellisville, MO): thapsigargin. Vector Laboratories 
(Burlingame, CA): Vectashield with DAPI. 
 
Additional antibodies: anti-galactocerebroside mouse hybridoma supernatant (GalC H8H9), anti-myelin 
basic protein rat hybridoma supernatant (MBP, gift of Virginia Lee, University of Pennsylvania). 
 
Primary Cortical Neuroglial Cultures. All experiments were performed in accordance with guidelines set 
forth by The University of Pennsylvania Institutional Animal Care and Use Committees (IACUC). Primary 
rat cortical neuroglial cultures were isolated from embryonic day 17 Sprague Dawley rat pups, as 
previously described (Chapter 3). Cortical cell suspensions isolated from pups were plated on poly-L-lysine 
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coated T25 tissue culture flasks (2 x 106 cells/flask) or 96-well tissue culture plates (0.5 x 105 cells/well). 
To attain pure astrocytic cultures, the cortical cell suspensions were initially plated in 10% fetal bovine 
serum (FBS) in DMEM and maintained at 37°C with 5% CO2 for 7-12 days. At this stage the cultures are 
confluent and astrocytes constitutes approximately 90% of cells. Cells were harvested from these cultures 
and re-plated onto poly-L-lysine coated 60mm dishes, with experiments conducted once cells had achieved 
75% confluency. Neuronal cultures were maintained in Neurobasal media with B27 supplement at 37°C 
with 5% CO2, with 10µM Ara-C added 24 hours after plating to establish pure neuronal cultures. Half of the 
media was replaced with fresh media every 7 days, with experiments conducted at 14 DIV.  
 
Primary Cortical Oligodendrocyte Cultures 
All experiments were performed in accordance with the guidelines set forth by The Children's Hospital of 
Philadelphia and The University of Pennsylvania Institutional Animal Care and Use Committees (IACUC). 
Primary rat oligodendrocyte precursor cell (OPC) cultures were isolated from postnatal day 4 Sprague 
Dawley rat pups obtained from Charles River Laboratories, as previously described in Chapter 4 for mouse 
oligodendrocyte isolation. Cortical cell suspensions isolated from rat pups using standard protocols were 
plated on poly-D-lysine coated 10-cm dishes in Neurobasal medium with B27 supplement at 37°C with 5% 
CO2. Cultures were switched to growth medium consisting of Neurobasal medium with B27, which 
contained 10 ng/ml bFGF, 2 ng/ml PDGF-AA, and 1 ng/ml NT-3 24 hours after initial plating. Following a 
week of growth, confluent cells were purified to 90-95% OPCs and 5-15% astrocytes using a gentle wash-
down procedure (Feigenson et al., 2009), and sub-cultured onto poly-lysine-coated coverslips. For 
differentiation, growth medium was replaced with differentiation medium, consisting of 50% DMEM, 50% 
Ham’s F12, Pen/Strep and 2 mM glutamine with 50 µg/ml transferrin, 5 µg/ml putrescine, 3 ng/ml 
progesterone, 2.6 ng/ml selenium, 12.5 µg/ml insulin, 0.4 µg/ml T4, 0.3% glucose, and 10 ng/ml biotin. 
 
MAP2 Cell-Based ELISA 
To quantify neuronal damage/death, a MAP2 cell-based ELISA was performed as previously described 
(Chapter 3). At the end of treatments, neuronal cultures in 96-well plates were fixed with 4% 
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paraformaldehyde and 4% sucrose for 30 minutes. Following blocking for 1 hour in PBS+5% normal goat 
serum, plates were incubated with MAP2 antibody overnight at 4°C. Plates were washed with PBS+0.1% 
Tween-20 (PBS-T), then incubated with goat anti-mouse secondary antibody conjugated to beta-lactamase 
TEM-1 for 30 minutes. Following subsequent PBS-T washes, the plate was incubated with fluorocillin 
green substrate for 1 hour in the dark. Fluorescence intensity was measured using a Fluoroskan Ascent 
plate reader (Thermo Electron, Waltham, MA) with excitation at 485 nm and emission at 527 nm.  
 
Immunofluorescence 
Oligodendrocytes were processed for detection of specific antigens as described in Chapter 4. Live cells 
were labeled for cell surface marker detection anti-GalC (mouse hybridoma supernatant, undiluted). For 
detection of internal antigens following acid alcohol fixation and permeabilization, anti-MBP (rat 
hybridoma supernatant, 1:2 dilution) was used. Secondary antibodies (1:100 dilution) were Rhodamine or 
Fluorescein conjugated. Vectashield with DAPI was used to mount coverslips and to stain all nuclei. 
Antigen-positive and DAPI-positive cells were counted in 10 fields in each of 3 coverslips using a Leica 
DM6000B fluorescence microscope at 40x magnification. A total of approximately 2000 cells were 
counted per condition.  
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Figure A1.1 Indirect Neuronal Toxicity Does Not Occur Following Incubation with Conditioned 
Medium from Antiretroviral-Treated Astrocytes 
Primary rat enriched neuronal cultures aged 14 days in vitro (DIV) on coverslips were exposed for 48 hours 
to a 1:20 dilution of supernatants derived from astrocytes which had been treated for 6 hours (A), 12 hours 
(B), or 24 hours (C) with Vehicle, AZT, Ritonavir, Saquinavir, Indinavir, ddC, d4T, or Thapsigargin. A 
MAP2 cell-based ELISA was performed to assess neuronal damage/death (n=3, vehicle: 0.02% DMSO, 
###p<0.001, One-Way ANOVA with post-hoc Newman-Keuls determined statistical significance).  
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Figure A1.2 Conditioned Medium from Antiretroviral-Treated Astrocytes Does Not Alter 
Oligodendrocyte Differentiation  
Primary rat oligodendrocyte cultures were exposed to a 1:20 dilution of supernatants derived from 
astrocytes which had been treated for 6 hours (A), 12 hours (B), or 24 hours (C) with Vehicle, AZT, 
Ritonavir, Saquinavir, Indinavir, ddC, d4T, or Thapsigargin during the 72 hour course of differentiation.   
Cells were fixed and stained with antibody to GalC, and MBP, with DAPI for total cell nuclei. 
Epifluorescent images were captured, with 10 fields on three coverslips per condition. Immature 
oligodendrocytes (GalC+ cells, left-hand column), mature oligodendrocytes (MBP+ cells, middle column), 
and total cell number (right-hand column) were counted using ImageJ software, represented as percentage 
normalized to untreated. Data are presented as mean ±SEM. (n=3, vehicle: 0.02% DMSO, ###p<0.001, 
##p<0.01, One-Way ANOVA with post-hoc Newman-Keuls determined statistical significance).  
 
 
 
 
